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The complexes [Cp*MCl(L)]PF6 (M = Ir (1a), Rh (2a)), (where Cp* = 
pentamethylcyclopentadiene) and [(η
6
-arene)RuCl(L)]PF6 (3a) [L = N-(pyridin-2-
ylmethylene)aniline] have been synthesized and the structure and purity of these were confirmed 
by single crystal XRD and elemental analyses. The catalytic performance of the complexes as 
catalysts for the dehydrogenation of primary alcohols was investigated. The Gibbs free energy 
     calculation was carried out to support the proposed reaction mechanism of the Rh complex 
(2a) using DFT study.  
 
Six new complexes of [Cp*IrCl(L)]PF6 (L = p-R-N-(pyridin-2-ylmethyl)aniline) (R = H (1b), F 
(2b), OCH3 (3b)), and [Cp*RhCl(L)]PF6 (R = H (4b), F (5b), OCH3 (6b)) have been synthesized 
and  characterized by various spectrometric techniques. The crystal structures of 1b and 6b have 
been resolved by X-ray crystallography. These complexes were used as catalysts for transfer 
hydrogenation of aromatic carbonyl compounds in water with sodium formate and formic acid as 
the hydrogen source under pH dependent acidic conditions.  
 










-p-cymene)OsX(L)]PF6 X = Cl (8c), I (9c)) (L=9-ethyl-N-(pyridine-
2-yl-methylene)-9H-carbazole-3-amine) complexes have been synthesized and characterized by 
various spectrometric techniques. The crystal structures of 2c and 6c have been confirmed by 
single crystal XRD. Anticancer study using complexes 1c-3c clearly showed potent inhibition of 
MCF-7 cell lines under in vitro conditions. 
 
New complexes of [RuCl2(L1)(COD)] (1d), [RuCl2(L2)(COD)] (2d), [RuCl2(L3)(COD)] (3d), 
[RuCl2(L4)(COD)] (4d), [RuCl2(L5)(COD)] (5d) (L = (p-R-N-(pyridin-2-yl-methylene)aniline), 
R = H (L1), Cl (L2), OCH3 (L3), CH3 (L4), L5 = (9-ethyl-N-(pyridin-2-yl-methylene)-9H-
carbazole-3-amine and COD = η
4
-cyclooctadiene) were synthesized and characterized by various 
spectrometric techniques. The structures of complexes 1d, 2d and 3d have been confirmed by 
iii 
 
single crystal XRD. Interactions of complexes 1d-5d with human serum albumin (HSA) were 
investigated. 
 
Six new complexes of [Cp*IrCl(L)] [L = (p-R-N-benzylidene-9-ethyl-9H-carbazol-3-amine)] (R 
= F (1e), CH3 (2e), OCH3 (3e)), and [Cp*RhCl(L)] (R = F (4e), CH3 (5e), OCH3 (6e)) have been 
synthesized and characterized by various spectrometric techniques. The crystal structures of the 
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1.1 Scope of the bidentate Schiff base ligands 
Over the past century, there has been substantial growth in the area of Schiff base and bidentate 
nitrogen donor ligands and the application of their transition metal complexes in homogeneous catalysis. 
Schiff base compounds were first prepared in 1879 at the Chemical Institute of the University of Florence 
by Hugo Schiff, a German chemist, born in 1834, in Frankfurt [1]. Schiff base compounds are synthesized 
by the condensation of primary amines with carbonyl groups forming a >C=N double bond [2-4] (Scheme 
1.1). The imine group of Schiff base ligands plays an important role in biological applications as well as 
in catalysis. In comparison to ketones, aldehydes react readily with amines to form Schiff base 
compounds. These types of compounds are unstable unless they have an aryl group attached to either the 
carbon or nitrogen atom [5, 6]. The formation of Schiff base compounds is dependent on various factors 
such as: the order in which reagents are added, reactivity of the substrates, solvents used and the reaction 
temperature. Equilibrium of these reactions is achieved after a short time when the metal salts are added 
last to the reaction mixture [7]. Formation of the Schiff base ligands are mainly determined by two 
factors: (i) facilitating removal of the N-H protons from the substrate and, (ii) enhancing nucleophilic 
attack at the carbonyl group present in the substrate [7]. Schiff bases are intermediates in biological 
systems involving interactions with amino or carbonyl groups of a substrate. There is a certain degree of 
flexibility in the structure of these ligands mainly due to their electronic nature and the presence of 
additional donor atoms apart from the imine nitrogen atoms [8]. 
 Attractive features of Schiff base ligands include their electronic fine tunability, structure 
flexibility and straight forward synthetic reaction routes. Research into Schiff base compounds has 
extended enormously, and embraces wide and diversified areas of organometallic chemistry. Schiff bases 
are widely associated with diverse inorganic and organic ligands such as chloride, arenes, various 
carbenes and cyclodienes [9]. Thus, Schiff bases are of great interest for making new active, versatile and 




Scheme 1.1: Schematic diagram of the formation of Schiff bases. 
1.2 Scope of the Schiff base metal complexes for catalytic and biological applications 
Schiff bases are an important class of ligands in organometallic chemistry which can coordinate 
to main group and transition metals through azomethine nitrogen atoms. The nitrogen based Schiff base 
N,Nʹ bidentate ligands containing metal complexes are widely used in bioinorganic, inorganic and 
organometallic chemistry [10-12].  
Schiff base compounds coordinate to transition metal ions in either bidentate or multidentate 
modes, yielding stable or highly active complexes for different catalytic and biological applications [13-
15]. Interestingly, Schiff base compounds form stable five or six-membered chelate rings with different 
transition metal precursors (Figs. 1.1-1.3), due to the second functional group in the vicinity of the metal 
coordination site [16]. The lone pair of electrons on the nitrogen atoms play an important role in the 
formation of highly stable chelated complexes with versatile applications in bioinorganic chemistry and 




, depending on 
the substituent on the nitrogen atom (alkyl or aryl), and their steric hindrance alters the behavior of the 
nitrogen atom in potential chemical applications [17]. The central metal atom present in these complexes 
act as an active site in biological applications and chemical transformation reactions [17] (Fig. 1.5).  
The oxidation of alcohols and the transfer hydrogenation of carbonyl compounds are among the 
important transformations in synthetic chemistry. High selectivity and productivity are important aspects 
for industrial processes and it can be achieved by tuning the ligand design and synthetic route to optimize 
the versatility of the catalysts. On the other hand adjusting the reaction temperature, solvents and co-
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catalysts can help to improve the activity of the catalyst for multi-organic transformation reactions. In 
homogeneous catalysis, pyridine-based Schiff base ligands play an important role due to their ability to 
coordinate to different transition, non-transition, lanthanide and actinide metals in different oxidation 
states [18]. Over the last decade, Schiff base complexes have become attractive compounds for the 
development of a new generation of catalysts with high activity and selectivity. Hence, the development 
of metal mediated catalytic oxidation of alcohols and transfer hydrogenation of carbonyl compounds 
under mild conditions are important [19, 20]. Oxidation of aromatic alcohols to their respective aldehydes 
and transfer hydrogenation of carbonyl compounds have been the focus of numerous articles and reviews 
[19, 20]. 
In bioinorganic chemistry, the scope of Schiff base complexes has been widely investigated due 
to their ability to offer synthetic models for metal containing sites for metalloproteins [2]. Transition 
metal complexes containing heterocyclic scaffold Schiff base ligands which have been reported have a 
wide range of biological applications in medicinal chemistry, especially for designing new drugs [10]. 
According to biological views, DNA is the primary pharmacological target of anticancer compounds to 
damage tumor cells. Transition metal complexes containing Schiff base ligands have shown a strong 
binding interaction with DNA through surface association or intercalation, and DNA cleavage via 
hydrolytic or oxidative mechanisms [21]. The N,N' ancillary ligands, such as bipyridine, phenanthroline, 
dipyrido-quinoxaline and dipyridophenazine presented metal complexes also play pivotal roles in their 
binding nature and intercalation with DNA. Planarity of the ancillary ligands can improve the nature of 
intercalation of complexes with DNA and, in turn, increase the binding potential. Furthermore, the N,N' 
bidentate phenanthroline ligand present in some complexes has drawn much attention to biological 
systems in which they exhibit high nucleolytic efficiency [22].  
In recent years, various scientific research groups have shown interest in the functionalization of 
Schiff base complexes with nanomaterials for therapeutic applications [14]. Many of the antharacene 
moieties and their derivatives present in Schiff base compounds are known to possess significant anti-
cancer activities against certain cancer cells, with their fluorescent chromophores acting as photo-
signalers for charge transfer complexes. Therefore, the antharacene chromophore present in metal 
complexes provides significant information about cellular processes because of their intrinsic 
fluorescence property within cells [23]. Hence, Schiff base complexes are widely used for biological 
applications such as antifungal, antibacterial, antiviral and anticancer activities [14, 15]. Schiff base 
complexes are also involved in different biochemical processcs like haloperoxidation, nitrogen fixation, 




Fig. 1.1 Aluminum Schiff base complexes for guanylation of aromatic amines. 
 
Fig. 1.2 Some Schiff base transition complexes for ethylene oligomerization. 
 
Fig. 1.3 (A) Vanadium Schiff base catalysts for the epoxidation of alkenes and (B) platinum Schiff base 




Fig. 1.4 Different Salen Schiff base metal complexes for various enantioselective chemical transformation 
reactions. 
 
Fig. 1.5 Some biologically active copper N,N' Schiff base ligand complexes.  
1.3 Schiff base coordinated Ru(II), Ir(III) and Rh(III) complexes in homogeneous 
catalysis 
1.3.1 Ru(II) complexes containing N,N'-, N,S-, N,Se-, P,P'- and N,P ligands for catalytic 
transfer hydrogenation and oxidation reactions  
The catalytic activities of Ir(III), Rh(III) and Ru(II) N,N' bidentate complexes were widely 
investigated by different research groups around the world using different reaction conditions and 
reagents (Scheme 1.2). Furthermore, catalytic TH is one of the widely accepted methods in industry as a 
green process for the production of a number of aromatic alcohols. Noyori and co-workers [27] first 
reported ruthenium metal complex systems which accelerate the catalytic TH of aromatic ketones to their 
respective alcohols under mild conditions. The chiral Ru(II)-Ts-dpen (Where Ts-dpen = N-(p-
toluenesulfonyl)-1,2-diphenylethylenediamine) catalyst is known for asymmetric transfer hydrogenation 
of aromatic ketones with high enantiomeric excess [28]. The Noyori-Ikariya Ru(II)-dpen modulated 
catalyst is highly active (Substrate/Catalyst = 1000/1) for asymmetric transfer hydrogenation of aromatic 
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ketones with a high enantiomeric excess in water using HCOOH-Et3N and HCOONa hydrogen sources 
under pH controlled reaction conditions [28-30]. Thus, the Ru(II)-Ts-dpen catalyst showed a catalytic TH 
process through a concerted delivery of an N-H proton as well as a Ru-H, via a six-membered transition 
state in an outer sphere mechanism.  
 
Scheme 1.2: Catalytic oxidation and transfer hydrogenation by ruthenium catalysts. 
In 1999, Mizushima et al. first reported the use of Ru(II) complexes chelated to both 
aminomethyl pyridine derivatives and phosphine ligands which exhibited good catalytic activity for 
asymmetric TH of aromatic ketones [31]. Recently, Ru(II) arene complexes bearing chalcogenated 
pyridine-based bidentate and tridentate N, S or Se ligands showed good catalytic TH activity towards 
aromatic ketones and they were also active in the oxidation of different aromatic alcohols [32, 33]. The 
same group reported the use of glycerol as a hydrogen donor for TH of carbonyl groups in water, 
catalyzed by Ir(III), Rh(III) and Ru(II) chalcogenated bidentate complexes [34]. Very recently, water 
soluble Ru(II) complexes bearing naphthyridine-carboxylate N,N' ligands showed catalytic TH of 




Fig. 1.6 Ru(II) catalysts containing different bidentate ligands for oxidation and transfer hydrogenation 
reactions. 
In TH reactions the reaction medium and hydrogen sources play an important role in achieving 
desirable reduced products. Metal complex catalyzed TH reactions have been executed in isopropyl 
alcohol or HCOOH-HCOONa in water or in an azeotropic mixture of HCOOH-Et3N (F/T), in which the 
molar ratio of F/T is 2.5:1 [36]. The advantage of the HCOOH-HCOONa and azeotropic mixture of 
HCOOH-Et3N is that it acts as a hydrogen donor as well as a base, which does not allow the reversibility 
of the reduction process of the ketone like the isopropyl alcohol does. HCOOH-HCOONa and HCOOH-
Et3N mixtures are good hydrogen donors compared to isopropyl alcohol due to the resulting CO2, which 
is thermodynamically stable and can be easily removed from the system, which results in the reactions 
being irreversible [36]. Moreover, a wide range of substrates are soluble in an acidic medium and 
HCOOH-HCOONa / HCOOH-Et3N is miscible with many organic solvents in the temperature range of 
20-60 °C [36]. This process is thus an environmentally benign process for TH applications. 
Nitrogen donor atoms present in ruthenium based organometallic complexes have recently been 
shown to play an important role in the oxidation of alcohols [37]. Notably, (η
6
-arene)Ru(II) complexes 
were among the best catalysts for this transformation, which can be performed on a wide range of 
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alcohols and amines [38, 39]. Furthermore, Prades et al. reported N-Heterocyclic carbene (NHC) 
triazolylidene ligands coordinated to Ru(II) complexes, which showed excellent reactivity in the catalytic 
oxidation of alcohols and cross coupling reactions of alcohols and amines under different reaction 
conditions [40]. The functionalized NHC-triazolylidene moieties act as potential nitrogen donor ligands 
for transition metal complexes and organometallic species. The advantage of NHC-based ligands is that 
they have a number of possible coordination modes of the carbene to the metal and accommodate positive 
and negative charges in the triazole moiety. A number of reported triazole based Ru(II) half sandwich 
complexes were active for the catalytic oxidation of alcohols [41]. Ohzu et al. reported photocatalytic 
primary alcohol oxidation reactions by Ru(II)-pyridylamine complexes with the use of [Ru(II)(bpy)3] as a 
photosensitizer [42].  
1.3.2 Ir(III) complexes for catalytic transfer hydrogenation and oxidation reactions 
 
Scheme 1.3: Catalytic oxidation and transfer hydrogenation by iridium catalysts. 
Iridium is a third row transition metal, in a group that also contains, cobalt and rhodium. Ir shows 
different oxidation states, commonly Ir(I), Ir(III), Ir(IV), coordination numbers (4, 6) and coordination 
geometries during organoiridium complex formation [43]. Some Ir(III) half-sandwich complexes are 
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reported as highly versatile catalysts for catalytic TH and oxidation reactions (Scheme 1.3), which contain 
an electron rich Cp* moiety, N,N' and C,N ligands [43]. 
The importance of green chemistry has drawn attention to the reduction of carbonyl compounds 
in water as a solvent, using Ir(III) and Rh(III) metal complexes. Half sandwich IrCp* complexes are 
versatile catalysts for the oxidative amine addition, TH and alcohol oxidation reactions. Half sandwich 
IrCp* complexes are versatile catalysts for the oxidative amine addition, TH and alcohol oxidation 
reactions. Yamaguchi et al. reported that the IrCp*(2-OH-pyridine)Cl and IrCp*(6-phenyl-2-pyridone)Cl 
complexes are highly active catalysts for the oxidation of aromatic alcohols [44, 45]. A turnover number 
of up to 700 for these catalysts was achieved in the oxidation of the aromatic alcohols, refluxing in 
toluene. Fujita and Yamaguchi reported several alcohol activation reactions and Oppenauer-type 
oxidations of primary and secondary alcohols using IrCp* complexes [46]. Brewster et al. reported a 
series of half-sandwich IrCp* and RhCp* compounds containing N,N'-, C,N- and carbene ligands that act 
as versatile catalysts for the hydrogenation of carboxylic acids under relatively mild conditions [47]. A 
wide range of substrates, including primary and secondary alcohols as well as different aromatic and 
aliphatic carbonyl compounds, catalyzed by IrCp* complexes under mild and harsh conditions have been 
investigated [20] (Fig. 1.7).  









compounds for transfer hydrogenation of carbonyl compounds in water using HCOONa as a hydrogen 
source [48]. Recently, IrCp* diamine and cyclometalated IrCp* imine complexes were reported as highly 
versatile catalysts by Villa et al. [49] and Wei et al. [50] for catalytic transfer hydrogenation in water 
using formic acid as a hydrogen source. Apart from water, many solvents meet the green protocol criteria 
and glycerol has attracted the attention of many researchers, due to its chemical properties, being readily 
available and cost effective. Recently, Ir(I) and Ir(III) NHC based complexes with 3,4,5-trimethoxybenzyl 
N-substituted complexes have been reported for catalytic transfer hydrogenation with glycerol as a 
solvent [51]. In a number of examples reported, glycerol has replaced isopropyl alcohol as a hydrogen 
source in ruthenium and iridium catalyzed transfer hydrogenation reactions [34]. The catalytic activities 
for a series of [IrCl2Cp*(NHC)] complexes were reported as being high for several C-O and C-N coupling 
reactions [52]. The protic NHC complexes bearing an ionizable proton at the β-position to the metal 








1.3.3 Rh(III) complexes containing bidentate ligands for catalytic transfer hydrogenation 
and oxidation reactions 
 
Scheme 1.4: Catalytic oxidation and transfer hydrogenation by rhodium catalysts. 
The η
5
-C5Me5 rhodium complexes are of great scientific interest because they can be used as 
precursors in the synthesis of many rhodium complexes, as well as be applied in a wide range of catalytic 
reactions [55] (Scheme 1.4). The pioneering work by Noyori et al. reported highly active enantioselective 
Ru(II)-(Ts-dpen) for asymmetric transfer hydrogenation reactions [27, 28]. After the remarkable 
discovery of this catalyst, new N,N' chiral ligands have been developed with Rh(III) and Ir(III) complexes 
for catalytic transfer hydrogenation reactions (Fig. 1.8). Rh(III)-(1R,2R)(Ts-cydn) has been reported as an 
excellent and stable catalyst for the asymmetric transfer hydrogenation of aromatic carbonyl compounds 
in water under air using HCOONa as a hydrogen source [56]. Recently Singh et al. have reported water 
soluble RhCp* complexes containing a (phenylthio)methyl-2-pyridine scaffold which showed promising 
results as an efficient catalyst for transfer hydrogenation of carbonyl compounds with a low catalyst 
loading (0.5 mol%) [34]. Moreover, when the reaction is carried out in water, the organic substrates can 
be easily separated by liquid-liquid extraction. However, most of the transition metal complexes were not 
stable toward hydrolysis or water as this hinders the transition states of the catalytic cycles through 
coordination of H2O molecules to the metal center [57]. Therefore, the design of a catalyst that is not only 
active in the aqueous phase, but also could be stable and completely soluble in this system would be most 
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desirable [57]. A core-shell structured heterogeneous Rh(III) catalysts (Fig. 1.8 (B)) have also been 
reported as a versatile and recoverable catalyst for asymmetric transfer hydrogenation reactions in 
aqueous media [58]. 
 
Fig. 1.8 Some of the homogeneous (A) and heterogeneous (B) rhodium catalysts for catalytic oxidation 
and transfer hydrogenation reactions. 
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Studies carried out by Qi et al. showed rhodium catalyzed efficient oxidative coupling between 
aromatic C-H bonds and allylic alcohols [59]. The synthesis of a functionalized β-aryl ketone and 
aldehyde achieved by a Rh catalyzed process afforded the products in good yields. Rhodium complexes 




) compounds via cleavage of 
unactivated C-H bonds, as reported by Li and Shi. [60]. Recently, oxidative coupling of monosubstituted 
arenes with alkynes to form benzannulated heterocyclic compounds catalyzed by Rh(III) compounds was 
reported by Wei et al. [61] and Wang et al. [62]. RhCp* compounds are also found as versatile catalysts 
for coupling reactions of benzylic alcohols with alkynes through OH directed C-H bond cleavage [63]. 
Recently, rhodium complexes containing hybrid NHC-phosphine and NHC-pyrazole bidentate ligands 
showed promising results as catalysts for hydroamination reactions, as demonstrated by Field et al. [54] 
and Gray et al. [64]. The coupling of amines with alkenes is known and has been an active field of 
interest for the last 40 years, with Coulson being the first to demonstrate the addition of ethylene to 
secondary amines catalyzed by rhodium homogeneous catalysts in 1971 [65]. 
1.4 Biologically important Schiff base ligands-containing transition metal complexes 
Transition metals, such as ruthenium, iridium, rhodium and osmium, with N,N' bidentate ligands 
exhibit diverse applications in the pharmaceutical, agrochemical, dye, and food industry, as well as in 
photo sensitizer, photo luminescence and fluorescence studies, in addition to catalysis and biological 
studies (anti-inflammatory and potential in vitro & in vivo studies) [13, 14, 66-68].  
1.4.1 Organoruthenium compounds for different biological applications 
Over the last few decades, ruthenium complexes have become of great interest in the field of 
chemotherapeutic studies with regard to the development of anti-cancer drugs [68]. In 1976, Durig et al. 
discovered biologically active Ru(III) complexes such as fac-Ru(NH3)3Cl3 which induces filamentous 
growth of E. coli at a similar concentration to cis-platin [69, 70]. These results suggested Ru could be 
considered as an alternative metal to platinum, to overcome the drawbacks of the platinum anti-cancer 
drugs in cancer treatment. Interestingly, many of the Ru compounds are not very toxic and some of the 
ruthenium compounds have been shown to be highly selective for cancer treatment [70, 71]. This high 
selectivity towards cancer cells suggested Ru has the ability to mimic iron in binding to biological cells 
[72]. Thus KP1019 (indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) and NAMI-A 
(imidazolium trans-[tetrachlorido(dimethyl sulfoxide)(1H-imidazole)ruthenate-(III)]) are pioneering 
ruthenium compounds (Fig. 1.9) for potential anticancer and antitumor activity in biological systems [71-
73]. Ru complexes containing Schiff base ligands have been involved in various biological studies, such 
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as protein binding, antifungal, antibacterial, antiviral, antimalarial, antiparasitic, antimetastatic, 
antiangiogenic and anti-inflammatory studies in medicinal chemistry [73-77]. Sadler and co-workers 
reported numerous N,N' bidentate ligands containing cationic arene Ru(II) complexes with potential 
cytotoxicity activities under in vitro and in vivo conditions [78-80].  





-p-toluene)Cl2(PTA)] (where PTA = 1,3,5-triaza-7-
phosphaadamantane), DAPTA-C [(Ru(η
6
-p-cymene)Cl2(DAPTA)], and DAPTA-T [(Ru(η
6
-p-
toluene)Cl2(DAPTA)] (where DAPTA = 3,7 diacetyl-1, 3, 7-triaza-5-phosphabicyclo[3.3.1]nonane) 
showed low toxicity profiles and antiproliferative effects in endothelial cells [75]. In recent years, 
organometallic ruthenium half sandwich octahedral low spin d
6
 metal complexes have been of great 
interest in chemotherapeutic studies because of the hydrophilic and hydrophobic nature of carbon bound π 
bonded arenes and substituted moieties. This arene moiety emerged as a versatile tool to develop novel 
compounds for antitumor activity studies, which is responsible for cell intake, targeting tumor cells and 
kinetic inertness of the complexes [78, 81]. 
 
Fig. 1.9 Structure of organoruthenium(II) and (IV) anticancer compounds. 
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1.4.2 Organoiridium compounds containing N,N'-, C,N-, and N,O- ligands for anti-cancer 
studies 
In recent years iridium metal complexes have become important in their application in 
chemotherapeutic studies, in which they show high antiproliferative activity towards cancer cells [82]. 
Iridium is an inert and corrosion-resistant metal with several common oxidation states (Ir(I), Ir(III) and 
Ir(IV)) and coordination geometries [83]. The Ir(III) oxidation state is one of the most stable low-spin 
inert d
6
 states while forming complexes with bidentate chelated ligands [84]. This stability and inertness 
also plays an important role in the design of anti-cancer drugs. Ir compounds were first investigated for 
anti-cancer studies in the later 1970s after the discovery of cis-platin [85]. The Ir(I) compounds, 
[Ir(acac)(COD)] and dinuclear [IrCl(COD)]2, were investigated for anti-tumor activity studies in mice, 
because of their square planner geometry like cis-platin [85, 86]. Comparatively, Ir(III) is more stable 
than Ir(I)
 
with higher coordination numbers, which can be stabilized by electron-rich 
pentamethylcyclopentadienyl (Cp*) and substituted Cp* moieties [87]. 
[Ir(acac)(COD)] and dinuclear [IrCl(COD]2 were investigated for anti-tumor activity properties 
and for targeted delivery of complexes to specific cancer tumor [88]. Sadler et al. have also recently 
investigated neutral N,N' ligands, such as bipyridine, 1,10-phenanthroline and ethylenediamine, chelated 
Ir(III) complexes which exhibited moderate anticancer activity against certain cancer cell lines [89]. The 
chelating N,N' ligands provide additional stability for the metal complex and contribute to tuning the 
electronic nature of the iridium metal center. The anticancer activity of metal complexes could be 
considerably increased by tuning via small modification in the ligands chelated to the metal center. The 
cytotoxicity effect of IrCp* complexes was increased drastically when phenyl or biphenyl groups were 
introduced in place of the methyl group on the Cp* moiety. Half-sandwich organometallic Ir(III) 











 (biphenyltetramethylcyclopentadienyl) with N,N’ donor 





) moieties could facilitate rapid hydrolysis by increasing the negative 
charge on the metal, making it easy for the chlorine group to dissociate from the complex [43]. The 
replacement of neutral N,N' chelated ligands by cationic C,N donor ligands in Ir(III) complexes 




Fig. 1.10 (A) Anti-cancer organoiridium polypyridyl complexes against MCF-7, HT-29 and HEK-293. 
(B) Photocytotoxic (diene)Ir(III) protein kinase inhibitors. (C) Anti-cancer organoiridium(III) complexes 
containing different bidentate ligands. 
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A significant number of (diene)Ir(III) complexes were reported in phototoxic activity studies 
towards cancer cells, protein and lipid kinase inhibitors [84]. The development of luminescent cellular 
probes containing organometallic complexes is important to understanding the assorted structures and 
functions of biological systems. There has been interest in studying luminescent inorganic and 
organometallic complexes in cellular systems through emission spectroscopy and scanning microscopy 
techniques. Recently, Zhang et al. reported a series of luminescent cyclometalated Ir(III) 
dipyridoquinoxaline complexes [(Ir(N,C)2(N,N'))PF6] (where N,N' = polypyridines) which were 
successfully investigated for cellular uptake studies [90].  
1.4.3 Biologically active organorhodium compounds containing N,N'- and S,S' ligands 
In the past decade structure-activity relationships of rhodium (Rh) compounds and their 
cytotoxicity effects on cancer cells were extensively studied by various research groups [91]. Rh(I), 
Rh(II) and Rh(III) compounds showed potential anti-tumor activity against human oral carcinoma, 
leukemia L1210 and P388, sarcoma 180, lung carcinoma, lymphocytic leukemia, L1210 and B16 
melanoma, and Ehrlich ascites carcinoma [92]. Upon the discovery of potential carcinostatic activity of 
Rh(II) carboxylates, investigations based on their chemical properties and biological activities have 
accelerated. The dirhodium tetracarboxylate complexes [(RCOO)4L2Rh2(II)] (where R = Me, Et, Ph or 
CF3; L = H2O or other solvents) exhibit anti-tumor activity against various tumor cells, but the toxicity of 
these complexes prevented their use [93]. The dirhodium tetraacetate complex 
[(CH3COO)4(H2O)2Rh2(II)] and [(RCOO)4Rh2(II)] (R = CH3, CH2CH3, CH2CH2CH3, CH2CH2CH2CH3) 
showed considerable anti-tumor activity against E. coli DNA polymerase I and Ehrlich ascites tumors 
[94-97]. The neutral and square planar rhodium(I) cyclooctadiene complexes [Cl(COD)NH3Rh(I)], 
[Rh(acac)(COD)] and [Cl(COD)-piperidineRh(I)] (COD = cis- 1,5 cyclooctadiene) displayed potential 
anti-tumor activity against the Ehrlich ascites tumor under in vivo conditions [98]. The square-planer 
Rh(I) complexes ([(COD)(PMI)Rh]Cl (where PMI = 2-pyridinalmethylimine), [(COD)(PEI)Rh]Cl (where 
PEI = 2-pyridinalethylimine), and [(COD)(PIP) Rh]Cl (where PIP = 2-pyridinalisopropylimine)) were 
also investigated for anti-tumor and anti-metastatic activities [99] (Fig. 1.11).  
A number of Rh(III) analogues of Ru(III) antitumor complexes also show significant 
antineoplastic activity in cancer treatment by reduction of Ru(III) to Ru(II) [100]. The N,N' bidentate 2,6-
diaminepyridine Rh(III) complex showed high activity on the humoral immune response of white mice 
[101]. 





 (where L = primaquine, mepacrine, amodiaquine, lepidine, plasmoquine, pentaquine, 
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and isopentaquine) have also been investigated for different anti-tumor activities [102]. Morrison and co-
workers reported potential phototoxic agents for the destruction of cancer cells using N,N' ligands 
containing bis(bipyridyl)Rh(III) complexes such as cis-[RhCl2(dppz)(phen)]Cl and cis-[RhCl2(3, 4, 7, 8 - 
Me4phen)2]Cl [103]. These photoluminescent activated drugs introduced a new kind of attractive drug 
treatment in chemotherapeutic studies, causing no harm to the living cells by attacking cancer affected 
cells only. 
 
Fig. 1.11 Biologically active organorhodium(III) complexes for various cancer cell lines. 
1.4.4 Organoosmium compounds containing N,N'-, O,O'- and sulphur ligands 
Since 2006, osmium compounds have become an emerging field for developing anti-cancer drugs 
as an alternative to the ruthenium analogues, due to their antiproliferative effect against cancer cells and 
activity towards DNA [104, 105]. Among the transition metals, Os compounds are less explored in 
medicinal chemistry compared to their ruthenium analogues. Biological studies of osmium complexes 
appear to have been restricted to osmium carbohydrate polymers which exhibit antiarthritic activity [79, 
105]. Normally, third row transition metal ions are relatively inert compared to the first and second row 
transition metal ions. Fine tuning the properties of N,N' O,O' and N,O ligands chelated Os(II)-arene 
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compounds, gave complexes with potential anti-tumor activity and which showed promising 
pharmacological properties for pro-drugs, like solubility in water and plasma, behavior of drug 
absorption, distrubtion, excretion and non-sterile bioavailability in biological systems [106].  
 





Os(II)–arene compounds with bidentate ligands, such as those with N,N'-, N,O-, O,O'-, or S,O- 
heteroatom have shown potential anticancer activity against different cancer cell lines [79, 104, 107, 108] 
] (Fig. 1.12). Complexes containing N,N' chelating ligands show promising potential anticancer activity in 
in vitro studies, regardless of the metal center (Ru or Os) in comparison to those with N,O- and O,O'- 




 complexes (Where LL = ethylenediamine or 
acetylacetonate) showed promising effects after hydrolysis and reactivity toward DNA nucleobases, like 
9-ethylguanine and 9-methyladenine, in biological systems. In general, the aqueous chemistry of (O,O')-, 
(N,O)- and (N,N')- chelated Os(II)-arene complexes are less studied than their congener Ru(II)-arene 
analogues [79, 107].  
1.5 Biologically active Ir(III) and Rh(III) compounds containing C,N ligands 
Cyclometalated complexes were synthesized by intramolecular C-H activation of C,N Schiff base 
ligands [108, 109]. The strong C–M sigma bond improved the stability of the complexes against 
biological reduction, ligand exchange and organic chemical transformation reactions [110, 111]. The 
biological properties and reaction rate of organic reactions are enhanced by introducing different 
substitutions in ancillary ligands. Normally, these complexes are kinetically inert. The activity, electronic 
and kinetic properties are changed by altering the structure of the C–N complexes or fine-tuning the 
properties of the ligands [43, 88, 112]. These complexes have opened a new field in organometallic and 
coordination chemistry due to this versatile application in chemical transformation reactions, such as in 
hydrogenation [113], TH [114], oxidation reactions [44], N-alkylation and carbon-heteroatom forming 
reactions [20] under relatively mild conditions, which may be difficult to achieve by conventional organic 
reactions.  
Sadler and his co-workers reported different C,N and N,N' Ir complexes which exhibited 
anticancer activity against A2780 human ovarian cancer cell lines [85, 88, 115] (Fig. 1.13). Rh(III) 
cyclometalated complexes showed janus kinase 2 enzyme phosphorylation activity and cytotoxicity 
towards human erythroleukemia cancer cells, as reported by Leung et al.  [116]. Recently Yellol et al. 
reported high antitumor activities of novel cyclometalated benzimidazole Ru(II), Rh(III) and Ir(III) 




Fig. 1.13 Some C,N ligands coordinated organoiridium(III) and organorhodium(III) complexes for anti-
cancer studies. 
1.6 Project aims and goals 
 The aims of this project are to synthesize and characterize a series of bidentate N,N' imine, N,N' 
amine and C,N Schiff base ligands and coordinate these ligands to different metal atoms such as iridium, 
rhodium, ruthenium and osmium in a bidentate manner. In order to investigate the catalytic behaviour of 
the synthesised novel metal complexes, they were used in catalytic transfer hydrogenation and oxidation 
reactions of primary aromatic alcohols. Furthermore, some of these novel metal complexes were chosen 
to determine whether these complexes could potentially inhibit cancer cells and bind with human serum 
albumin in biological systems.   
 The definitive goal of this project was to prepare catalysts which are active in environmently 
benign reaction conditions, as well as versatile for different catalytic applications. Being eco-friendly, the 
catalysts will be active under relatively mild reaction conditions in greener solvents when compared to 
other catalytic systems, which require harsh reaction conditions to obtain desired products. The correct 
choice of the metal atom or ion was essential to obtain desired and satisfactory results under the required 
criteria. Thus, iridium, rhodium, ruthenium and osmium were chosen to give versatile catalytic and 




Fig. 1.14 Structures of the N,N' and C,N bidentate ligands and complexes that are presented in this thesis. 
1.7 Scope of the thesis and graphical abstracts 
This thesis summarizes and presents research carried out involving the synthesis and 
characterization of different half-sandwich Ir(III), Rh(III), Ru(II) and Os(II) complexes coordinated to a 
series of N,N' and C,N bidentate ligands. Catalytic and biological investigations of the respective 
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Catalytic oxidation of primary aromatic alcohols using half sandwich Ir(III), 
Rh(III) and Ru(II) complexes: A practical and theoretical study 
 
Abstract 
The complexes [Cp*IrCl(N-(pyridin-2-ylmethylene)aniline)]PF6 (1a), [Cp*RhCl(N-(pyridin-2-
ylmethylene)aniline)]PF6 (2a), (where Cp* = 1,2,3,4,5-pentamethylcyclopentadiene) and [η
6
-
areneRuCl(N-(pyridin-2-ylmethylene)aniline)]PF6 (3a) have been synthesized and the structure and purity 
of these were confirmed by single crystal XRD and elemental analyses respectively. Iridium and rhodium 
complexes exhibit the monoclinic P21/n space group, the ruthenium complex the P21/c space group and 
all three complexes show the expected pseudo octahedral “piano-stool” geometry. The performance of 
these complexes as catalysts for the dehydrogenation of primary alcohols to their respective aldehydes 
with different bases and solvents was investigated. The complexes of iridium and ruthenium gave good 
conversions in different alkaline solutions. Density functional theory was applied to determine the 
respective MO energy levels, bond lengths, bond angles and binding energies of all the metal complexes. 
It was also used to study the activity, stability and intermediates of the complexes. A Gibbs free energy 
     DFT calculation was carried out to help understand the reaction mechanism / catalytic cycle of the 
Rh complex (2a). The energy barrier for oxidation of aromatic alcohols by the rhodium hydride complex 
is much lower (-8.50 kcal/mol) than the barrier for hydride transfer of the corresponding Rh benzyloxo 
species (21.41 kcal/mol), in agreement with mechanisms proposed for related systems. 
Keywords: Catalytic oxidation; N,N' bidentate ligand; half sandwich metal complexes; primary alcohols; 
DFT.  
2.1  Introduction  
Oxidation of primary aromatic alcohols to their respective aldehydes is an important chemical 
transformation in synthetic chemistry [1]. Alcohols are generally inactive and require harsh methods to 
activate the hydroxyl group present [2-5]. In transition metal chemistry, the metal can mediate the 
dehydrogenation of alcohols to yield the aldehydes [5-9] and there are many reports on the oxidation of 
alcohols to aldehydes and ketones. Indeed, metal catalyzed aromatic alcohol oxidation reactions are 
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recognized as one of the greener methods [10-13]. There are several water soluble homogeneous metal 
complexes that have been reported for the oxidation of alcohols, such as those of copper, palladium and 
gold [14, 15]. Many classical methods and reagents are available for these reactions, like “activated 
DMSO” methods, NaOCl/TEMPO (TEMPO = 2,2,6,6-tetramethyl-1-piperidinyloxyl), hypervalent iodine 
reagents and chromium and manganese oxides [16-18]. 
 







arene)Ru(II) half sandwich complexes exhibit a wide range of applications in homogeneous catalysis due 
to their high stability in solution, rapid formation of metal-hydride intermediate, steric and electronic 
properties around the metal center can be easily tuned by these ligands [18, 19]. To explore the metal 
complex systems, researchers also have developed eco-friendly and efficient catalytic metal complex 
systems for the oxidation of alcohols using less toxic oxidants such as oxygen, hydrogen peroxide and 
acetone [19-21].  
 
In a homogeneous catalytic system, the borrowing of hydrogen and hydrogen auto transfer 
reactions usually occur via the formation of a metal hydride intermediate to complete the catalytic cycle 
[22, 23]. In recent years the hydrogen gas evolved alcohol dehydrogenation process has generated great 
interest from the view point of atom economy [22, 23]. There are different homogeneous catalytic 
systems which effectively dehydrogenate primary alcohols to their respective aldehydes, which include 
metals such as iridium, rhodium and ruthenium [24-26]. As per existing literature, many of the complexes 
were reported with high catalyst loading and using oxidizing agents for oxidation of alcohols under harsh 
reaction conditions. In this study we compared the catalytic activity of iridium, rhodium and ruthenium 
complexes containing N,N' functional bidentate N-(pyridin-2-ylmethylene)aniline ligand over oxidation 
of alcohols without oxidizing agents under mild reaction conditions using inexpensive bases such as 
Cs2CO3, K2CO3, Na2CO3 and NaHCO3. We also report a DFT modelling study of the complexes, HOMO-
LUMO energy differences and reactivity. 
2.2    Experimental section 
2.2.1 Methods and analysis 
 Unless otherwise noted, all manipulations were performed using standard Schlenk tube 
techniques under argon atmosphere. The reagents and solvents were purchased from Sigma-Aldrich, 
Fluka and Merck and used without further purification. The solvents were dried by standard procedures 
and distilled prior to use. Gas chromatography (GC) analysis was performed using a Perkin-Elmer Clarus 
500 GC with a HP-Pona-50m*0.2mm, 0.5µ capillary column. The NMR solvent DMSO-d6 was 
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purchased from Merck Germany. 
1
H NMR (400 MHz) and
 13
C (100 MHz) NMR were recorded in 
DMSO-d6 solvent systems using a Bruker Topspin 400 spectrometer. Solid and liquid state infrared 
spectra were recorded using an FT-IR Perkin Elmer Spectrum 100 spectrophotometer between 4000 - 400 
cm
-1
. Elemental analyses were performed on a Thermo-Scientific Flash 2000 CHNS/O analyser. 
 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data collection was 
carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream cooling system (Oxford 
Cryostat). Cell refinement and data reduction were performed using the program SAINT [27]. The data 
were scaled and absorption corrections performed using SADABS. The structure was solved by direct 
methods using SHELXS-97 and refined by full-matrix least-squares methods based on F
2
 using 
SHELXL-97 [28]. For the structures and graphics, ORTEP-3 [29] and DIAMOND [30] programs were 
used. The crystals of all the metal complexes were obtained by slow evaporation of a mixture of hexane 
and acetonitrile at ambient temperature. The electronic absorption spectroscopy (UV-Vis) studies were 
recorded using a Perkin Elmer precisely Lambda35 instrument. The TGA-DSC analyses were performed 
using a Thermal Analyser SDT Q600 instrument and a heating rate of 10 °C.min
-1
 and nitrogen flow of 
100 mL.min
-1
. The metal precursors (IrCl2Cp*)2, (RhCl2Cp*)2 and (RuCl2C6H6)2 were prepared according 
to the literature methods [31-33]. 
2.2.2 Synthesis and characterization of complexes 1a-3a. 
A mixture of (MCl2Cp
*
)2 (M = Ir / Rh) (0.13 / 0.16 mmol), the Schiff base imine ligand L (0.26 / 0.32 
mmol) and NH4PF6 (0.26 / 0.32 mmol) was stirred at room temperature in methanol (15 mL) for 2 hours. 
The yellow precipitate was separated out and filtered off through filter paper, washed with cold methanol 





(IrCl2Cp*)2 (100 mg), the Schiff base imine ligand (46 mg) and NH4PF6 (41 mg). Yield (140mg, 0.21 
mmol, 70 %). Mp. 270.0 °C (dec). 
1
H NMR (400 MHz, DMSO-d6, 25 °C, ppm) δ = 9.38 (s, 1H, imine 
CH), 9.05 (d, 1H, JH-H = 5.40 Hz, α proton of Py), 8.45 (d, 1H, JH-H = 7.52 Hz Py), 8.32 (m, 1H, Py), 7.95 
(m, 1H, Py), 7.68 (d, 2H, JH-H = 7.60 Hz, ph), 7.61 (t, J = 7.45 Hz, 2H, ph), 7.52 (t, J = 7.24 Hz, 1H, ph), 
1.43 (s, 15H, C5Me5) 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ = 169.12 (imine C-H), 155.33 (Py), 
152.26 (Py), 148.69 (Py), 140.52 (Py), 130.47 (ph), 130.01 (ph), 129.54 (ph), 129.33 (Ph), 122.45 (ph), 
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89.69 (C, C5Me5), 7.98 (CH3, C5Me5). FT-I  (γ/cm
-1
): 1615 (s, C=N), 830 (s, P-F). MS (ESI
+
): m/z 545.20 
(M-PF6)
+





(RhCl2Cp*)2 (100 mg), the Schiff base imine ligand (59 mg) and NH4PF6 (53 mg). Yield (132 mg, 0.22 
mmol, 68%). Mp. 275.0 °C (dec). 
1
H NMR (400 MHz, DMSO-d6, 25
 
°C, ppm) δ = 9.07 (s, 1H, imine 
CH), 8.96 (d, 1H, JH-H = 2.48 Hz, Py), 8.37 (m, 1H, Py), 8.31 (d, 1H, JH-H = 6.92 Hz, Py), 7.97 (m, 1H, 
Py), 7.72 (d, 2H, JH-H = 7.56 Hz, Ph), 7.64 (t, 2H, J = 8.00 Hz, Ph), 7.54 (t, 1H, J = 7.36 Hz, Ph), 1.43 (s, 
15H, C5Me5). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ = 167.78 (imine C-H), 153.74 (Py), 152.76 
(Py), 148.35 (Py), 140.48 (Py), 129.94 (ph), 129.87 (Ph), 129.48 (ph), 129.35 (ph), 122.38 (ph), 97.11 - 
97.03 (C, C5Me5), 8.23 (CH3, C5Me5). FT-I  (γ/cm
-1
): 1595 (s, C=N), 830 (s, P-F). MS (ESI
+
): m/z 455.10 
(M-PF6)
+





To a suspension (RuCl2C6H6)2 (100mg, 0.15 mmol), and the Schiff base ligand 1a (58mg, 0.32 mmol) 
was dissolved and stirred at room temperature in acetonitrile solvent (10ml) for 1 hour. The mixture was 
evaporated and dryness, the residue was treated with NH4PF6 (52mg, 0.32 mmol) in ethanol (10ml) one 
hour. The yellow color solid of 3a (140mg, 0.26 mmole, 83%) was separated out and filtered through 
filter paper, washed with diethyl ether and dried in vacuum. Mp. 232.0°C (dec). 
1
H NMR (400 MHz, 
DMSO-d6, 25 °C, δ) 9.67 (d, 1H, JH-H = 5.4 Hz, α proton of Py) 8.91 (s, 1H, imine CH), 8.31 - 8.27 (m, 
2H, Py), 7.88 (m, 1H, Py), 7.82 (d, 2H, JH-H = 7.48 Hz, ph), 7.65 – 7.58 (m, 3H, ph), 5.95 (s, 6H, C6H6). 
13
C NMR (100 MHz, DMSO-d6, 25°C, δ) 168.01 (imine C-H), 156.22 (Py), 154.64 (Py), 151.77 (Py), 
140.04 (Py), 129.95 (ph), 129.65 (ph), 129.45 (Ph), 128.73 (ph), 128.28 (ph), 122.38 (Ph), 87.20 (C, 
C6H6). FT-IR (γ/cm
-1
): 1591 (s, C=N), 824 (s, P-F). MS (ESI
+
): m/z 397.0 (M-PF6)
+
. Anal. Calcd. for 
C22H25ClF6N2PRu: C, 39.90; H, 2.98; N, 5.17; Found: C, 39.97; H, 2.95; N, 5.00. 
2.2.3 DFT calculations 
All the calculations were performed using the Guassian 09 program package [34]. The structural 
and energetic results calculated using M05-2X were more consistent with the experimental observations 
[35]. The hybrid exchange-correlation functional M05-2X, developed by Zhao and Truhlar [36, 37], have 
been shown to describe weak bonding interaction better than the other density functionals such as M06 
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classes, M05, B3LYP, and PBE functional. So, all the complex structures were optimized at M05-2X 
level of theory using the LANL2DZ basis set. Frequency calculation was carried out at the same level of 
theory and to characterize the structures to be the minima or transition states. The one imaginary 
frequencies confirmed that (A)TS1 transition state had stable minima. The HOMO and LUMO energy gap 
was calculated from the DFT method. The frontier molecular orbital plot was drawn using the chemcraft 
program package (http://www.chemcraftprog.com). Using Gaussian NBO (ver. 3.1), natural population 
analysis (NPA) and natural bond orbital (NBO) analysis has been performed to investigate the change in 
electron density from proton donor to proton acceptor for optimized metal complexes at the M05-
2X/LANL2DZ level of theory. Second order perturbation energy (E
(2)
) was used to estimate the 
magnitude of electron delocalization [38]. 
2.2.4 General procedure for the oxidation of benzyl alcohol 
Benzyl alcohol (1 mmol), catalyst (2 mol%), base (5 mol%) and solvent (20 mmol) were placed 
in a Schlenk tube under argon or nitrogen atmosphere. The mixture was stirred magnetically under reflux 
over the specified time. The yield of the benzaldehyde was determined by GC analysis using 
chlorobenzene as an internal standard. 
2.2.5 Procedure for the oxidation of benzyl alcohol derivatives catalysed by complexes 1a 
and 3a 
The benzyl alcohol derivatives (1 mmol), catalyst 1a or 3a (2 mol%), base (5 mol%) and toluene 
or p-xylene (20 mmol) were added to a Schlenk tube under argon or nitrogen atmosphere. The mixture 
was stirred magnetically at reflux temperature. The yields of the products were analyzed by GC 
chromatography using chlorobenzene as an internal standard. 
2.3     Results and discussion 
2.3.1 Synthesis of ligand and metal complexes  
 The N,N' bidentate ligand precursor N-(pyridin-2-ylmethylene)aniline and metal complexes of 
iridium, rhodium and ruthenium were synthesised according to methods discussed elsewhere [39-41]. The 
structure and purity of the synthesized metal complexes, along with the ligands were confirmed by single 
crystal XRD, NMR, IR and electronic absorption spectral studies. The thermal stability of the prepared 




Fig. 2.1 The metal complexes of Ir(III) (1a), Rh(III) (2a) and  Ru(II) (3a). 
2.3.2 X –Ray crystallography  
 The crystallographic data of complexes 1a-3a are given in Table 2.1. The ORTEP view of the 
metal complexes iridium (1a), rhodium (2a) and ruthenium (3a) are shown in Figs. 2.2-2.4. In complexes 
1a and 2a, the iridium and rhodium metal centers are coordinated via the nitrogen atoms of the ligand, 
five carbon atoms of the Cp* moiety and a Cl. In complex (3a), the ruthenium metal is coordinated via 
the nitrogen atoms of the ligand, η
6
 coordination to the benzene ring and to chloride. This gives pseudo-
octahedral half sandwich “piano-stool” structures around the iridium, rhodium and ruthenium metal 
centers in the complexes [41]. The Cp*/arene moieties of complexes 1a, 2a and 3a occupy the triangular 
face of an octahedron. The N1, N2 nitrogen atoms form a five membered chelate ring with the metal 
center. A chloride completes the coordination sphere. The M-Cl bond length in complexes 1a-3a are 
2.400(10) Å, 2.393(8) Å and 2.393(10) Å, respectively. These values are consistent with related reported 










[41]. The M-C (Cp*/arene) bond lengths in the complexes are 2.153(3) - 2.205(3) Å (1a), 2.136(3) - 
2.192(3) Å (2a) and 2.171(4) - 2.192(4) Å (3a), respectively. Non-covalent interactions of C-H···F and C-
H···Cl bonds in the complexes of 1a, 2a and 3a are observed. In the crystal structure of complexes 1a-3a 
C-H···Cl and C-H···F non-covalent intra and intermolecular interactions are seen (Figs. 2.5-2.7). In all 
three complexes, the counter ion PF6 is involved in C-H···F non-covalent inter-molecular interactions. 
The P-F···π intermolecular interaction is observed in complexes 1a and 3a and C-H···π intermolecule 






Table 2.1 Crystallographic data and summary of structural refinement of the metal complexes 1a, 2a and 
3a 
























Goodness-of-fit on F2 
Final   indexes [I>=2σ (I)] 
Final R indexes [all data] 


















0.16 × 0.14 × 0.12 
3.96 to 57.26° 
81251 
6006[R(int) = 0.0495] 
6006/0/303 
1.034 
R1 = 0.0225, wR2 = 0.0458 



















0.18 × 0.14 × 0.11 
7.34 to 54.92° 
94755 
5403[R(int) = 0.0806] 
5403/0/303 
1.072 
R1 = 0.0344, wR2 = 0.0692 



















0.16 × 0.12 × 0.11 
7.22 to 55.76° 
94614 
4716[R(int) = 0.0847] 
4716/0/262 
1.132 
R1 = 0.0450, wR2 = 0.0960 













Table 2.2 C-H···X intermolecular interactions in complexes 1a-3a 
C-H···X D-H H···A D···A D-H···A 
Complex 1 
C(8)-H(8a) ···F(4) 0.98 2.54 3.502(4) 167 
C(10)-H(10C) ···F(1) 0.98 2.44 3.332(5) 151 
C(11)-H(11) ···F(2) 0.95 2.35 3.093(5) 135 
C(13)-H(13)…Cl(1) 0.95 2.79 3.622(4) 146 
C(14)-H(14) ···F(5) 0.95 2.50 3.235(4) 134 
C(21)-H(21) ···F(2) 0.95 2.54 3.313(4) 138 
Complex 2 
C(10)-H(10A) ···F(6) 0.98 2.43 3.341(4) 154 
C(11)-H(11) ···F(5) 0.95 2.35 3.122(4) 137 
C(13)-H(13) ···Cl(1) 0.95 2.79 3.607(3) 145 
C(14)-H(14) ···F(2) 0.95 2.51 3.227(4) 132 
C(21)-H(21) ···F(5) 0.95 2.54 3.315(4) 139 
Complex 3 
C(4)-H(4) ···F(6) 0.95 2.35 3.295(6) 172 
C(17)-H(17) ···F(5) 0.95 2.48 3.374(6) 157 
 
Table 2.3 Y-X···π intermolecular interactions in complexes 1a-3a 
Y-X···Cg(Pi-Ring) X···Cg (Bond length (Å)) Y-X···Cg (Bond angles (°)) 
Complex 1 
P(1)-F(1) ···Cg(2) 3.111(3) 128.00(13) 
Complex 2 (C-H···Cg) 
C(7)-H(7B) ···Cg(3) 2.89 137 
Complex 3 
P(1)-F(5) ···Cg(1) 3.329(4) 129.22(18) 





Fig. 2.2 ORTEP diagram of the metal complex 1a with atom numbering scheme. Displacement ellipsoids 
are drawn at the 50% probability level and hydrogen atoms are omitted for clarity. 
 
Fig. 2.3 ORTEP diagram of the metal complex 2a with atom numbering scheme. Displacement ellipsoids 




Fig. 2.4 ORTEP diagram of the metal complex 3a with atom numbering scheme. Displacement ellipsoids 
are drawn at the 50% probability level and hydrogen atoms are omitted for clarity. 
 
 









Fig. 2.7 Non-covalent π···π and C-H···F interactions in the metal complex 3a. 
2.3.3 Electronic absorption spectroscopy 
The electronic absorption spectra of all the metal complexes were recorded by preparing a 10 µM 
(v/v DCM) solution. The resulting spectra of the metal complexes are depicted in the wavelength range 
between 200 nm to 600 nm (Fig. 2.8). The low energy bands of the metal complexes appeared at 382.92 
nm (1a), 369.77 nm (2a), 416.27 nm (3a) and the conjugated intra ligand based π-π* and metal ligand 
charge transfer (MLCT) transitions were observed in the region of 315.23 to 284.92 nm for (1a), 324.17 
to 274.82 nm for (2a) and 313.87 to 261.25 nm for (3a) [43]. 
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 Iridium complex         (1)  
 Rhodium complex     (2)
 Ruthenium complex  (3)
 
Fig. 2.8 UV-vis spectra of the metal complexes 1a, 2a and 3a (Dichloromethane, 10µM, v/v). 
2.3.4 TG-DSC studies 
TG curves of all complexes are shown in Figs. 2.9-2.10. In the TG curves, no degradation was 
observed until ~270º C, which indicates the high inherent stability of complexes 1a-3a. The calculated 
weight loss of the complexes at ~270 ºC was 2.28% (1a), 3.12% (2a) and 7.85% (3a) respectively. The 
DSC curves of exothermic peaks indicates the complexes undergoes phase transition (might be Chloride 
cleavge) on melting at 290 ºC (1a), 280 °C (2a) and 270 °C (3a) and the following exothermic peaks 
indicates possible phase transition during which the complexes are completely decomposed as metal 
oxides [44b]. The sharp exothermic peaks presented in the DSC curves (Fig. 2.10) further confirms the 
crystalline nature of the metal complexes [44].  
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  Iridium complex        (1a) 
  Rhodium complex     (2a)
  Ruthenium complex  (3a)
 
Fig. 2.9 TGA curves of the complexes 1a, 2a and 3a. Heating rate 10 °C min
-1
. 

























Temperature / ° C
 Iridium complex        (1a)
 Rhodium complex    (2a)
 Ruthenium complex (3a)
exo
 




2.3.5 Catalytic activity studies 
2.3.5.1 Oxidation of primary alcohols 
The oxidation of benzyl alcohol under reflux conditions was carried out with various bases and 
solvents using the three complexes of iridium (1a), rhodium (2a) and ruthenium (3a) (Table 2.4). No 
44 
 
benzyl alcohol conversion was achieved in the absence of catalysts 1a-3a. In the presence of catalysts 1a-
3a (1 mol% or 2 mol%) and bases (5 mol%) in toluene under reflux, benzyl alcohol to benzaldehyde 
conversion reached up to 90% (Table 2.4). In the presence of the catalyst 1a (2 mol%) and the bases (5 
mol%) Na2CO3, NaHCO3, K2CO3 and Cs2CO3, the yield of benzaldehyde reached 44%, 33%, 63% and 
89% respectively (Entries 3-6). In the presence of catalysts 2a (2 mol%) and 3a (2 mol%) with Na2CO3 as 
the base in toluene,  the benzaldehyde yield obtained was 49% and 44% respectively (Entries 9 and 15). 
For catalyst 3a with NaHCO3, the yield further increased to 58% (Entry 16). When catalysts 2a (2 mol%) 
and 3a (2 mol%) were refluxed with K2CO3 as the base in toluene, a 60% yield of the benzaldehyde was 
achieved in both systems (Entries 11 and 17). However, overall catalyst 1a with Cs2CO3 as base under 
reflux in toluene gave the best yield to benzaldehyde (89%) (Entry 6).  
 
When the reaction was carried out with different solvents, the benzaldehyde yield varied. In the 
presence of K2CO3 as base and p-xylene as a solvent, the maximum benzaldehyde yields of 29% and 56% 
were achieved over catalysts 1a and 2a respectively (Entries 19 and 22). In the presence of all three 
catalysts, the use of 1,4 dioxane and DMSO as solvents gave a lower yield of benzaldehyde. The yield of 
benzaldehyde obtained from all the reactions using different solvents and K2CO3 as base are summarized 
in the Table 2.4 (Entries 19-27). However, in the case of catalyst 3a, the yield of benzaldehyde was as 
high as 76% (Entry 25), likely due to the higher solubility of catalyst 3a in p-xylene than catalysts 1a and 
2a. 
 









1 1a None 24
b
 24 24 1 
2 1a None 39 39 20 1 
3 1a
 
Na2CO3 44 44 22 1 
4 1a
 
NaHCO3 34 33 17 1 
5 1a
 
K2CO3 64 63 32 1 
6 1a
 







 36 36 1 
8 2a
 
None 38 38 19 1 
9 2a
 
Na2CO3 52 49 26 1 
10 2a
 
NaHCO3 26 25 13 1 
11 2a
 
K2CO3 63 60 32 1 
12 2a
 
Cs2CO3 62 60 31 1 
13 3a None 16
b
 16 16 <1 
14 3a
 
None 26 26 13 1 
15 3a
 
Na2CO3 48 44 24 1 
16 3a
 
NaHCO3 60 58 30 1 
17 3a
 
K2CO3 63 60 32 1 
18 3a
 













































 37 20 1 
a 
Benzyl alcohol (1 mmol) and catalyst (2 mol%) in toluene (20 mmol) under reflux 48 hrs.  
b
 Benzyl alcohol (1 mmol) and catalyst (1 mol%) in toluene (20 mmol) under reflux 48 hrs.  
c
 Determined by GC (average of two runs). 
d 
p-xylene (20 mmol). 
e
 1,4 dioxane (20 mmol).    
f
 DMSO (20 mmol). Turnover number (TON) = [(mol of product)/(mol of catalyst)]. 









2.3.5.2 Effect of substituents on the oxidation of benzyl alcohol over the catalysts 1a and 3a  
Catalyst 1a showed good activity for oxidizing substituted benzyl alcohols in the presence of 
Cs2CO3 as base and toluene as solvent (Table 2.5). It is evident that substrates with groups present in the 
para position (Entries 2, 5, 7 and 8) were oxidized faster than those with steric ortho-substituted groups 
present in benzyl alcohol, in the presence of base [24, 44] (Entries 3 and 6). A bulky ortho substitution 
could cause a decrease in the benzyl alcohol oxidation rate [46] (Entries 2 and 5). On the other hand, 
bulky 3,4- and 2,5-OCH3 substituted benzyl alcohol also showed moderate conversion with catalyst 1a 
(Entries 9 - 11). In contrast, para dimethylaminobenzyl alcohol showed lower conversion due to the high 
electron donating ability of dimethylamino group on the aromatic ring (Entry 12). The electronic nature of 
the aromatic ring present in the substrate plays a big role in oxidation reactions [15]. The efficient 
catalytic activity of the iridium complex (1a) could be explained by the electronic effect of the ligand on 
the iridium metal. The N,N' ligand gives a greater donor strength than in the rhodium and ruthenium 
complexes [47]. The theoretical natural atomic populations study for the iridium complex coincides well 
with this statement (Section 3.6). Catalyst 1a showed 100% and 97% (Entries 2 and 8) conversion of 
electron rich and poor benzyl alcohols.  
The mesomeric effect is a permanent effect and operates in compounds containing at least one 
double bond and another double bond or a lone pair separated by a single bond. The mesomeric effect is a 
result of p-orbital overlap (resonance) and has absolutely no effect on this inductive effect, as the 
inductive effect purely deals with the electronegativity of the atoms. Hence, mesomeric effect might be 
influencing a phenyl ring rather than a reacting alcohol group. The strength of the inductive effect is also 
dependant on the distance between the substituent group and the main group that react, the greater the 
distance, the weaker the effect. Hence, para substituted alcohols have no effect by inductive effects 
(Entries 2, 5, 7 and 8). It may be possible to ortho substitute alcohols due to a short distance between 
substituent and the reacting alcohol group. The lower conversion of ortho substituted alcohols might be 






















1 R – H 90
b
 89 45 1 
2 R –4-NO2 100 98 50 2 
3 R –2-NO2 83
b
 80 42 1 
4 R –2-OH 100 95 50 2 
5 R –4-Cl 91 89 46 2 
6 R –2-Cl 80
b
 78 40 1 
7 R –4-CH3 90 89 45 2 
8 R –4-OCH3 97 96 49 2 
9 R –3,4 –OCH3 72
b
 70 36 1 
10 R –2,5 –OCH3 48
b
 46 24 1 
11 R –4-OH 3–OCH3 64 62 32 1 
12 R –4–N(CH3)2 33
b
 30 17 <1 
a 
Substrate (1 mmol) in toluene (20 mmol) under reflux 24 hrs. 
b 
Substrate (1 mmol) in toluene (20 mmol) 
under reflux 48 hrs. 
c
 Determined by GC (average of two runs). Turnover number (TON) = [(mol of 
product)/(mol of catalyst)]. Turnover frequency (TOF) = [TON/h]. 
Catalyst 3a showed up to 96% (Entry 4, Table 2.6) conversion in the oxidation of primary 
alcohols to their corresponding aldehydes using K2CO3 as base with p-xylene as the solvent (Table 2.6). 
In this catalytic system, the electron rich para substituted benzyl alcohols (Entries 7, 8 and 11) oxidized 
better than electron poor para substituted benzyl alcohols (Entries 2 and 5). The bulky groups present in 
the ortho position of benzyl alcohol caused lower conversion of these substituted benzyl alcohols (Entries 
3, 6 and 10). A plausible coordination site for the substrate is the electronically unsaturated ruthenium 
center, which is generated after liberation of the labile chloride atom. The base K2CO3 is expected to 
promote the formation of the metal-alkoxide species, which could then undergo β-hydride elimination to 
form a ruthenium-hydride complex [48, 49]. A faster oxidation rate of the ortho-hydroxy benzyl alcohol 
48 
 
to the corresponding aldehyde in both catalytic systems 1a and 3a was observed (Entry 4, Table 2.5 and 
Entry 4, Table 2.6).  











1 R –H 78
b
 76 39 1 
2 R –4-NO2 45
b
 44 23 <1 
3 R –2-NO2 40
b
 37 20 <1 
4 R –2-OH 96 92 48 2 
5 R –4-Cl 65
b
 63 33 1 
6 R –2-Cl 50
b
 47 25 1 
7 R –4-CH3 77 76 39 2 
8 R –4-OCH3 85 84 43 2 
9 R –3,4–OCH3 68
b
 64 34 1 
10 R –2,5-OCH3 51
b
 48 26 1 
11 R –4-OH 3–OCH3 91 90 46 2 
12 R –4–N(CH3)2 no reaction
b
 - - - 
a 
Substrate (1 mmol) in p-xylene (20 mmol) under reflux for 24 hrs. 
b 
Substrate (1 mmol) in p-xylene (20 
mmol) under reflux for 48 hrs. 
c
 Determined by GC (average of two runs). Turnover number (TON) = 
[(mol of product)/(mol of catalyst)]. Turnover frequency (TOF) = [TON/h]. 
2.3.5.3 Proposed catalytic reaction mechanism for oxidation of primary alcohols 
A proposed reaction mechanism (supported by theoretical calculations, Section 3.6) for the 
oxidation of primary alcohols by catalysts 1a-3a is illustrated in Scheme 2.1. The first step of this reaction 
cycle is the generation of the metal benzyloxo species (A) from the base. In the second step, the β-hydride 
elimination occurs to form the dehydrogenated product of benzaldehyde and a metal hydride (B) 
complex. In step 3, the metal hydride (B) intermediate promotes a protonolysis to form the metal complex 
(C) intermediate, followed by dihydrogen release from the metal complex (C) intermediate to form the 
16e
-
 species (D) in step 4. The key steps of this catalytic cycle is the generation of the metal hydride 
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intermediate in step 2. A similar kind of iridium hydride intermediate has been characterized and reported 
by Fujita et al. [46].  
 
Scheme 2.1 Proposed reaction mechanism of the oxidation of primary alcohols by catalysts 1a-3a. 
2.3.6 Density Functional Theory (DFT) Calculations 
DFT calculations were carried out to understand structural properties, such as type of molecular 
energy levels, bond lengths, bond angles and the binding nature of the metal complexes. A Gibbs free 
energy calculation on the rhodium catalytic cycle was carried out to support the proposed mechanism 
given in Scheme 2.1. The energy difference between the HOMO (highest occupied molecular orbitals) 
and the LUMO (lowest unoccupied molecular orbitals) orbitals is called the energy gap, which is 
important to understand the stability of the structures of the metal complexes. The analysis of the orbitals 
indicates that the electron absorption corresponds to the transition state from the ground state to the first 
excited state, which mainly describes the one electron excitation from the HOMO to the LUMO, which is 
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correlated to the energy gap and the chemical reactivity. A larger energy gap between HOMO and LUMO 
indicates good stability of the structure and lower reactivity, and a smaller energy gap difference implies 
higher reactivity of the complexes [50] (Figs. 2.11 and 2.13).   
 
The HOMO is highly concentrated over the metal centers, benzene or the Cp* ring, but with a 
small contribution from the Cl atom. Consequently, the LUMO is localized over the N1 and N2 atoms. 
The HOMO is constituted of a π-orbital in the Cp* ring or benzene. The LUMO is dominated by the π* 
orbital of the pyridine ring. This suggests that the higher value of the HOMO of a d orbital of the metal 
has a tendency to donate electrons to the p orbital of the N1, N2 acceptor atoms. Calculated bond lengths 
and bond angles are given in the Table 2.7. The experimentally obtained results of bond distances and 
bond angles are close to the theoretical values, except for the angle C(5)-Ir(1)-Cl(1). The lone pair 
electrons of the Cl coordinated with the iridium center are placed closer to the N1 and N2 atoms, as 
compared to the rhodium (2a) and ruthenium (3a) complexes, which causes repulsion between Cl and the 
nitrogen atoms. Thus, the DFT method could not predict the C(5)-Ir(1)-Cl(1) bond angle accurately, due 
to the presence of the lone pair electrons of the Cl [52]. 
 
The calculated energy gaps from HOMO-LUMO for the iridium complex (1a), rhodium complex 
(2a) and ruthenium complex (3a) were 120.59 kcal/mol, 130.67 kcal/mol and 124.49 kcal/mol 
respectively. The higher energy gap of the rhodium complex (2a) indicates that it is more stable and less 
reactive when compared to the iridium and ruthenium complexes. Lowest vibrational frequency 
calculations have been carried out to predict the minimum energy structure with the lowest vibrational 
frequency for the Ir(III) complex (17.731 cm
-1
), the Rh(III) complex (30.332 cm
-1
) and the Ru(II) 
complex (3.797 cm
-1
) and this is shown in the SI S2.  
 
NPA analysis describes the charge transfer from chloride or nitrogen atoms to the metal (Ir(III), 
Rh(III) and Ru(II)) ions, which plays a pivotal role in determining metal complex properties (Fig. 2.12). 
The atomic charges of each atom in the complexes collected from NPA are presented in the SI S3, the 
metal ions gain charges of 2.79e (Ir(III)), 2.73e (Rh(III)) and 1.94e (Ru(II)) in the metal complexes. The 
positive charge of the metal ions decreases significantly in all the complexes and especially the iridium 
metal ion strongly co-ordinated with neighboring atoms. The bidentate ligand N,N' donor electron 
strength on the iridium (N1 = -0.441 & N2 = -0.405) is higher than on rhodium and ruthenium and this 
would account for the iridium complex being more reactive than the other complexes. On the complexes 
1a-3a, the chloride group transfers higher charges of 0.66e to the Ru(II) metal ion when compared with 
lesser charge transfer from chloride (0.59e) to the Rh(III) and 0.61e to the Ir(III) metal ion (S5, Table 
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2.3). The electron densities of the Cl group attached to the iridium (0.212) and ruthenium (0.057) are less 
than that of the Cl group attached to the rhodium (0.273). These electron density values confirm that the 
Rh-Cl (2) bond is stronger and this would account for it being a less reactive complex compared to the 
latter two complexes [51].  
 
The proposed reaction mechanism for the complexes is given in Scheme 2.1. The iridium 
benzyloxo (A) complex has a higher energy gap (116.59 kcal/mol) than the iridium hydride (B) complex 
(106.83 kcal/mol), which indicates that A is more stable (less reactive) than complex B. A similar iridium 
hydride (B) complex has been studied and reported as being a highly active species by Fujita et al. [46] 
and its frontier orbital diagram is shown in Fig. 2.13. 
 
Gibbs free energy calculations of the rhodium catalytic cycle, thus support the proposed 
mechanism (Scheme 2.1). The result of the Gibbs free-energy      DFT calculation for the reaction 
mechanism of catalyst 2a is shown in Fig. 2.14. Gibbs free-energy      profile calculations rationalize 
the stability and reactivity of various transformations of catalyst 2a as per the proposed mechanism. In the 
reaction mechanism, the Rh-H step was processed via β-hydride elimination with a high activation free 
energy barrier of 21.41 kcal/mol. The calculated activation free energy barrier of the Rh-H intermediate 
(B) was lower (-8.50 kcal/mol) than the corresponding Rh-benzyloxo (A) species, which correlates to the 
rate-determining step of the proposed reaction cycle. The Rh-H intermediate is the thermodynamically 
more favored stable state in the proposed reaction mechanism. The calculated Gibbs free energy barrier 
for the Rh-H species (-8.50 kcal/mol) was in good agreement with a reported value for a similar species 
[52]. The calculated activation free energy barrier of the 16e
- 
Rh complex D was higher (31.85 kcal/mol) 
than the respective Rh complex C (20.34 kcal/mol), which indicates that the proposed reaction 
mechanism is more favorable through the C transition state than the D 16e
-
 Rh complex D. The calculated 
Gibbs free energy values of the reaction intermediates fall in the following order: A > B (Stable state) < C 
< D, which confirms that the calculated low activation free energy transition intermediates (Rh-H species) 
can facilitate the oxidation of aromatic benzyl alcohols to their respective aldehydes. The Gibbs free-
energy profile      and the structures of the optimized rhodium catalytic cycle transition states are given 





Fig. 2.11 Molecular orbital diagrams of the metal complexes 1a, 2a and 3a. 
 





























DFT Complex 2a 
Crystal 
data 










Ir(1) – C1 (Cp*) 2.174(3) 2.229 Rh(1) – C1 (Cp*) 2.157(3) 2.267 Ru(1) – C1 (arene) 2.192(4) 2.42 
Ir(1) – C2 (Cp*) 2.204(3) 2.265 Rh(1) – C2 (Cp*) 2.192(3) 2.286 Ru(1) – C2 (arene) 2.192(4) 2.405 
Ir(1) – C3 (Cp*) 2.205(3) 2.233 Rh(1) – C3 (Cp*) 2.192(3) 2.271 Ru(1) – C3 (arene) 2.185(4) 2.387 
Ir(1) – C4 (Cp*) 2.153(3) 2.256 Rh(1) – C4 (Cp*) 2.136(3) 2.224 Ru(1) – C4 (arene) 2.192(4) 2.393 
Ir(1) – C5 (Cp*) 2.171(3) 2.268 Rh(1) – C5 (Cp*) 2.157(3) 2.275 Ru(1) – C5 (arene) 2.171(4) 2.374 
Ir(1) – Centroid 
(Cp*) 
1.803 1.858 
Rh(1) – Centroid 
(Cp*) 
1.789 1.970 Ru(1) – C6 (arene) 2.192(4) 2.388 
Ir(1) – Cl(1) 2.400(10) 2.468 Rh(1) – Cl(1) 2.393(8) 2.439 
Ru(1) – Centroid 
(arene) 
1.681 1.766 
Ir(1) – N(1) 2.096(3) 2.077 Rh(1) – N(1) 2.106(2) 2.064 Ru(1) – Cl(1) 2.393(10) 2.426 
Ir(1) – N(2) 2.106(2) 2.059 Rh(1) – N(2) 2.119(2) 2.085 Ru(1) – N(1) 2.093(3) 2.063 
      







N(1)-Ir(1)-Cl(1) 84.76(7) 84.251 N(1)-Rh(1)-Cl(1) 85.88(7) 86.533 N(1)-Ru(1)-Cl(1) 86.34(9) 83.31 
N(2)-Ir(1)-Cl(1) 86.67(8) 86.710 N(2)-Rh(1)-Cl(1) 87.74(6) 91.300 N(2)-Ru(1)-Cl(1) 86.12(9) 86.807 
N(1)-Ir(1)-N(2) 76.21(10) 77.117 N(1)-Rh(1)-N(2) 76.58(9) 77.932 N(1)-Ru(1)-N(2) 76.99(12) 78.165 
C(1)-Ir(1)-Cl(1) 155.43(9) 156.906 C(1)-Rh(1)-Cl(1) 155.14(8) 153.452 C(1)-Ru(1)-Cl(1) 123.09(14) 120.139 
C(2)-Ir(1)-Cl(1) 116.77(9) 122.115 C(2)-Rh(1)-Cl(1) 116.74(8) 117.742 C(2)-Ru(1)-Cl(1) 94.29(13) 93.505 
C(3)-Ir(1)-Cl(1) 93.29(8) 93.316 C(3)-Rh(1)-Cl(1) 92.76(8) 91.904 C(3)-Ru(1)-Cl(1) 89.23(14) 90.532 
C(4)-Ir(1)-Cl(1) 103.85(9) 97.505 C(4)-Rh(1)-Cl(1) 103.32(8) 100.223 C(4)-Ru(1)-Cl(1) 112.12(16) 113.687 






125.68 124.258 C(6)-Ru(1)-Cl(1) 160.77(13) 154.42 






2.4  Conclusions 
 In summary, the catalytic activity of half sandwich Ir(III), Rh(III) and Ru(II) complexes in the 
oxidation of primary aromatic alcohols to their respective aldehydes was demonstrated. It is clear that the 
Ir(III) complex in the presence of Cs2CO3 and the Ru(II) complex in the presence of K2CO3 improved the 
oxidation of benzyl alcohol significantly. In the proposed reaction mechanism, the iridium-hydride 
intermediate was more reactive than iridium-benzyloxo species, which is supported by HOMO and 
LUMO energy gap differences. DFT calculation of selected bond lengths and angles essentially matched 
the obtained crystal data. Furthermore, the calculated electron density of the metal complexes and the 
calculated energy differences between the HOMO and LUMO coincide with the observed reactivity of the 
Ir(III) and Ru(II) complexes. The HOMO and LUMO energy gap difference of complex 1a is lower than 
those of 2a and 3a, which indicates the following order of reactivity: 1a > 3a > 2a. Gibbs free energy 
calculations for Rh(III) catalytic cycle further confirmed the proposed reaction mechanism processed via 
a Rh-H intermediate.  
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Appendix A. Supplementary Information 
The vibrational free energy, HOMO-LUMO calculations and NBO analysis for complexes 1a-3a, iridium 
reaction intermediate and rhodium catalytic cycle Gibbs free energy calculations are also shown in the SI. 
CCDC-1020802 (1a), CCDC-1020803 (2a), and CCDC-1020804 (3a) contain the supplementary 
crystallographic data for this paper. These data can be obtained free of charge from the Cambridge 
crystallographic data center via www.ccdc.cam.ac.uk/data_request/cif. 
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Synthesis and structural investigation of new half sandwich Ir(III) and 
Rh(III) amine complexes and their catalytic transfer hydrogenation of 




Six new complexes, [Cp*IrCl(para-R-N-(pyridin-2-ylmethyl)aniline)]PF6 (R = H (1b); F (2b); OCH3 
(3b)), and [Cp*RhCl(para-R-N-(pyridin-2-ylmethyl)aniline)]PF6 (R = H (4b); F (5b); OCH3 (6b)), 
(where Cp* = pentamethylcyclopentadiene) have been synthesized. The synthesized complexes were 
characterized by 
1
H NMR, 2D NMR, 
13
C NMR, HR-MS spectroscopy, IR spectroscopy and elemental 
analysis. 
1
H NMR studies revealed that the N,N' amine bidentate ligands coordinated to the Ir(III) and 
Rh(III) metals ions and complexes 1b-6b exhibit diastereoisomerism in DMSO-d6 solution at room 
temperature. Time dependent 
1
H NMR studies show that the Ir(III) amine complexes 1b-3b are oxidized 
to imine complexes by molecular oxygen, due to the highly acidic hydrogen bonded to the nitrogen atom. 
The crystal structures of the [Cp*IrCl(N-(pyridin-2-ylmethyl)aniline)]PF6 (1b) and [Cp*RhCl(para-
OCH3-N-(pyridin-2-ylmethyl)aniline)]PF6 (6b) complexes have been resolved by single crystal X-ray 
diffraction. The Ir(III) and Rh(III) amine complexes were used in catalytic transfer hydrogenation 
reaction. The Rh(III) catalyst loadings used to reduce the aromatic ketones and aromatic aldehydes were 
0.5 and 0.1 mol%, respectively. The Rh(III) amine and imine complexes were found to be versatile and 
particularly effective for the catalytic transfer hydrogenation of aromatic carbonyl groups in water with 
sodium formate and formic acid as the hydrogen source under pH dependent acidic conditions.  
 
Keywords: Half sandwich complexes; Transfer hydrogenation; N,N' chiral ligands; Ir(III), Rh(III) amine 
complexes; sodium formate / formic acid. 
 
3.1 Introduction 
Transfer hydrogenation (TH) of carbonyl groups using organometallic compounds is an emerging 
field in transition metal chemistry as well as in industry [1]. Using an aqueous medium for TH reactions 
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is of great interest in chemistry due to water having important advantages over conventional organic 
solvents [2, 3]. Water is readily available, inexpensive, non-toxic, non-carcinogenic, non-flammable and 
easy to handle.  
 
Conventional TH reactions require neither explosive hydrogen gas nor high pressure vessels for 
reducing carbonyl groups. Generally, isopropyl alcohol is used as a hydrogen source for reducing 
carbonyl groups in catalytic TH reactions [4]. The reversibility of the reaction equilibrium using isopropyl 
alcohol as a solvent is a major drawback in this system. To overcome the drawbacks, alternative hydrogen 
sources such as HCOOH-HCOONa mixtures, formic acid-Et3N azeotropic mixtures, and HCOONa were 
used in aqueous TH reactions [5-7]. Recently, in a number of examples reported, glycerol has replaced 
isopropyl alcohol as a hydrogen source for aqueous TH reactions using Ir(III), Rh(III) and Ru(II) metal 
complexes[8, 9]. The advantage of the HCOOH / HCOONa mixture is that it acts as both hydrogen 
source and base in the aqueous reaction medium. A HCOOH / HCOONa mixture is a better hydrogen 
source compared to isopropyl alcohol due to the resulting CO2 being thermodynamically more stable and 
easily removed from system, which results in the reactions becoming irreversible. Moreover, it offers 
wide range of the substrates solubility in acidic medium and miscibility with many organic solvents in the 
range of 20-60 ºC [10]. This process is an example of an environmentally benign process for TH 
applications.  
 
Noyori, Ikariya and co-workers have reported many of the metal-ligand bifunctional ruthenium 
catalysts that reduce organic carbonyl compounds under aqueous reaction conditions [11-14]. Indeed, the 
majority of catalytic TH reactions reported used ruthenium species rather than iridium or rhodium species 
[10, 15-18]. Recently, Talwar et al. explored iridium cyclometalated compounds for transfer 
hydrogenative reductive amination using ammonium formate both as a nitrogen and hydrogen source 
[19]. Yadav et al. have reported an effective and versatile N,N' dipyrrin ligand coordinated to Ir(III) and 
Rh(III) half sandwich catalysts for aqueous catalytic TH reactions [20]. There are very few reported 
rhodium complexes with coordinated N,N' chelated ligands for homogeneous or heterogeneous catalytic 
TH reactions carried out in aqueous medium [8, 21-23].  
 
Using half sandwich complexes of iridium, rhodium and ruthenium for TH reactions can give 
high selective reactivity of one functional (carbonyl) group in the presence of others in organic 
compounds and can show a broad range of the substrate scope in the aqueous medium [24]. A β-protic 
pyrazole containing metal-ligand bifunctional iridium catalysts was reported by Kuwata and Ikariya [25], 
in which the labile N-H proton at the β-position to the metal may be activated to give a potential and more 
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accessible β-protic bifunctional catalyst [25]. Several pyridinebisimidazolines coordinated ruthenium, 
iridium and rhodium catalysts have been reported, where the effect of the N-H groups on 
enantioselectivity of products as well as their effects on TH reactions was reported [4, 26, 27]. The nature 




 and the lability and hemilability of the nitrogen donor atom is defined by 
the electronic nature of the substituent groups present on nitrogen.  
 
The chiral ligands present in the catalysts may undergo easy association or dissociation during the 
reaction conditions, which may influence the selectivity of the reaction, but it is controlled by metal 
stereochemistry [28]. This statement is strongly supported when the metal is an additional center of 
chirality in the ligand-associated form [29]. For the TH reactions mainly, N-H bond bearing N,N' 
bidentate ligands were used and they control the TH reaction mechanism according to Noyori’s proposal 
[10]. The pH dependence of TH reactions catalyzed by iridium and ruthenium complexes was reported by 
Ogo et al. [30, 31]. Recently Wei et al. reported cyclometalated Ir(III) complexes for TH of carbonyl 
groups under pH controlled reactions conditions [5]. To the best of our knowledge, only a few 
homogeneous and heterogeneous rhodium catalyzed TH reactions in water have been reported in 
literature [8, 21, 32].  
 
In this chapter, we report the synthesis and characterization of new amine Ir(III) and Rh(III) half 
sandwich complexes with a chiral metal center coordinated to N,N' chelated ligands. The highly acidic N-
H bond in the ligand allows oxidation from the amine to the imine in the iridium complexes. The labile 
N-H bond is present on the β position with respect to the metal. The coordination nature and 
stereochemistry of the complexes were studied by single crystal XRD, 
1
H NMR and 1D NOE studies. 
Their catalytic TH was carried out in pH dependent aqueous medium using a HCOOH / HCOONa 
mixture as a hydrogen donor.  
3.2 Experimental section 
3.2.1 Reagents and Methods 
Unless otherwise noted, all manipulations were performed using standard Schlenk tube 
techniques under an argon atmosphere. The reagents 2-pyridinecarboxaldehdye, IrCl3·3H2O (≥99% 
purity), RhCl3·3H2O (≥99% purity), KOH pellets and solvents were purchased from Sigma-Aldrich, 
Capital Labs, South Africa and were used without further purification. HCOONa and HCOOH (85 wt%) 
were purchased from Fluka chemicals. The solvents were dried by standard procedures and distilled prior 
to use [33]. Melting points were recorded on a Stuart
TM
 Scientific apparatus SMP 3 and are uncorrected. 
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The NMR solvent DMSO-d6 was purchased from Merck, Germany. Solid and liquid state infrared spectra 
were recorded using an FT-IR Perkin Elmer Spectrum 100 spectrophotometer between 4000 - 400 cm
-1
. 
Low and high resolution mass spectra were recorded using a Waters Micromass LCT Premier TOF-MS 
instrument. Optical rotations were measured using an ADP410 Polarimeter that operated at  = 589.3 nm, 
which corresponds to the LED / interference filter and at ambient temperature. Elemental analyses were 
performed on a Thermo-Scientific Flash 2000 CHNS/O analyser. Gas chromatography (GC) analysis was 
performed using a Perkin-Elmer Clarus 500 GC with a HP-Pona-50 m*0.2 mm, 0.5µ capillary column. 
pH measurements of a HCOOH / HCOONa mixture was carried out using a pH 211 microprocessor pH 




H NMR (400 MHz) stability studies and
 13
C (100 MHz) and 2D NMR were 
recorded in DMSO-d6 solvent systems using a Bruker Topspin 400 spectrometer. The variant temperature
 
1
H NMR (600 MHz) and 1D NOE studies were performed by a Bruker Topspin 600 spectrometer using 
TXLZ/AV 600 probe. X-ray single crystal intensity data were collected on a Bruker Smart APEX11 
Nonius Kappa-CCD diffractometer using graphite monochromated MoK radiation ( = 0.71073 Å). The 
precursors (IrCl2Cp*)2 and (RhCl2Cp*)2 were prepared according to literature methods [34-36]. Iridium 
complexes 1b-3b were completely oxidized to imine complexes during the synthesis of the amine 
complexes in room temperature by molecular oxygen [37]. The oxidized imine Ir(III) (1a) and Rh(III) 
(2a) complexes were synthesized [38], in order to compare the catalytic activity of the amine and imine 
complexes for catalytic TH reactions. 
3.2.2 Synthesis and characterization of complexes 1b-6b 
A mixture of (MCl2Cp
*
)2 (M = Ir / Rh) (0.13 / 0.16 mmol), the amine ligands L1-L3 (0.26 / 0.32 
mmol) and NH4PF6 (0.26 / 0.32 mmol) was stirred at room temperature in methanol (15 mL) for 2 hours. 
The pale yellow precipitate was separated out and filtered off through filter paper, washed with cold 
methanol and diethyl ether and dried under vacuum. The above common procedure was followed to 
synthesize complexes 1b-6b.  
3.2.2.1 [(η
5
-C5Me5)IrCl(L1)]PF6  (1b) 
(IrCl2Cp
*
)2 (100 mg), amine ligand L1 (48 mg) and NH4PF6 (43 mg). Yield (126 mg, 0.18 mmol, 
73 %). Mp. 274.0 °C (dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm); Major isomer (73 %) ( δ = 8.71 
(d, 1H, JH-H  = 5.48 Hz, α proton of Py), 8.16 (t, 1H, Py), 7.93 (d, 1H, JH-H = 7.68 Hz, Py), 7.73 (d, 1H, JH-




JCH-NH = 11.20 Hz, -CH2), 4.63 - 4.56 (d-d, 1H, 
3
JCH-NH = 2.72 Hz, -CH2), 1.24 (s, 15H, C5Me5); Minor 
isomer (27 %) δ = 8.79 (d, 1H, JH-H  = 5.52 Hz, α proton of Py), 8.18 (t, 1H, Py), 7.97 (d, 1H, JH-H = 6.08 
Hz, Py), 7.80 (d, 1H, JH-H  = 7.72 Hz, Py), 7.70 (m, 2H, Ph), 7.57 - 7.54 (m, 2H, Ph), 7.48 (d, 1H, JH-H = 
7.96 Hz, Py), 7.34 (t, 1H, N-H), 4.89 - 4.82 (d-d, 1H, 
3
JCH-NH = 10.12 Hz, -CH2), 4.64 (d-d, 1H, 
3
JCH-NH = 
6.08 Hz, -CH2), 1.40 (s, 15H, C5Me5); 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm); Major isomer δ = 
159.53, 151.66, 145.94, 139.90, 129.44 (Py), 129.21, 126.45, 126.15, 122.49, 122.38, 119.85 (Ph), 87.32 
(C, C5Me5), 58.15 (C, CH2), 7.58 (CH3, C5Me5); Minor isomer δ = 155.33, 150.69, 146.22, 140.66, 
130.52 (Py), 129.61, 129.29, 127.19, 126.34, 122.12, 120.33 (Ph), 87.08 (C, C5Me5), 61.05 (C, CH2), 7.76 
(CH3, C5Me5). FT-I  (γ/cm
-1
): 3128 (s, N-H), 3042, 1616, 1598, 1403, 1033, 831 (s, P-F). HR-MS (TOF 
MS ES
+
) C22H27ClIrN2 Calculated: 547.1492, Found: 547.1475. [α]    = –1.94 (c = 2.05, CH3CN). Anal. 
Calcd for C22H27ClF6IrN2P: C, 38.18; H, 3.93; N, 4.05; Found: C, 37.83; H, 4.02; N, 3.89. 
3.2.2.2 [(η
5
-C5Me5)IrCl(L2)]PF6  (2b) 
(IrCl2Cp
*
)2 (100 mg), amine ligand L2 (53 mg) and NH4PF6 (43 mg). Yield (130 mg, 0.18 mmol, 
73 %). Mp. 286.0 °C (dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm); Major isomer (64 %) δ = 8.71 
(d, 1H, JH-H  = 5.52 Hz, α proton of Py), 8.16 (t, 1H, Py), 7.92 (d, 1H, JH-H = 7.80 Hz, Py), 7.68 (t, 1H, Py), 
7.48 - 7.44 (m, 4H, Ph), 7.35 (t, 1H, N-H), 4.95 - 4.93 (d-d, 1H, 
3
JCH-NH = 10.92 Hz, -CH2), 4.61 - 4.58 (d-
d, 1H, 
3
JCH-NH = 2.32 Hz, -CH2), 1.26 (s, 15H, C5Me5). Minor isomer (36 %) δ = 8.78 (d, 1H, JH-H  = 5.48 
Hz, α proton of Py), 8.18 (t, 1H, Py), 7.82 (d, 1H, JH-H = 7.64 Hz, Py), 7.64 (t, 1H, Py), 7.47 (m, 4H, Ph), 
7.33 (t, 1H, N-H), 4.84 - 4.78 (d-d, 1H, 
3
JCH-NH = 10.00 Hz, -CH2), 4.63 - 4.62 (d-d, 1H, 
3
JCH-NH = 2.48 Hz, 
-CH2), 1.41 (s, 15H, C5Me5). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm); major isomer δ = 160.99, 
159.33, 151.71, 142.35, 139.98 (Py), 126.51, 124.26, 122.39, 121.71, 116.04, 115.82 (Ph), 87.37 (C, 
C5Me5), 58.48 (C, CH2), 7.67 (CH3, C5Me5). ); minor isomer δ = 160.57, 158.56, 150.71, 142.35, 139.98 
(Py), 126.42, 124.18, 122.33, 121.79, 116.14, 115.91 (Ph), 87.17 (C, C5Me5), 61.20 (C, CH2), 7.83 (CH3, 
C5Me5). FT-I  (γ/cm
-1
): 3212 (s, N-H), 1613, 1510, 1471, 1449, 1027, 833 (s, P-F). HR-MS (TOF MS 
ES
+
) C22H24ClFIrN2 Calculated: 563.1241, Found: 563.1251. [α]    = –4.85 (c = 2.06, CH3CN). Anal. 
Calcd for C22H26ClF7IrN2P: C, 37.21; H, 3.69; N, 3.95; Found: C, 37.17; H, 3.22; N, 3.83. 
3.2.2.3 [(η
5
-C5Me5)IrCl(L3)]PF6  (3b) 
(IrCl2Cp
*
)2 (100 mg), amine ligand L3 (56 mg) and NH4PF6 (43 mg). Yield (127 mg, 0.18 mmol, 
70 %). Mp. 279.0 °C (dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm); Major isomer (70 %) δ = 8.70 
(d, 1H, JH-H  = 5.48 Hz, α proton of Py), 8.15 (t, 1H, Py), 7.91 (d, 1H, JH-H = 7.68 Hz, Py), 7.66 (t, 1H, Py), 




JCH-NH = 11.00 Hz, -CH2), 4.59 - 4.56 (d-d, 1H, 
3
JCH-NH = 2.80 Hz, -CH2), 3.78 (s, 3H, OCH3), 1.26 (s, 
15H, C5Me5); Minor isomer (30 %) δ = 8.79 (d, 1H, JH-H  = 5.56 Hz, α proton of Py), 8.17 (t, 1H, Py), 7.81 
(d, 1H, JH-H = 7.64 Hz, Py), 7.69 (t, 1H, Py), 7.37 (m, 2H, Ph), 7.19 (m, 2H, Ph), 7.03 (t, 1H, N-H), 4.80 - 
4.74 (d-d, 1H, 
3
JCH-NH = 10.24 Hz, -CH2), 4.55 - 4.52 (d-d, 1H, 
3
JCH-NH = 4.04 Hz, -CH2), 3.77 (s, 3H, 
OCH3), 1.40 (s, 15H, C5Me5). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm); Major isomer δ = 159.58, 
157.20, 151.66, 149.25, 139.87, (Py), 138.99, 126.41, 123.43, 122.30, 120.97, 114.16 (Ph), 87.33 (C, 
C5Me5), 58.60 (C, CH2), 55.46 (C, OCH3), 7.70 (CH3, C5Me5); Minor isomer δ = 160.73, 157.91, 150.61, 
149.43, 139.90, (Py), 139.15, 126.31, 124.10, 122.26, 114.42, 114.24 (Ph), 87.08 (C, C5Me5), 61.56 (C, 
CH2), 55.44 (C, OCH3), 7.82 (CH3, C5Me5). FT-I  (γ/cm
-1
): 3214 (s, N-H), 1613, 1512, 1451, 1253, 
1031, 837 (s, P-F). HR-MS (TOF MS ES
+
) C23H27ClIrN2O Calculated: 575.1441, Found: 575.1445. [α]    
= –3.05 (c = 1.97, CH3CN). Anal. Calcd for C23H29ClF6IrN2OP: C, 38.25; H, 4.05; N, 3.88; Found: C, 
38.49; H, 4.17; N, 4.13. 
3.2.2.4 [(η
5
-C5Me5)RhCl(L1)]PF6  (4b) 
(RhCl2Cp
*
)2 (100 mg), amine ligand L1 (59 mg) and NH4PF6 (53 mg). Yield (130 mg, 0.22 
mmol, 67 %). Mp. 242.0 °C (dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm); Major isomer (72 %) δ 
= 8.72 (d, 1H, JH-H  = 5.40 Hz, α proton of Py), 8.13 (t, 1H, Py), 7.82 (d, 1H, JH-H = 7.80 Hz, Py), 7.74 - 
7.70 (m, 2H, Py & Ph), 7.51 (d, 2H, JH-H = 7.44 Hz, Ph), 7.46 (d, 2H, JH-H = 8.08 Hz, Ph), 7.29 (t, 1H, N-
H), 5.01 - 4.95 (d-d, 1H, 
3
JCH-NH = 11.60 Hz, -CH2), 4.34 - 4.31 (d-d, 1H, 
3
JCH-NH = 4.24 Hz, -CH2), 1.27 (s, 
15H, C5Me5); Minor isomer (28 %) δ = 8.80 (d, 1H, JH-H  = 5.48 Hz, α proton of Py), 8.15 (t, 1H, Py), 7.68 
(m, 1H, Py), 7.74 - 7.64 (m, 2H, Py & Ph), 7.55 (d, 2H, JH-H  = 5.52 Hz, Ph), 7.48 (s, 1H, Ph), 7.34 (t, 1H, 
N-H), 4.63 - 4.56 (d-d, 1H, 
3
JCH-NH = 10.44 Hz, -CH2), 4.42 - 4.38 (d-d, 1H, 
3
JCH-NH = 3.20 Hz, -CH2), 1.43 
(s, 15H, C5Me5). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) Major isomer δ = 158.85, 151.89, 150.35, 
145.65, 139.74 (Py), 129.29, 126.07, 125.57, 122.65, 121.95, 119.58 (Ph), 95.59 (d, C, C5Me5), 56.47 (C, 
CH2), 7.81 (CH3, C5Me5); Minor isomer δ = 158.96, 150.35, 146.25, 139.79, 129.48 (Py), 129.34, 126.82, 
125.98, 122.39, 122.22, 119.61 (Ph), 95.36 (d, C, C5Me5), 59.89 (C, CH2), 8.01 (CH3, C5Me5). FT-IR 
(γ/cm
-1
): 3138 (s, N-H), 2973, 2918, 1614, 1599, 1494, 1444, 1024, 830 (s, P-F). HR-MS (TOF MS ES
+
) 
C22H27ClN2 h Calculated: 457.0918, Found: 457.0905. [α]    = +3.16 (c = 1.90, CH3CN). Anal. Calcd for 
C22H27ClF6N2PRh: C, 43.84; H, 4.51; N, 4.65; Found: C, 43.52; H, 4.10; N, 4.70. 
3.2.2.5 [(η
5
-C5Me5)RhCl(L2)]PF6  (5b) 
(RhCl2Cp
*
)2 (100 mg), amine ligand L2 (65 mg) and NH4PF6 (53 mg). Yield (141 mg, 0.23 
mmol, 70 %). Mp. 274.0 °C (dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm); Major isomer (66 %) δ 
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= 8.73 (d, 1H, JH-H  = 5.36 Hz, α proton of Py), 8.13 (t, 1H, Py), 7.80 (d, 1H, JH-H  = 7.72 Hz, Py), 7.71 (t, 
1H, Py), 7.57 (d, 1H, JH-H  = 10.84 Hz, Ph), 7.48 (t, 1H, Ph), 7.39 (d, 1H, JH-H = 8.72 Hz, Ph), 7.39 (t, 1H, 
N-H), 4.98 - 4.91 (d-d, 1H, 
3
JCH-NH = 11.44 Hz, -CH2), 4.34 - 4.30 (d-d, 1H, 
3
JCH-NH = 2.28 Hz, -CH2), 1.29 
(s, 15H, C5Me5); Minor isomer (34 %) δ = 8.79 (d, 1H, JH-H  = 5.40 Hz, α proton of Py), 8.15 (t, 1H, Py), 
7.77 (m, 3H, Py & Ph), 7.66 (d, 2H, JH-H  = 7.72 Hz, Ph), 7.51 (m, 1H, Ph), 7.39 (d, 1H, JH-H = 8.72 Hz, 
Ph), 7.32 (t, 1H, N-H), 4.58 - 4.51 (d-d, 1H, 
3
JCH-NH = 10.40 Hz, -CH2), 4.41 - 4.37 (d-d, 1H, 
3
JCH-NH = 3.72 
Hz, -CH2), 1.44 (s, 15H, C5Me5). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm); Major isomer δ = 158.62, 
151.90, 150.34, 142.05, 139.79 (Py), 126.12, 124.05, 122.66, 121.43, 116.10, 115.88 (Ph), 95.64 (d, C, 
C5Me5), 56.81 (C, CH2), 7.87 (CH3, C5Me5); Minor isomer δ = 158.80, 150.35, 142.60, 140.26, 139.22 
(Py), 126.03, 123.96, 122.23, 121.33, 116.18, 115.96 (Ph), 95.45 (d, C, C5Me5), 56.47 (C, CH2), 8.07 
(CH3, C5Me5). FT-I  (γ/cm
-1
): 3152 (s, N-H), 1610, 1509, 1480, 1213, 1084, 1030, 829 (s, P-F). HR-MS 
(TOF MS ES
+
) C22H24ClFN2 h Calculated: 473.0667, Found: 473.0669. [α]    = –1.93 (c = 2.07, CH3CN). 
Anal. Calcd for C22H26ClF7N2PRh: C, 42.57; H, 4.22; N, 4.51; Found: C, 42.32; H, 4.17; N, 4.56. 
3.2.2.6 [(η
5
-C5Me5)RhCl(L3)]PF6  (6b) 
(RhCl2Cp
*
)2 (100 mg), amine ligand L3 (69 mg) and NH4PF6 (53 mg). Yield (170 mg, 0.27 
mmol, 83 %). Mp. 285.0 °C (dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm); Major isomer (65 %) δ 
= 8.72 (d, 1H, JH-H  = 5.36 Hz, α proton of Py), 8.12 (t, 1H, Py), 7.80 - 7.78 (d, 1H, JH-H  = 7.76 Hz, Py), 
7.71 - 7.69 (t, 1H, Py), 7.48 (t, 1H, Ph), 7.39 (d, 1H, JH-H = 8.72 Hz, Ph), 7.07 (t, 1H, N-H), 4.96 - 4.89 (d-
d, 1H, 
3
JCH-NH = 11.40 Hz, -CH2), 4.32 - 4.28 (d-d, 1H, 
3
JCH-NH = 2.44 Hz, -CH2), 3.78 (s, 3H, -OCH3), 1.29 
(s, 15H, C5Me5); Minor isomer (35 %) δ = 8.79 (d, 1H, JH-H  = 5.40 Hz, α proton of Py), 8.33 (d, 1H, JH-H 
= 9.76 Hz, Py), 8.14 (t, 2H, Py), 7.65 (d, 1H, JH-H = 7.84 Hz, Ph), 7.41 (broad, 2H, Ph), 7.03 (t, 1H, N-H), 
4.55 - 4.48 (d-d, 1H, 
3
JCH-NH = 10.56 Hz, -CH2), 4.35 - 4.32 (d-d, 1H, 
3
JCH-NH = 3.60 Hz, -CH2), 3.77 (s, 
3H, -OCH3), 1.44 (s, 15H, C5Me5). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm); Major isomer δ = 
159.40, 152.38, 150.78, 140.20, 140.17 (Py), 139.15, 126.53, 123.84, 123.09, 121.24, 114.82 (Ph), 96.08 
(d, C, C5Me5), 57.49 (C, CH2), 55.95 (C, OCH3), 8.41 (CH3, C5Me5); Minor isomer δ = 158.24, 157.39, 
154.45, 140.97, 140.19 (Py), 139.68, 126.43, 124.51, 122.66, 121.20, 114.99 (Ph), 95.83 (d, C, C5Me5), 
60.99 (C, CH2), 55.88 (C, -OCH3), 8.59 (CH3, C5Me5). FT-I  (γ/cm
-1
): 3232 (s, N-H), 1610, 1600, 1514, 
1482, 1448, 1284, 1253, 1182, 1070, 1018, 824 (s, P-F). HR-MS (TOF MS ES
+
) C23H27ClN2ORh 
Calculated: 485.0867, Found: 485.0867. [α]  
 
 = –3.98 (c = 2.01, CH3CN). Anal. Calcd for 




Suitable crystals for X-ray analysis were grown by slow evaporation of hexane into an 
acetonitrile solution. The crystals were selected and glued onto the tip of glass fibers, then mounted in a 
stream of cold nitrogen at 173 (2) K and centered in the X-ray beam by using a video camera. The crystal 
refinement and data collection were performed on a Bruker Smart APEX11 diffractometer using graphite 
crystal monochromatised Mo - K radiation (ʎ = 0.71073 Å) and a diffractometer to crystal distance of 
4.00 cm. The initial cell matrix was obtained from three series of scans at different starting angles. Each 
series consisted of 12 frames collected at intervals of 0.5° in a 6° range with the exposure time of about 
10 seconds per frame. The reflections were successfully indexed by an automated indexing routine built 
in the APEXII program suite. The final cell constants were calculated from a set of 6460 strong 
reflections from the actual data collection. The data collection method involved ω scans of width 0.5°. 
Data reduction was carried using the program SAINT+ [39]. The structure of crystal was resolved by the 
SHELX [40] program. The full-matrix least-squares on F
2
 refinement method with the SHELX program 
package was used to refine the positions and thermal parameters of all non-hydrogen atoms in the crystal 
[40]. All H atoms were positioned geometrically and allowed to ride on their respective parent atoms. All 
H atoms were refined isotropically. The structure and graphics of the crystals and N-H···Cl interactions 
were generated by ORTEP-3 [41] and MERCURY [42] programs. Structural refinement data as well as 
crystal data for compound 1b are given in Table 3.1. Those of compound 6b are provided in the 
supplementary information and are only reported to support connectivity to the metal center, as the data 











Table 3.1 Structure refinement and crystal data of complex 1b 
Complex 1b 
Empirical formula C22H29ClF6IrN2P 
Formula weight 692.07 
Temperature/K 173(2) K 
Crystal system triclinic 




















 0.220 × 0.190 × 0.180 
Radiation Mo Kα (λ = 0.71073) 
2ɵ range for data collection/° 3.654 to 57.56 
Index ranges -10 ≤ h ≤ 12, -15 ≤ k ≤ 15, -16 ≤ l ≤ 16 
Reflections collected 26957 





Final   indexes [I>=2σ (I)] R1 = 0.0157, wR2 = 0.0407 
Final R indexes [all data] R1 = 0.0159, wR2 = 0.0408 




3.2.4 General procedure for catalytic transfer hydrogenation of aromatic ketones 
Ketone (1 mmol), catalyst (0.5 mol%) and a mixture of HCOOH (85 wt%) (3.75 mmol) and 
HCOONa (2 mmol) in 2 mL of deionized water were placed in a Schlenk tube under argon or nitrogen 
atmosphere. The mixture was stirred magnetically at specified temperature over the specified time. After 
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completion of the reaction, the reaction mixture was cooled to room temperature, quenched with aqueous 
NaHCO3 solution, and extracted with diethyl ether. The organic layer was washed with brine solution, 
dried over MgSO4, the solvent was removed by rotary evaporator and the resulting residue passed through 
a short silica column. The fractions were collected and the conversion of the respective products was 
determined by GC analysis using chlorobenzene as an internal standard. All experiments were done at 
least in duplicate. 
3.2.5 General procedure for catalytic transfer hydrogenation of aromatic aldehydes 
The above-mentioned procedure was followed to carry out the TH of aromatic aldehydes. 
Aldehyde (5 mmol), catalyst (0.5 mol%) and a mixture of HCOOH (85 wt%) (7.50 mmol) and HCOONa 
(4 mmol) in 4 mL of deionized water were placed in a Schlenk tube under argon or nitrogen atmosphere.  
3.2.6 General procedure for catalyst recyclability and catalytic activity  
Acetophenone (1 mmol), catalyst (0.5 mol%) and a mixture of HCOOH / HCOONa (3.75 mmol / 
2.0 mmol) were dissolved in 2 mL deionized water in a Schlenk tube under an argon or nitrogen 
atmosphere. The mixture was stirred magnetically at 60 ºC over the specified time. After completion of 
the reaction, the reaction mixture was cooled to room temperature and the organic phase was extracted 
with ethyl acetate. The solvent was removed by distillation and the resulting residue was treated with 
diethyl ether to precipitate the catalyst which was dried under vacuum overnight. A new TH reaction was 
started by introducing acetophenone (1 mmol), recovered catalyst (0.5 mol%) and a mixture of HCOOH / 
HCOONa in 2 mL of deionized water. After degassing with nitrogen or argon, the mixture was stirred 
magnetically at 60 ºC over required time. 
3.3 Results and discussion 
3.3.1 Complex synthesis 
In the present work, the new half sandwich metal complexes 1b-6b have been synthesised using 
N,N' amine bidentate ligands (Scheme. 3.1). The reaction between the chloro bridged dimer (MCl2Cp
*
)2 
(M = Ir and Rh) with N,N' para-R-N-(pyridine-2-ylmethyl)-aniline (R = H (L1), F (L2), OCH3 (L3)) and 
NH4PF6 afforded the new [(η
5
-C5Me5)MCl(L1-L3)]PF6 (M = Ir (1-3) and Rh (4b-6b)) complexes 1b-6b 
in good yield in methanol. Complexes 1b-3b are pale yellow and 4b-6b are yellow crystalline solids 
which are air stable, non-hygroscopic and highly soluble in common polar solvents such as DMSO, DMF, 
70 
 
acetonitrile, dichloromethane, acetone, ethyl acetate, methanol, ethanol and soluble in water up to 3 mg / 
mL at room temperature. These complexes are insoluble in diethyl ether, petroleum ether and hexane.  
During the synthesis of the iridium complexes 1b-3b, small amounts of the amine oxidized 
products, i.e. imine complexes, were observed to form when molecular oxygen was not totally eliminated 
from the reaction medium. When the reaction was done in air, the iridium amine complexes were 
oxidized to the corresponding imine complexes completely over time. This reaction was monitored and 
the amine and imine complexes were confirmed by 
1
H NMR (See SI S17-S19). The highly acidic N-H 
proton present on the ligand promoted the formation of the oxidized product of the imine iridium 
complexes in the reaction medium. In contrast, this was not observed during the synthesis of the rhodium 
complexes 4b-6b. We were unable to separate the iridium amine and imine complexes by 
chromatography [43]. The mechanism of the amine to imine oxidation is unknown [27]. Gomez et al. 
reported that ruthenium coordinated to secondary amine ligands activates their oxidation to imines by 
molecular oxygen in a base-catalyzed reaction [37].  
Characterization of the ligand and metal complexes 1b-6b were carried out by 
1
H NMR, 2D 
NMR (COSY, NOESY), 
13
C NMR, IR spectroscopy, melting point analysis, HR-MS spectroscopy and 
elemental analyses. The crystal structures of complexes 1b and 6b have been further authenticated by 
single crystal X-ray crystallography.  
 
Scheme 3.1: Synthesis of complexes 1b-6b. 
3.3.2 Solution NMR studies 
Spectral details of complexes 1b-6b have been summarized in the Experimental section. The 
1
H 
NMR spectra of the free N,N' amine ligands, L1-L3, showed a CH2 group proton doublet in the range of 
4.29 - 4.33 ppm and a doublet for the α proton in the pyridine ring appeared in the range of 8.53 - 8.50 
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ppm. The N-H proton present in ligands L1-L3 coupled with the CH2 protons and showed a triplet in the 
1
H NMR spectra. When the N,N' amine ligands L1-L3 were coordinated with the iridium and rhodium 
precursors, the doublet of the α proton in the pyridine ring shifted down-field to 8.71 (1b & 2b), 8.70 
(3b), 8.73 (4b & 5b), and 8.72 (6b) ppm. The aromatic region and N-H signal of complexes 1b-6b were 
also shifted down-field compared to the free ligand signals. The secondary amine ligands L1-L3 have 
chiral nitrogen atoms and hence complexes 1b-6b are found as a mixture of diastereomers (RM, SN-H) and 





C NMR spectra of complexes 1b-6b. Unfortunately, some aromatic phenyl group signals of 
the major and minor diastereomers overlapped together in the 
1
H NMR spectra, and the distinct signals of 
complexes 1b-6b and the respective peaks of each diastereomer were resolved by 2D NMR studies (See 
SI S2-S16). The dd coupling constant of the CH2 protons present in the complexes 1b-6b are 11-12 and 2-
3 Hz, which may be associated to the diastereomers present in solution. 
 
Interestingly, the signals of each proton of the CH2 fragment appeared separately as doublets of 
doublets (dd) in the range of 4.28 - 5.03 ppm for complexes 1b-6b. This is as a result of the two 
diastereomeric protons present in the CH2 group. The diastereoselectivity of complexes 1b-6b have been 
determined by interpretation of the respective 
1
H NMR signals of each isomer and the diastereomeric 
ratios of the major and minor diastereomers in solution are given in Table 3.2. The Cp* (C(CH3))5 
carbons in the 
13
C NMR spectra showed a doublet instead of a singlet for complexes 4b-6b, which could 
be due to rhodium coupling with the Cp* (C(CH3))5 carbon atoms [44]. By lowering the temperature of 
the solutions of the complexes 1b and 4b to 293 K, these inter conversion was “frozen”, according to 
variable-temperature 
1
H NMR experiment. At 293 K, the CH2 signal split into two peaks, as did the Cp* 






H COSY and 1D NOE analyses of complexes 1b and 4b showed the interaction 
between the CH2 protons and Cp* protons (See SI S20 & S21) (Schem 3.2). The diastereomers of the 




C NMR and 2D NMR studies. Pfeffer and co-workers [43, 45, 46] also reported chiral primary and 
secondary amines cyclometalated with Ir(III), Rh(III) and Ru(II) half sandwich complexes showing 
diastereomeric behavior in solution. Their solution NMR analysis showed the characteristic key NOE 
interactions between the Cp* protons and the aromatic or benzylic protons.     
 
The stereochemistry of complexes 1b and 4b can be explained as follows: the N-H proton is 
coupled to the CH2 protons with coupling constants of 
3
JCHNH = 2.72 (1b), 4.24 (4b), 11.20 (1b), and 
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11.60 (4b) Hz, where the latter two values suggest the anti-positioning of one CH2 proton to the N-H 
group, as per the Karplus law [43]. A low value of 
3
JCHNH (2.72 (1b) & 4.24 (4b) Hz) is associated with 
the syn-position of the other CH2 proton to the N-H group. The configuration of the nitrogen atom is 
assigned as S, as per the above observation. The analysis of the single crystal XRD further confirms the 
configuration of the nitrogen, which correlates with the NMR studies. 
 
With regard to the configuration around the metal of complex 1b (SM, R(N-H)), we assume the 
following decreasing priority sequence: 1 (η
5
-C5Me5), 2 (Cl), 3 (Naryl), 4 (N-H) [46]. The determination of 
the metal configuration is important in order to understand the TH activities and selectivity [46]. Strong 
1D NOE cross interaction of the signals Ph/CH2 and Cp*/CH2 are observed in complexes 1b and 4b, 
which strongly indicates that the metal configuration is Sm. This means that the (SM, RN-H) diastereomer 
exists as a major diastereomer in solution compared to the (RM, SN-H) minor diastereomer [45]. Moreover, 
no conversion of (RM, SN-H / SM, RN-H) to (SM, SN-H / RM, RN-H) was observed in solution by 
1
H NMR at 
room temperature over 24 hours. This observation indicates that the absolute configuration around the 
metal center remains unchanged in solution, which is important for asymmetric TH reactions [29]. A 
similar stereochemistry was observed for the rest of the complexes. 
 
Scheme 3.2: Possible conformations of the complexes 1b and 4b. For clarity, the charges on the complex 
and counter ion PF6 were omitted. 
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Table 3.2 Proportions of the diasteromers present in the complexes 1b-6b 
a
 
Complex Major isomer (%) Minor isomer (%) 
1 73 27 
2 64 36 
3 70 30 
4 72 28 
5 66 34 
6 65 35 
a
 Determined by 
1

















H NMR spectra of the aromatic protons of the complexes 1b and 4b at 20 °C. 
75 
 
3.3.3 IR spectroscopy 
IR spectra of the ligands L1-L3 exhibit a sharp peak for the N-H stretch in the range 3279 - 3367 
cm
-1
, and the equivalent N-H bands of complexes 1b-6b were shifted to lower frequencies in the range of 
3128 - 3232 cm
-1
. This is attributed to the nitrogen atom of the N-H group now being coordinated to 
iridium or rhodium. The PF6 stretching frequency was observed for all the complexes in the range of 824 
- 837 cm
-1
, which indicates that the PF6 counter ion is present in the metal complexes. Thus, IR data show 
that the Schiff base ligands were coordinated to iridium and rhodium through the N,N' nitrogen atoms. 
3.3.4 Molecular structure of complex 1b  
Single crystal of the (RM, SN-H) iridium complex 1b was grown by slow evaporation of hexane 
into their acetonitrile solution and analyzed by X-ray diffraction. The ORTEP drawings for the complex 
1b is shown in Fig. 3.4, while selected bond lengths and bond angles, as well as hydrogen bonds in the 
crystal, are given in Tables 3.3 and 3.4 for 1b. 
 
The molecular structure of complex 1b show the N-(pyridin-2-ylmethyl) aniline ligand which 
coordinated to the Ir(III) center via it is two N atoms in a bidentate manner forming five member 
metallacycles. The geometries around the two metal centers of complex is pseudooctahedral in which the 
two N atoms and a Cl atom form the base, while the π-bonds of the Cp* ring form the apex of a piano 
stool. The average Ir-Cp* centroid bond distances is 1.785 (Å), while the Ir-Namine, Ir-N1 and Ir-Cl bond 
distances are 2.167(16), 2.112(17) and 2.405(6) (Å) respectively and fall within the expected ranges of 
related compounds [8, 17, 20, 27, 43, 47]. The Ir-amine bond is relatively longer than that of the Ir-Naryl 
bond. H11a is in a syn-position to the N-H proton, while H11b is in an anti-position to the N-H proton based 
on the torsion angles involving the two protons, H-C(11)-N(2)-H11a and H-C(11)-N(2)-H11b (-57.12° and -







Fig. 3.4 ORTEP view of the complex 1b with atom numbering scheme. Displacement of the ellipsoids are 
drawn at the 50% probability level. 
Table 3.3 Selected bond distances (Å), bond angles (°) and torsion angles (°) of complex 1b 
Selected bond distances (Å) Selected bond angles (°) 
N(1) – Ir(1) 2.112(17) Cp* Centroid – Ir(1) – N(2) 135.53 
N(2) – Ir(1) 2.167(16) Torsion angles (°) 
Cl(1) – Ir(1) 2.405(5) H11a – C(11) – N(2) - H -57.12 
Cp* centroid – Ir(1) 1.785 H11b – C(11) – N(2) - H -177.28 
Selected bond angles (°) H11a – C(16) – N(1) 156.05 
N(1) – Ir(1) – N(2) 75.40(6) H11b – C(16) – N(1) -83.82 
N(1) – Ir(1) – Cl(1) 85.73(5) H – N(2) – Ir(1) – N(1) -75.42 
N(2) – Ir(1) – Cl(1) 83.56(5) H – N(2) – Ir(1) – Cl(1) 11.82 
Cp* Centroid – Ir(1) - Cl 165.70 Ir(1) – N(1) – C(16) – C(11) -6.11 






Table 3.4 Hydrogen bonds present in the complex 1b 
C-H···F D-H (Å) H···A (Å) D···A (Å) D-H···A (º) 
N(2)-H(2) ···Cl(1) 1.00 2.34 3.2032(17) 144 
Cl(1)-H(11b) ···F(3) 0.99 2.46 3.424(3) 164 
C(15)-H(15) ···F(5) 0.95 2.42 3.112(3) 129 
N(2)-H(2) ···Cl(1) 1.00 2.34 3.2032(17) 144 
Cl(1)-H(11b) ···F(3) 0.99 2.46 3.424(3) 164 
C(15)-H(15) ···F(5) 0.95 2.42 3.112(3) 129 
 
3.3.5 Catalytic activity studies 
3.3.5.1 Transfer hydrogenation (TH) of aromatic ketones and aldehydes 
The synthesised Ir(III) and Rh(III) amine half sandwich complexes were investigated for catalytic 
transfer hydrogenation (TH) of aromatic ketones and aldehydes under pH dependent reaction conditions 
in water as a solvent (Table 3.5). 
 
The experiments were carried out using a mixture of acetophenone, catalyst and an aqueous 
solution of HCOOH / HCOONa in water and were heated to the required temperature. A HCOOH / 
HCOONa mixture was used as hydrogen source and base for this catalytic TH, to create an 
environmentally benign process. The catalyst loading was also optimized at different pH in water. As 
seen from the results, aromatic ketones required a higher catalyst loading (0.5 mol%, Table 3.5) than 
aromatic aldehydes (0.1 mol%, Table 3.6), likely due to the steric hindrance of the methyl group. Low pH 
reaction conditions may increase the activation of ketones by hydrogen bonding with the highly acidic N-
H proton in the catalyst through a six numbered transition state [2, 48] (Scheme 3.3). However, at low pH 
the reaction rate of the postulated metal-hydride intermediate was also expected to be fast. Thus low pH 
reaction conditions offer a wide range of substrate scope in TH. 
 
The complexes 1b and 4b were investigated as pre-catalysts for catalytic TH to establish the 
optimized reaction conditions. The different aqueous pH reaction conditions vs acetophenone conversions 
are summarized in Table 3.5. The pH of the aqueous solutions was changed by varying the quantity of 
HCOONa. No conversion of acetophenone was achieved without catalysts 1b and 4b. In buffer solutions 
at pH = 2.60, the reduction of acetophenone took longer at 40 ºC with 0.1 and 0.5 mol% catalyst loading 
of 1b or 4b compared to the reaction at 60 ºC (Entries 1-4 & 13-16). The complexes 1b and 4b showed 
better catalytic activity at the lower pH of 2.60 compared to a pH of 3.60 and 4.60 in aqueous solution of 
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HCOOH / HCOONa with 0.5 mol% catalyst loading at 60 °C (Entries 4, 5, 6, 16, 17 & 18). Overall, at 
pH = 2.60, 99% of acetophenone conversion was achieved within an hour by complex 4b (Entry 16).  
 
Other hydrogen sources also examined for acetophenone reduction under different reaction 
conditions. The complexes 1b and 4b showed poor conversion (26 & 28%) of acetophenone in HCOOH 
and Et3N azotropic mixture over 48 h at 60 °C (Entries 7 & 19). With isopropyl alcohol and KOH as base, 
complexes 1b and 4b showed 98 and 93% conversion of acetophenone respectively, but this system 
required longer reaction times (4 h) and higher catalyst loading (2 mol%) than the HCOOH / HCOONa 
system (0.5 mol%) (Entries 12 & 24).  
 
Under the acidic conditions (pH = 2.60 to 4.60) the aromatic carbonyl compounds reduced faster 
than under basic conditions with complexes 1b and 4b. The complexes 1b and 4b decomposed under the 
basic conditions (pH = 8.70), which is indicated by the formation of a black precipitate in the reaction 
mixture (Entries 8, 9, 20 & 21). It can be seen that TH of acetophenone smoothly increased with 
decreasing pH values with 0.5 mol% catalyst loading (Entries 4-6 & 16-18). In the presence of the Rh 
complex 4b (0.5 mol%), acetophenone was reduced completely (99%) in aqueous pH = 2.60 solution of 
HCOOH / HCOONa at 60 ºC (Entry 16). Complexes Ir(III) and Rh(III) (2b, 3b, 5b & 6b) with electron 
donating (OCH3) and withdrawing groups (F) substituted on the ligand showed the best conversion (96, 
95, 98 & 99%) of acetophenone to 1-phenyl ethanol with 0.5 mol% catalyst loading (Entries 25-28) under 
aqueous pH = 2.60 reaction conditions.  
 
The Ir(III) complexes (1b-3b) normally required longer reaction times (4 to 6 h) than the Rh(III) 
complexes (4b-6b) under the specified reaction conditions. This is due to the highly acidic N-H proton, 
which promotes the formation of imine Ir(III) complexes in the reaction medium [37]. The oxidized Ir(III) 
imine (1a) and Rh(III) imine (2a) complexes were also synthesized and investigated for the TH of 
acetophenone (Entries 29 & 30), in order to compare their catalytic activity with the Ir(III) (1b) and 
Rh(III) (4b) amine complexes. The oxidized Ir(III) (1a) and Rh(III) (2a) imine complexes showed 96% 
and 99% conversion of acetophenone respectively, but this imine complexes required longer reaction 
times in aqueous pH of 2.60 solution of HCOOH / HCOONa at 60 ºC (Entries 29 & 30). The catalytic 
activity of the Ir(III) and Rh(III) imine complexes lower than respective amine complexes. However, 
overall optimization results showed a HCOOH / HCOONa mixture in aqueous solution at pH = 2.60 is an 
ideal reaction condition for this catalytic system at 60 ºC. These reaction conditions are also applicable 
for different substituted benzaldehyde derivatives. The chirality of the product was analysed by chiral GC 
and the ratio of the isomers 49:51 (racemic mixture) were obtained in all the cases (See SI S21-S22). 
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Table 3.5 Optimization conditions of TH for acetophenone by complexes 1b-6b 
 
Entry Complex Catalyst 
loading 
(mol%) 













40 24 28 280 12 
2 1b 0.1 
a
HCOOH/HCOONa 60 24 30 300 13 




40 7 88 176 25 
4 1b 0.5 
a
HCOOH/HCOONa 60 4 96 192 48 
5 1b 0.5 
b
HCOOH/HCOONa 60 4 90 180 45 
6 1b 0.5 
c
HCOOH/HCOONa 60 4 73 146 37 
7 1b 0.5 
d
HCOOH/Et3N 60 48 26 52 1 
8 1b 0.5 
e
HCOONa 60 48 12 24 <1 
9 1b 0.5 
e
HCOONa 100 48 27 54 1 
10 1b 0.5 
f
IPA/KOH 60 48 25 50 1 
11 1b 1 
f
IPA/KOH 82 12 87 87 7 
12 1b 2 
f
IPA/KOH 82 4 98 49 12 




40 24 44 440 18 
14 4b 0.1 
a
HCOOH/HCOONa 60 24 47 470 20 




40 3 98 196 65 
16 4b 0.5 
a
HCOOH/HCOONa 60 1 99 198 198 
17 4b 0.5 
b
HCOOH/HCOONa 60 1 92 184 184 
18 4b 0.5 
c
HCOOH/HCOONa 60 1 80 160 160 
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19 4b 0.5 
d
HCOOH/Et3N 60 48 28 56 1 
20 4b 0.5 
e
HCOONa 60 48 14 28 1 
21 4b 0.5 
e
HCOONa 100 48 31 62 1 
22 4b 0.5 
f
IPA/KOH 60 48 34 68 1 
23 4b 1 
f
IPA/KOH 82 12 84 84 7 
24 4b 2 
f
IPA/KOH 82 4 93 47 12 
25 2b 0.5 
a
HCOOH/HCOONa 60 6 96 192 32 
26 3b 0.5 
a
HCOOH/HCOONa 60 6 95 190 32 
27 5b 0.5 
a
HCOOH/HCOONa 60 2 98 196 98 
28 6b 0.5 
a
HCOOH/HCOONa 60 2 96 192 96 
29 g1a 0.5 
a
HCOOH/HCOONa 60 24 96 192 8 
30 g2a 0.5 
a
HCOOH/HCOONa 60 2 99 198 99 
a 
HCOOH (7.50 mmol) / HCOONa (3.50 mmol) in 2 mL H2O pH = 2.60) 
b 
HCOOH (7.50 mmol) / HCOONa (11.0 mmol) in 2 mL H2O pH = 3.60) 
c 
HCOOH (7.50 mmol) / HCOONa (29.0 mmol) in 2 mL H2O pH = 4.60) 
d 
Azeotropic mixture (0.2 mL / 1 mL of F/T) 
e 
HCOONa (5.0 mmol) in 2 mL H2O pH = 8.70 
f 
IPA (5 mL), KOH (5.0 mol%) (where IPA = isopropyl alcohol) 
g
1a = Ir(III) imine complex; 2a = Rh(III) imine complex 
Turnover number (TON) = [(mol of product)/(mol of catalyst)] 
Turnover frequency (TOF) = [TON/h]
 
From the optimization results, the rhodium complexes 4b and 2a showed the best conversion of 
acetophenone in the aqueous HCOOH / HCOONa mixture at pH = 2.60 at 60 °C. This reaction condition 
was investigated for further substituted acetophenone derivatives (Table 3.6). Generally, the electronic 
nature of the aromatic ring present on the substrate plays a big role in TH reactions. Generally, the 
electron-withdrawing groups (4-NO2, 4-F & 4-Cl) on the acetophenone ring promotes the reaction rate of 
TH reactions rather than electron-donating groups (4-I, 4-OMe & 4-Me) under pH dependent reaction 
conditions [5, 21]. This is also observed here, where substrates with p-electron-withdrawing substituents 
(Table 3.6, Entries 1-4) were more easily reduced than substrates with p-electron-donating groups (Table 
3.6, Entries 5-7) on the acetophenone. Both rhodium amine (4b) and imine (2a) complexes reduced 
acetophenone derivatives with good yield under aqueous reaction conditions (Table 3.6). But generally 
rhodium amine (4b) complex is reduced acetophenone derivatives faster than the respective rhodium 
imine (2a) complex.  
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 TON TOF 
1 Acetophenone 4b 1 99 (96) 198 198 
  2a 2 99 (94) 198 99 











3 4-F acetophenone 4b 2 99 (93) 198 99 
  2a 2 100 (95) 200 100 
4 4-Cl acetophenone 4b 2 100 200 100 
  2a 6 92 184 31 
5 4-I acetophenone 4b 24 54 108 5 
  2a 24 50 100 4 























1 mmol substrate, 0.5 mol% catalyst, HCOOH (7.50 mmol) / HCOONa (3.50 mmol) 
b 
Determined by GC 
Isolated yields mentioned in parenthesis 
Turnover number (TON) = [(mol of product)/(mol of catalyst)] 
Turnover frequency (TOF) = [TON/h]
 
 
The rhodium complexes 4b and 2a showed efficient TH of aromatic aldehydes to their respective 
alcohols with lower catalyst loading (S/C = 1000) in the aqueous HCOOH / HCOONa system (Table 3.7). 
The aromatic aldehydes containing both electron-donating and electron-withdrawing groups reduced to 
the respective alcohols faster over the rhodium amine (4b) and imine (2a) complexes compared to the 
benzaldehyde substrate (Table 3.6). Thus, rhodium complexes 4b and 2a showed versatile reducing 
activity for the aromatic ketones and aldehydes. The catalytic loading (0.1 mol%) equivalent for effective 
aromatic aldehyde TH is lower than that required for aromatic ketones (0.5 mol%). Overall the studies 
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demonstrated that the rhodium amine 4b and imine 2a complexes reduced aromatic ketones and 
aldehydes to their respective alcohols faster than the iridium complexes. 
 
A possible reduction reaction pathway for rhodium catalyzed TH is explained in Scheme 3.3 [3, 
13]. Metal catalyzed transfer hydrogenation of aromatic ketones in aqueous solution is a well documented 
process [2, 3, 13, 30]. In the reaction mechanism, β-hydride elimination occurs to form a metal hydride 
complex, which interacts with the carbonyl group of acetophenone to form a six membered transition 
state as per Noyori’s proposal [13]. Thus, the further reduction takes place and gives the final product of 
1-phenyl ethanol. 
Table 3.7 Transfer hydrogenation of aromatic aldehydes by complexes 4b and 2a
a 
 




 TON TOF 
1 Benzaldehyde 4b 2.5 94 940 376 
  2a 4 96 960 240 
2 4-NO2 benzaldehyde 4b 1 94 940 940 
  2a 1.5 92 920 613 
3 4-F benzaldehyde 4b 1 96 960 960 
  2a 2 93 930 465 
4 4-Cl benzaldehyde 4b 1 92 920 920 
  2a 3 94 940 313 
5 4-OMe benzaldehyde 4b 1 93 930 930 
  2a 2 90 900 450 
6 4-Me benzaldehyde 4b 1 91 910 910 
  2a 3 87 870 290 
a 
5 mmol substrate, 0.5 mol% catalyst, HCOOH (15.0 mmol) / HCOONa (7.0 mmol) 
b
 Isolated yields 
Turnover number (TON) = [(mol of product)/(mol of catalyst)] 





3.3.6 Recyclability of the catalyst 4b 
One important feature of this system is that the catalyst can be recovered due to easy organic 
layer separation of the catalyst from the aqueous reaction medium. The upper organic layer was extracted 
with ethylacetate and the solvent was removed by vacuum distillation. The obtained residue was treated 
with diethylether to precipitate the catalyst. A sticky solid was obtained, which was dried under vacuum 
overnight and examined by 
1
H NMR. The 
1
H NMR analysis of the fresh, recovered and recovered catalyst 
4b after 3
rd
 cycle in DMSO-d6 is shown in Fig. 3.6. The 
1
H NMR spectra of the recovered catalyst 4b 
show all the characteristic peaks present for the fresh catalyst 4b. 
 
The catalytic activity of the recovered catalyst 4b was examined for TH of acetophenone (Table 
3.8). The recovered catalyst 4b showed similar conversion of acetophenone in 1 h for the 1
st
 recycle, no 
significant loss in the catalytic activity was observed (Table 3.8, Entry 2). To achieve a similar 
conversion, took 1.5 h on the 2
nd
 recycle (Table 3.8, Entry 3). However, it required 5 h to achieve this 
conversion in the 3
rd
 recycle (Table 3.8, Entry 4). This decrease in catalytic activity is due to the partial 
decomposition of catalyst in the reaction mixture, which is supported by the 
1
H NMR spectra of the 
recovered catalyst after the third catalytic cycle (Fig. 3.6).   
Table 3.8 Catalytic activity of the recovered catalyst 4b 
a
 
Entry Catalytic recycle Substrate Conversion 
b
 Reaction time (hrs) 
1 Fresh catalyst  Acetophenone 99 1 
2 1
st
    Acetophenone 98 1 
3 2
nd
  Acetophenone 96 1.5 
4 3
rd
   Acetophenone 95 5 
a 
1 mmol substrate, 0.5 mol% recovered catalyst, HCOOH (7.50 mmol) / HCOONa (3.50 mmol) in 2 mL    
H2O at 60 °C 
b 







H NMR spectra of the fresh, recovered and recovered catalyst 4b after 3
rd











In conclusion, new half sandwich Ir(III) and Rh(III) complexes were synthesized and 
characterized. The crystal structure further confirms that the iridium 1b exhibited a pseudooctahedral 
geometry. Solution NMR studies revealed that the iridium and rhodium complexes are diasteromers in 
solution. It was further confirmed that the (RM, SN-H) diastereomer exists as the major diastereomer in 
solution compared to the minor (SM, RN-H) diastereomer. Interestingly, we indentified the cross 
interactions between the CH2 to Cp* moiety as well as CH2 to phenyl ring by 1D NOE NMR studies.  
 
The catalytic activity of the Ir(III) and Rh(III) amine complexes in the TH of aromatic ketones 
and aldehydes was demonstrated in water, with no need of organic solvents. Among the complexes, the 
rhodium amine 4b and imine 2a complexes in an aqueous HCOOH and HCOONa mixture at pH = 2.60 at 
60 °C showed the best catalytic activity for the TH reactions. These catalysts achieved good TON for TH 
of aromatic ketones (200 / 200) and aldehydes (960 / 1000) under optimized reaction conditions. The 
highly acidic N-H proton present in the rhodium amine complex facilitated the TH of aromatic ketones 
and aldehydes more effectively. The aromatic aldehydes normally required lower catalyst loading (S/C = 
1000) than aromatic ketones (S/C = 200) for effective TH reactions under the specified reaction 
conditions. The recovered catalyst showed good catalytic activity up to three catalytic recycles. These 
studies offer new possibilites for developing versatile catalysts for catalytic TH and other applications in 
water or organic solvents.  
Acknowledgements  
Authors would like to thank the NRF, THRIP (Grant no. TP 1208035643) and the University of KwaZulu 
- Natal, Durban, South Africa for financial support. 





C NMR, 2D NMR, NMR stability data, 1D NOE analysis and crystal data of the complexes 
are also shown in the SI.  
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Synthesis and characterization of new half sandwich Ir(III), Rh(III), Ru(II) 




A new carbazole N,N' ligand containing [(η
5










-p-cymene)OsX(L)]PF6 X = Cl (8c), I (9c)) (L = 9-ethyl-N-(pyridine-2-yl methylene)-9H-




C NMR, 2D 
NMR, melting point analysis, infrared spectroscopy, HR-MS and elemental analyses. The structures of 
the 3c and 6c have been determined by single crystal XRD. Anticancer study of the synthesized 
complexes 1c-3c clearly showed them as potent inhibitors of human breast cancer cells (MCF-7) under in 
vitro conditions. The inhibitory concentrations (IC50) of complexes 1c-3c were determined at low (5, 6 
and 8 μM) concentration against the MCF-7 human breast cancer cell line. Further cytotoxic, cell cycle 
and nuclear studies confirmed that the novel half sandwich Ir(III), Rh(III) and Ru(II) complexes could be 
effective against MCF-7 human breast cancer cell proliferation. Moreover the results indicate that 
anticancer in vitro activity of complexes 1c-3c follows the order of 1c > 2c > 3c. Molecular docking study 
of the complexes 1c-3c showed the nature of binding energy, H-bond and hydrophobic interactions with 
the COX-2 receptor. 
Keywords: Half sandwich complexes; MCF-7 cancer cell line; cytotoxicity; cell morphology; molecular 
docking 
4.1 Introduction 
Since the remarkable discovery of cis-platin for anticancer treatment, metal mediated anticancer 
drugs have received great attention in the treatment of various types of cancers for chemotherapeutic 
studies [1, 2]. Various platinum based metallo-drugs, such as carboplatin and oxalioplatin [3, 4] are 
available. Toxicity, side effects and platinum drug resistance of living cells lead to the discovery and 
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design of novel organometallic drugs for the therapeutic treatment of cancer. To replace the classic 
platinum based metallodrugs, various transition metals have been investigated to identify suitable 
metallodrugs for in vitro and in vivo anticancer studies [5, 6]. For example, Zeglis et al. developed Cu(II) 
complexes containing α-heterocyclic-N
4
-substituted thiosemicarbazone ligands promoting excellent 
topoisomerase-IIα inhibition and antiproliferative activity [7]. Among the transition metals, ruthenium 
metal based metallodrugs KP1019 (indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] and 
NAMI-A (imidazolium trans-[tetrachlorido(dimethyl sulfoxide)(1H-imidazole)ruthenate-(III)]) showed 
high antitumor activity under in vitro and in vivo conditions in clinical trials [8, 9]. Recently arene 





-p-toluene)Cl2(PTA)] (where PTA = 1,3,5-triaza-7-phosphaadamantane), DAPTA-C [(Ru(η
6
-p-
cymene)Cl2(DAPTA)], and DAPTA-T [(Ru(η
6
-p-toluene)Cl2(DAPTA)] (where DAPTA = 3,7 diacetyl-1, 
3, 7-triaza-5-phosphabicyclo[3.3.1]nonane) showed low toxicity profiles and antiproliferative effects in 
endothelial cells [10]. In recent years, organometallic half sandwich octahedral low spin d
6
 metal 
complexes have been of great interest in chemotherapeutic studies because of the hydrophilic and 
hydrophobic nature of carbon bound π bonded arenes and the cyclopentadienyl moieties respectively. 
This arene and cyclopentadienyl moieties emerged as versatile tool to develop novel compounds for 
antitumor activity studies, which is responsible for cell intake, targeting and kinetic inertness of the 
complexes [11, 12].  
The half sandwich [(η
6
-arene)M(LL)X][Z] (M = Ru or Os, LL = ethylenediamine or 
acetylacetonate (Ru), LL = N-(2-pyridylmethylene)-(S)-1-phenylethylamine or N-(2-pyridylmethylene)-




 (Os), and Z = counter ion) complexes exhibit excellent anti-
cancer activities and their activities were in some cases found to be higher than those of cis-platin and 
carbo-platin [13-15]. Recently, half sandwich and cyclometalated isoelectronic Ir(III) complexes 
containing a pentamethylcyclopentadienyl (Cp*) stabilizing moiety were found to exhibit high antitumor 
activity against human ovarian A2780 due to their rapid hydrolysis in solution and direct binding to DNA 
nucleobases, which is accompanied by Cp* intercalation between the nucleobases like 9-ethylguanine and 
9-methyladenine [16, 17].  
The N,N' chelating donor ligands containing Cp*Ir(III), Cp*Rh(III) and (η
6
–arene)Ru(II) half 
sandwich complexes exhibit a wide range of applications in bio-organometllic chemistry due to their air 
stability, rapid hydrolysis, cell accumulation, hydrophobicity, effective distribution within cells, 
intercalation with DNA and anticancer activity [16, 18]. Furthermore, recently reported C,N 
cyclometalated Cp*Ir(III), Cp*Rh(III) and (η
6
-arene)Ru(II) complexes containing novel benzimidazole 
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chelating ligands exhibit anticancer activities against HT29, T47D, A2780 and A2780cisR cancer cell 
lines which were almost comparable to that of the cis-platin drug [19].  
The 5H-benzo[b]carbazoles, 3,6-dibromocarbazole piperazine, 9-hydroxy-5,6-dimethyl-6H-
pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their derivatives exhibit 
various biological activities in chemotherapeutic studies, such as antitumor, inhibition of cytochrome c, 
inhibition of DNA topoisomerase II and intercalation into DNA. The carbazole core moiety present, 9-
hydroxy-2-methylellipticinium acetate III (ellipticinium), has been used for osteolytic metastases of breast 
cancer [20-24]. There are a number of carbazole based drugs reported in literature, such as carvedilol for 
antioxidative [25], P7C3 for neuroprotective [26], carbazomycin B for antibiotic [27], caprofen for anti-
inflammatory [28] activity and carbazomadurin A as a neuronal cell-protecting agent [29]. These 
biological applications of carbazole moiety drugs influenced us to synthesize and evaluate the anticancer 
activity of new metal carbazole complexes. This work describes the synthesis and characterization of new 
N,N’ carbazole chelating ligand containing compounds [(η
5
-C5Me5)M(III)(L)]PF6 (M = Ir (1c) and Rh 
(2c)) and [(η
6
-C6H6)Ru(II)(L)]PF6 (3c) and morphological studies on MCF-7 cancer cells using 
fluorescence and DAPI staining methods, as well as in vitro anticancer activity studies against the MCF-7 
human breast cancer cell lines. In order to understand the binding interactions of these metal complexes 
with the COX-2 receptor, molecular docking studies was carried out.    
4.2 Experimental Section 
4.2.1 Reagents and Methods 
 Unless otherwise noted, all manipulations were performed using standard Schlenk tube techniques 
under nitrogen atmosphere. The reagents 2-pyridinecarboxaldehdye, glacial acetic acid, IrCl3·3H2O 
(≥99% purity),  hCl3·3H2O (≥99% purity), hydrated  uCl3·xH2O (≥99% purity), OsCl3·xH2O (≥99% 
purity) and solvents were purchased from Sigma-Aldrich, Capital Labs, South Africa and were used 
without further purification. The NMR solvent DMSO-d6 and D2O was purchased from Merck Germany. 
The solvents were dried by standard procedures and distilled prior to use [30]. Melting points were 
recorded on a Stuart
TM
 Scientific apparatus SMP 3 and are uncorrected. Time-dependent 
1
H NMR (400 
MHz) stability studies and
 13
C (100 MHz) NMR were recorded in DMSO-d6 / D2O and DMSO-d6 solvent 
systems respectively using a Bruker Topspin 400 spectrometer. Elemental analyses were performed on a 
Thermo-Scientific Flash 2000 CHNS/O analyser. Solid and liquid state infrared spectra were recorded 
using an FT-IR Perkin Elmer Spectrum 100 spectrophotometer between 4000 - 400 cm
-1
. High resolution 
mass spectra were recorded using a Waters Micromass LCT Premier TOF-MS instrument. UV-Vis 
studies were recorded using a Perkin Elmer precisely Lambda35 instrument. X-ray single crystal intensity 
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data were collected on a Bruker Smart APEX11 Nonius Kappa-CCD diffractometer using graphite 
monochromated MoK radiation ( = 0.71073 Å). The Eclipse E400 biological microscope (Nikon 
Eclipse, Inc, Japan) at 400x magnification with an excitation filter at 480 nm used to visualize the MCF-7 
cells. The ligand precursor 3-amino-9-ethyl-9H-carbazole [31] and metal precursors (IrCl2Cp*)2, 
(RhCl2Cp*)2, [RuX(η
6
-arene)2]2 (arene = benzene or p-cymene, X = Cl or Br or I) and  [OsX(η
6
-arene)2]2 
(arene = benzene or p-cymene, X = Cl or I) were prepared according to literature methods [15, 32-35].  
4.2.2 Synthesis and Characterization of the ligand and complexes 
4.2.2.1 Synthesis procedure for 9-ethyl-N-(pyridine-2-yl methylene)-9H-carbazole-3-amine 
(L) 
A mixture of the 9-ethyl-9H-carbazole-3-amine (2.5 mmol, 530 mg), 2-pyridinecarboxaldehyde 
(2.5 mmol, 0.25 mL) and 2 drops of the glacial acetic acid in toluene (10 mL) was stirred at room 
temperature for 24 h. The reaction was monitored by TLC. Once the reaction was completed, diluted 
NaHCO3 solution was added to the reaction mixture to neutralize the glacial acetic acid. The solvent was 
distilled off under reduced pressure to leave the crude product. The crude product was dissolved in 
diethylether (30 mL) and the organic layer was washed with brine solution (15 mL) twice and dried over 
anhydrous Na2SO4. The combined organic layer was concentrated under vacuum and the resulting residue 
was purified by column chromatography on silica gel [ethyl acetate:n-hexanes] yielding a dark brown oil 
as the product. Yield (700 mg, 93%). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm) δ = 8.83 (s, 1H, imine 
CH), 8.73 (d, 1H, JH-H = 4.72 Hz, α proton of Py), 8.30 (d, 1H, JH-H = 1.92 Hz, Carb 1
st
 ring), 8.24 (t, 2H, 
Py & Carb 3
rd
 ring), 7.97 (t, 1H, Py), 7.66 (d, 1H, JH-H = 8.64 Hz, Carb 1
st





 ring), 7.51 - 7.49 (m, 1H, Py), 7.48 (t, 1H, Carb 3
rd
 ring), 7.23 (m, 1H, Carb 3
rd
 ring), 4.47 - 4.42 
(q, 2H, N - CH2), 1.33 (t, 3H, N -CH3). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ = 157.52 (imine 
C-H), 154.63, 149.58, 136.91, 126.04 (Py), 141.91, 140.14, 138.28, 125.06, 122.77, 122.37, 120.73, 
120.70, 120.32, 118.90, 113.29, 109.53, 109.29 (Carb), 37.08 (CH2, N - CH2CH3), 13.69 (CH3, N - 
CH2CH3). FT-I  (γ/cm
-1
): 3050, 2974, 2931, 1733, 1581 (s, C=N), 1478 (s), 1469 (s), 1234 (s) 744 (s), 
728 (s). UV-Vis (dichloromethane, v/v): λmax(nm) = 242, 291, 321, 377. 
4.2.2.2 Synthesis of complexes 1c and 2c 
A common procedure was followed to synthesize [(η
5
-C5Me5)IrCl(L)] (1c) and [(η
5
-
C5Me5)RhCl(L)] (2c) (L = 9-ethyl-N-(pyridine-2-yl methylene)-9H-carbazole-3-amine). A mixture of 
(IrCl2Cp
*
)2 (100 mg, 0.13 mmol), the Schiff base carbazole ligand (78 mg, 0.26 mmol) and NH4PF6 (41 
mg, 0.25 mmol) was stirred at room temperature in methanol (15 mL) for five hours. The orange colored 
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precipitate separated out and was filtered with filter paper, washed with cold methanol and diethyl ether 
and dried under vacuum. 
4.2.2.3 [(η
5
-C5Me5)IrCl(L)] (1c)  
Yield (145 mg, 0.18 mmol, 72%). Mp. 287.0 °C (dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, 
ppm) δ = 9.44 (s, 1H, imine CH), 9.07 (d, 1H, JH-H  = 5.44 Hz, α proton of Py), 8.51 (s, 1H, Carb 1
st
 ring), 
8.44 (d, 1H, JH-H  = 7.48 Hz, Py), 8.37 (t, 1H, Py), 8.17 (d, 1H, JH-H = 7.68 Hz, Carb 3
rd
 ring), 7.96 (t, 1H, 
Py), 7.87 (s, 2H,Carb 1
st
 ring), 7.74 (d, 1H, JH-H = 8.28 Hz Carb 3
rd
 ring), 7.58 (t, 1H, Carb 3
rd
 ring), 7.32 
(t, 1H, Carb 3
rd
 ring), 4.57 - 4.51 (q, 2H, N - CH2), 1.46 (s, 15H, C5Me5), 1.38 (t, 3H, N -CH3). 
13
C NMR 
(100 MHz, DMSO-d6, 25 °C, ppm) δ = 167.02 (imine C-H), 155.70, 152.28, 140.99, 140.65, 140.51 (Py), 
139.74, 130.07, 129.40, 126.83, 121.83, 121.77, 121.01, 120.42, 119.68, 114.68, 109.94, 109.57 (Carb), 
89.74 (C, C5Me5), 37.36 (CH2, N - CH2CH3), 13.69 (CH3, N - CH2CH3), 8.05 (CH3, C5Me5). FT-I  (γ/cm
-
1
): 3069, 2983, 2941, 1596 (s, C=N), 1479 (s), 1470, 1459, 1231, 826 (s, P-F). HR-MS (TOF MS ES
+
) 
C30H32ClIrN3 Calculated: 662.1914, Found: 662.1907. Anal. Calcd for C30H32ClF6IrN3P: C, 44.64; H, 






)2 (100 mg, 0.16 mmol), Schiff base carbazole ligand (96 mg, 0.32 mmol) and NH4PF6 
(53 mg, 0.32 mmol). Yield (195 mg, 0.27 mmol, 84%). Mp. 306.0 °C (dec.). 
1
H NMR (400 MHz, 
DMSO-d6, 25 ºC, ppm) δ = 9.08 (d, 1H, JH-H  = 5.32 Hz, α proton of Py), 9.05 (s, 1H, imine CH), 8.55 (d, 
1H, JH-H  = 1.92 Hz, Carb 1
st
 ring), 8.40 (t, 1H, Py), 8.32 (d, 1H, JH-H = 6.88 Hz, Carb 3
rd
 ring), 8.17 (d, 
1H, JH-H  = 7.76 Hz, Py), 7.97 (d-d, 1H, Carb 1
st
 ring), 7.94 (t, 1H, Py), 7.88 (d, 1H, JH-H = 8.76 Hz Carb 1
st
 
ring), 7.74 (d, 1H, JH-H = 8.16 Hz, Carb 3
rd
 ring), 7.58 (t, 1H, Carb 3
rd
 ring), 7.33 (t, 1H, Carb 3
rd
 ring), 
4.57 - 4.51 (q, 2H, N - (CH2)CH3), 1.44 (s, 15H, C5Me5), 1.39 (t, 3H, N - CH2(CH3)). 
13
C NMR (100 
MHz, DMSO-d6, 25 °C, ppm) δ = 165.62 (imine C-H), 154.11, 152.74, 140.60, 140.49, 139.65 (Py), 
129.42, 129.37, 126.80, 121.88, 121.05, 120.41, 119.65, 114.40, 109.92, 109.61 (Carb), 97.14 (C, 
C5Me5), 37.35 (CH2, N - CH2CH3), 13.70 (CH3, N - CH2CH3), 8.31 (CH3, C5Me5). FT-I  (γ/cm
-1
): 3094, 
2971, 2939, 1581 (s, C=N), 1490, 1478 (s), 1240 (s), 1022, 833 (s, P-F). HR-MS (TOF MS ES
+
) 
C30H32ClN3Rh Calculated: 572.1340, Found: 572.1334. Anal. Calcd for C30H32ClF6N3PRh: C, 50.19; H, 
4.49; N, 5.85; Found: C, 49.86; H, 4.51; N, 6.10. 
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4.2.2.5 Synthesis of complexes 3c-9c 
The following common procedure was followed for the syntheses of complexes 3c-9c. A mixture 
of [MX(η
6
-arene)]2 (M = Ru or Os; arene = benzene or p-cymene; X = Cl or Br or I) and Schiff base 
carbazole ligand was dissolved in acetonitrile. The resulting mixture was stirred at room temperature for 
three hours, and the solvent was evaporated and treated with NH4PF6 in ethanol for an hour. The orange 
colored precipitate was separated and filtered through filter paper, washed with cold methanol and 






-C6H6))2 (100 mg, 0.20 mmol), Schiff base carbazole ligand (120 mg, 0.40 mmol) and 
NH4PF6 (65 mg, 0.40 mmol). Yield (180 mg, 0.27 mmol, 87%). Mp. 270.0 °C (dec.). 
1
H NMR (400 MHz, 
DMSO-d6, 25 ºC, ppm) δ = 9.68 (d, 1H, JH-H  = 5.48 Hz, α proton of Py), 8.99 (s, 1H, imine CH), 8.57 (d, 
1H, JH-H  = 2.08 Hz, Carb 3
rd
 ring), 8.34 (d-d, 1H, Carb 1
st
 ring), 8.28 - 8.24 (m, 2H, Py), 8.04 (d-d, 1H, 
Carb 3
rd
 ring), 7.89 (t, 1H, Py), 7.85 (d, 1H, JH-H = 8.84 Hz, Carb 3
rd
 ring), 7.74 (d, 1H, JH-H = 8.24 Hz, 
Carb 3
rd
 ring), 7.58 (t, 1H, Carb 1
st
 ring), 7.36 (t, 1H, Carb 3
rd
 ring), 5.99 (s, 6H, C6H6), 4.58 - 4.53 (q, 2H, 
N - (CH2)CH3), 1.41 (t, 3H, N - CH2(CH3)). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ = 165.86 
(imine C-H), 156.14, 154.95, 139.99, 129.31, 128.28 (Py), 144.30, 140.49, 139.81, 126.76, 122.04, 
121.93, 120.72, 119.56, 113.77, 109.84, 109.51 (Carb), 87.32 (C6H6), 37.34 (CH2, N - CH2CH3), 13.81 
(CH3, N - CH2CH3). FT-I  (γ/cm
-1
): 3089, 3061, 3027, 2980, 1627, 1611, 1595 (s, C=N), 1494, 1477 (s), 
1244 (s) 837, 822, 810 (m, P-F), 766, 753. HR-MS (TOF MS ES
+
) C26H23ClN3Ru Calculated: 514.0624, 
Found: 514.0634. Anal. Calcd for C26H23ClF6N3PRu: C, 47.39; H, 3.52; N, 6.38; Found: C, 47.62; H, 






-p-cymene))2 (100 mg, 0.16 mmol), Schiff base carbazole ligand (96 mg, 0.32 mmol) 
and NH4PF6 (53 mg, 0.32 mmol). Yield (185 mg, 0.20 mmol, 79%). Mp. 260.0 °C (dec.). 
1
H NMR (400 
MHz, DMSO-d6, 25 ºC, ppm) δ = 9.59 (d, 1H, JH-H  = 5.44 Hz, α proton of Py), 8.99 (s, 1H, imine CH), 
8.60 (d, 1H, JH-H  = 1.60 Hz, Carb 3
rd
 ring), 8.32-8.25 (m, 3H, Carb 1
st
 ring and Py), 8.01 (d-d, 1H, Carb 
3
rd
 ring), 7.89-7.84 (m, 1H, Py and Carb 3
rd
 ring), 7.75 (d, 1H, JH-H = 8.28 Hz, Carb 3
rd
 ring), 7.59 (t, 1H, 
Carb 1
st
 ring), 7.34 (t, 1H, Carb 3
rd
 ring), 6.12 (d, 1H, JH-H  = 6.20 Hz, p-cymene), 5.79 (d, 1H, JH-H  = 6.16 
Hz, p-cymene), 5.67 (d, 1H, JH-H  = 6.12 Hz, p-cymene), 5.62 (d, 1H, JH-H  = 6.08 Hz, p-cymene), 4.58 - 
4.53 (q, 2H, N - (CH2)CH3), 2.21 (s, 3H, p-cymene), 1.42 (t, 3H, N - CH2(CH3)), 1.03 (d, 3H, JH-H  = 6.88 
Hz, p-cymene), 0.99 (d, 3H, JH-H  = 6.84 Hz, p-cymene). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ = 
95 
 
165.53 (imine C-H), 155.89, 154.85, 139.89, 129.33, 128.41 (Py), 144.17, 140.52, 139.91, 126.80, 
122.02, 121.97, 121.32, 120.77, 119.59, 114.03, 109.84, 109.54 (Carb), 105.07, 102.96, 86.44, 85.90, 
85.49, 85.40 (Ph, p-cymene), 37.37 (CH2, N - CH2CH3), 30.48 (CH, (CH(CH3)2), p-cymene), 21.82, 21.43 
((CH3)2 (CH(CH3)2), p-cymene), 18.26 (CH3, p-cymene), 13.83 (CH3, N - CH2CH3). FT-I  (γ/cm
-1
): 3054, 
2979, 1627, 1598(s, C=N), 1491, 1481 (s), 1242 (s) 829 (s, P-F), 780, 755, 555. HR-MS (TOF MS ES
+
) 
C30H31ClN3Ru Calculated: 570.1250, Found: 570.1238. Anal. Calcd for C30H31ClF6N3PRu: C, 50.39; H, 






-p-cymene))2 (100 mg, 0.13 mmol), Schiff base carbazole ligand (78 mg, 0.26 mmol) 
and NH4PF6 (42 mg, 0.32 mmol). Yield (170 mg, 0.22 mmol, 88%). Mp. 250.0 °C (dec.). 
1
H NMR (400 
MHz, DMSO-d6, 25 ºC, ppm) δ = 9.58 (d, 1H, JH-H  = 5.48 Hz, α proton of Py), 8.98 (s, 1H, imine CH), 
8.63 (d-d, 1H, JH-H  = 1.64 Hz, Carb 3
rd
 ring), 8.30 (d, 2H, JH-H  = 4.24 Hz, Carb 1
st
 ring), 8.26 (d, 1H, JH-H  
= 7.72 Hz, Py), 8.05 (d-d, 1H, Carb 3
rd
 ring), 7.87-7.84 (m, 2H, Py), 7.75 (d, 1H, JH-H = 8.28 Hz, Carb 3
rd
 
ring), 7.59 (t, 1H, Carb 1
st
 ring), 7.34 (t, 1H, Carb 3
rd
 ring), 6.10 (d, 1H, JH-H  = 6.24 Hz, p-cymene), 5.80 
(d, 1H, JH-H  = 6.20 Hz, p-cymene), 5.67 (d, 1H, JH-H  = 6.12 Hz, p-cymene), 5.63 (d, 1H, JH-H  = 6.12 Hz, 
p-cymene), 4.58 - 4.53 (q, 2H, N - (CH2)CH3), 2.30 (s, 3H, p-cymene), 1.42 (t, 3H, N - CH2(CH3)), 1.04 
(d, 3H, JH-H  = 6.88 Hz, p-cymene), 0.98 (d, 3H, JH-H  = 6.88 Hz, p-cymene). 
13
C NMR (100 MHz, DMSO-
d6, 25 °C, ppm) δ = 165.31 (imine C-H), 156.39, 154.85, 139.77, 129.40, 128.26 (Py), 144.37, 140.53, 
139.97, 126.81, 122.02, 121.95, 121.62, 120.76, 119.60, 114.24, 109.86, 109.51 (Carb), 105.93, 102.17, 
86.13, 86.03, 85.97, 85.64 (Ph, p-cymene), 37.38 (CH2, N - CH2CH3), 30.63 (CH, (CH(CH3)2), p-
cymene), 21.86, 21.34 ((CH3)2 (CH(CH3)2), p-cymene), 18.82 (CH3, p-cymene), 13.82 (CH3, N - 
CH2CH3). FT-I  (γ/cm
-1
): 3054, 2984, 2965, 2932, 1629, 1598 (s, C=N), 1484, 1476, 1461, 1234 (s), 841, 
834 (s, P-F), 767, 745, 557. HR-MS (TOF MS ES
+
) C30H31BrN3Ru Calculated: 614.0745, Found: 







-p-cymene))2 (100 mg, 0.10 mmol), Schiff base carbazole ligand (60 mg, 0.20 mmol) and 
NH4PF6 (34 mg, 0.20 mmol). Yield (145 mg, 0.21 mmol, 88%). Mp. 240.0 °C (dec.). 
1
H NMR (400 MHz, 
DMSO-d6, 25 ºC, ppm) δ = 9.57 (d, 1H, JH-H  = 5.56 Hz, α proton of Py), 8.95 (s, 1H, imine CH), 8.66 (d-
d, 1H, JH-H  = 1.68 Hz, Carb 3
rd
 ring), 8.32-8.23 (m, 3H, Py and Carb 1
st
 ring), 8.08 (d-d, 1H, JH-H  = 1.80 
Hz, Carb 3
rd
 ring), 7.85-7.79 (m, 2H, Py), 7.74 (d, 1H, JH-H = 8.28 Hz, Carb 3
rd





ring), 7.34 (t, 1H, Carb 3
rd
 ring), 6.06 (d, 1H, JH-H  = 6.24 Hz, p-cymene), 5.82 (d, 1H, JH-H  = 6.20 Hz, p-
cymene), 5.68 (d, 1H, JH-H  = 6.24 Hz, p-cymene), 5.61 (d, 1H, JH-H  = 6.08 Hz, p-cymene), 4.58 - 4.53 (q, 
2H, N - (CH2)CH3), 2.43 (s, 3H, p-cymene), 1.41 (t, 3H, N - CH2(CH3)), 1.05 (d, 3H, JH-H  = 6.84 Hz, p-
cymene), 0.96 (d, 3H, JH-H  = 6.88 Hz, p-cymene). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ = 
164.81 (imine C-H), 155.68, 154.88, 139.54, 129.55, 127.90 (Py), 144.69, 140.56, 140.09, 126.83, 
122.13, 122.00, 121.92, 120.72, 119.63, 114.68, 109.88, 109.44 (Carb), 107.70, 101.27, 86.85, 86.55, 
85.80, 85.51 (Ph, p-cymene), 37.39 (CH2, N - CH2CH3), 30.98 (CH, (CH(CH3)2), p-cymene), 21.98, 21.23 
((CH3)2 (CH(CH3)2), p-cymene), 19.89 (CH3, p-cymene), 13.81 (CH3, N - CH2CH3). FT-I  (γ/cm
-1
): 3058, 
2982, 2962, 1629, 1599 (s, C=N), 1485, 1475, 1461, 1241, 1233 (s), 841, 832 (s, P-F), 821, 767, 743, 
557. HR-MS (TOF MS ES
+
) C30H31IN3Ru Calculated: 662.0606, Found: 662.0579. Anal. Calcd for 






-C6H6))2 (100 mg, 0.15 mmol), Schiff base carbazole ligand (90 mg, 0.30 mmol) and 
NH4PF6 (50 mg, 0.30 mmol). Yield (143 mg, 0.19 mmol, 65%). Mp. 283.0 °C (dec.). 
1
H NMR (400 MHz, 
DMSO-d6, 25 ºC, ppm) δ = 9.62 (d, 1H, JH-H  = 5.48 Hz, α proton of Py), 9.36 (s, 1H, imine CH), 8.51 (d-
d, 1H, JH-H  = 1.24 Hz, Carb 3
rd
 ring), 8.41 (d, 1H, JH-H  = 7.64 Hz, Carb 1
st
 ring), 8.31 - 8.23 (m, 2H, Py), 
7.94 (d, 1H, JH-H  = 8.64 Hz, Carb 3
rd
 ring), 7.85 - 7.81 (m, 2H, Py and Carb 3
rd
 ring), 7.74 (d, 1H, JH-H = 
8.24 Hz, Carb 3
rd
 ring), 7.59 (t, 1H, Carb 1
st
 ring), 7.33 (t, 1H, Carb 3
rd
 ring), 6.13 (s, 6H, C6H6), 4.58 - 
4.53 (q, 2H, N - (CH2)CH3), 1.41 (t, 3H, N - CH2(CH3)). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ 
= 166.93 (imine C-H), 156.24, 155.86, 139.88, 129.39, 129.31 (Py), 144.08, 140.49, 140.30, 126.79, 
121.99, 121.92, 121.82, 120.86, 119.58, 114.37, 109.86, 109.53 (Carb), 78.85 (C6H6), 37.39 (CH2, N - 
CH2CH3), 13.85 (CH3, N - CH2CH3). FT-I  (γ/cm
-1
): 3062, 2973, 1598 (s, C=N), 1492, 1482, 1233 (s) 
833 (s, P-F), 809, 779, 750. HR-MS (TOF MS ES
+
) C27H23ClN2Os Calculated: 602.1165, Found: 







-p-cymene))2 (100 mg, 0.13 mmol), Schiff base carbazole ligand (76 mg, 0.26 mmol) 
and NH4PF6 (42 mg, 0.32 mmol). Yield (170 mg, 0.21 mmol, 84%). Mp. 262.0 °C (dec.). 
1
H NMR (400 
MHz, DMSO-d6, 25 ºC, ppm) δ = 9.53 (d, 1H, JH-H  = 5.52 Hz, α proton of Py), 9.39 (s, 1H, imine CH), 
8.52 (d, 1H, JH-H  = 1.56 Hz, Carb 3
rd
 ring), 8.42 (d, 1H, JH-H  = 7.64 Hz, Py), 8.30-8.25 (m, 2H, Carb 1
st
 
ring and Py), 7.89 (d-d, 1H, Carb 3
rd
 ring), 7.84-7.82 (m, 2H, Py and Carb 3
rd
 ring), 7.74 (d, 1H, JH-H = 
97 
 
8.24 Hz, Carb 3
rd
 ring), 7.57 (t, 1H, Carb 1
st
 ring), 7.36 (t, 1H, Carb 3
rd
 ring), 6.40 (d, 1H, JH-H  = 5.80 Hz, 
p-cymene), 6.00 (d, 1H, JH-H  = 5.76 Hz, p-cymene), 5.86 (d, 1H, JH-H  = 5.72 Hz, p-cymene), 5.78 (d, 1H, 
JH-H  = 5.76 Hz, p-cymene), 4.58 - 4.53 (q, 2H, N - (CH2)CH3), 2.29 (s, 3H, p-cymene), 1.42 (t, 3H, N - 
CH2(CH3)), 0.96 (d, 3H, JH-H  = 6.88 Hz, p-cymene), 0.93 (d, 3H, JH-H  = 6.88 Hz, p-cymene). 
13
C NMR 
(100 MHz, DMSO-d6, 25 °C, ppm) δ = 166.48 (imine C-H), 156.25, 155.62, 139.98, 129.26, 126.82 (Py), 
144.16, 140.51, 140.08, 121.97, 121.32, 120.71, 120.83, 119.61, 114.47, 109.85, 109.56 (Carb), 96.81, 
96.59, 78.55, 78.04, 75.97, 75.90 (Ph, p-cymene), 37.39 (CH2, N - CH2CH3), 30.68 (CH, (CH(CH3)2), p-
cymene), 21.98, 21.80 ((CH3)2 (CH(CH3)2), p-cymene), 18.26 (CH3, p-cymene), 13.84 (CH3, N - 
CH2CH3). FT-I  (γ/cm
-1
): 3063, 2976, 1597 (s, C=N), 1491, 1473, 1242, 1234, 830 (s, P-F), 779, 754, 
556. HR-MS (TOF MS ES
+
) C30H31ClN3Os Calculated: 660.1821, Found: 660.1802. Anal. Calcd for 






-p-cymene))2 (100 mg, 0.9 mmol), Schiff base carbazole ligand (52 mg, 0.18 mmol) and 
NH4PF6 (30 mg, 0.18 mmol). Reddish brown solid. Yield (124 mg, 0.21 mmol, 81%). Mp. 187.0 °C 
(dec.). 
1
H NMR (400 MHz, DMSO-d6, 25 ºC, ppm) δ = 9.53 (d, 1H, JH-H  = 5.52 Hz, α proton of Py), 9.32 
(s, 1H, imine CH), 8.59 (s, 1H, Carb 3
rd
 ring), 8.44 (d, 1H, JH-H  = 7.72 Hz, Py), 8.24-8.20 (m, 2H, Py and 
Carb 1
st
 ring), 8.01 (d, 1H, JH-H  = 8.84 Hz, Carb 3
rd
 ring), 7.84 (d, 1H, JH-H  = 8.80 Hz, Carb 3
rd
 ring), 7.77 
- 7.72 (m, 2H, Py and Carb 3
rd
 ring), 7.59 (t, 1H, Carb 1
st
 ring), 7.34 (t, 1H, Carb 3
rd
 ring), 6.33 (d, 1H,  
JH-H  = 5.88 Hz, p-cymene), 6.02 (d, 1H, JH-H  = 5.84 Hz, p-cymene), 5.86 (d, 1H, JH-H  = 5.80 Hz, p-
cymene), 5.79 (d, 1H, JH-H  = 5.80 Hz, p-cymene), 4.58 - 4.53 (q, 2H, N - (CH2)CH3), 2.52 (s, 3H, p-
cymene), 1.41 (t, 3H, N - CH2(CH3)), 0.99 (d, 3H, JH-H  = 6.88 Hz, p-cymene), 0.90 (d, 3H, JH-H  = 6.88 
Hz, p-cymene). 
13
C NMR (100 MHz, DMSO-d6, 25 °C, ppm) δ = 165.53 (imine C-H), 156.78, 156.18, 
139.63, 129.34, 128.65 (Py), 144.88, 140.56, 140.17, 126.85, 122.49, 121.96, 121.92, 120.74, 119.63, 
115.05, 109.88, 109.45 (Carb), 98.88, 94.36, 78.14, 77.91, 77.79, 77.73 (Ph, p-cymene), 37.38 (CH2, N - 
CH2CH3), 30.97 (CH, (CH(CH3)2), p-cymene), 21.94, 21.37 ((CH3)2 (CH(CH3)2), p-cymene), 20.02 (CH3, 
p-cymene), 13.82 (CH3, N - CH2CH3). FT-IR (γ/cm
-1
): 3039, 2975, 1628, 1610, 1596 (s, C=N), 1491, 
1473, 1441, 1233, 832 (s, P-F), 769, 753, 556. HR-MS (TOF MS ES
+
) C30H31IN3Os Calculated: 
752.1178, Found: 752.1147. Anal. Calcd for C30H31ClF6N3PRu: C, 40.23; H, 3.49; N, 4.69; Found: C, 




Details of the crystal structures of complexes 2c and 6c are given in Table 4.1. A suitable crystal 
for single crystal XRD was grown by slow evaporation of hexane into an acetonitrile, methanol (1:1) 
mixture. The crystal was selected and glued onto the tip of a glass fibre, then mounted in a stream of cold 
nitrogen at 100 (1) K and centred in the X-ray beam by using a video camera. The crystal refinement and 
data collection were performed on a Bruker Smart APEX11 diffractometer using graphite crystal 
monochromatised Mo - K radiation (ʎ = 0.71073 Å) at 100 (1) K. The intensity data was collected by 
the ω scan mode within 3.44° ˂ ϴ ˃ 65.08° for hkl (-15 ≤ h ≤13, -22 ≤ k ≤22, -28 ≤ l ≤ 27) (2c) in the 
orthorhombic system and 1.47 ˂ ϴ ˃ 28.70° for -28≤h≤28, -36≤k≤36, -13≤l≤14 (6c) in the monoclinic 
system. The structure of the crystal was resolved by using, the SHELX program. The full-matrix least-
squares on F
2
 refinement method with the SHELX program package was used to refine the positions and 
thermal parameters of all non-hydrogen atoms in the crystals [36]. For the structures and graphics, 
ORTEP-3 [37] and DIAMOND [38] programs were used. 
4.2.4 Cells and culture conditions 
The human breast cancer MCF-7 cell line was obtained from the National Centre of Cell Science 
(Pune, India). The cells were maintained in Dulbecco’s Modified Eagles medium supplemented with 2 
mM l-glutamine and Earle’s BSS adjusted to contain 1.5 g L
-1
 Na bicarbonate, 0.1 mM nonessential 
amino acids, and 1.0 mM of Na pyruate in a humidified atmosphere containing 5% CO2 at 37 °C. 
4.2.5 Cell viability assay 
Cell viability was determined by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay [39]. Briefly, exponentially growing cells (1x10
4
 cells/well) were seeded into a 96 well plate 
and allowed to attach overnight. Cells were treated with the various concentrations of complexes in at 
least six replicate wells and left in contact for 48 h. 500 μM mL
-1
 of MTT was added to each well, and the 
plate was further incubated at 37 °C for another 4 h. The formazan crystals formed were dissolved in 
DMSO. Cell viability was expressed as follows: 
        Test 
Cell viability (%) =             X 100% 




4.2.6 Morphological study 
The MCF-7 cells that were grown on cover slips (1×10
5
 cells/cover slip) were incubated for 6-24 
h with compounds at the IC50 concentration, and they were then fixed in an ethanol:acetic acid solution 
(3:1 v/v). The cover slips were gently mounted on glass slides for the morphometric analysis. Three 
monolayers per experimental group were photo micrographed. The morphological changes of the MCF-7 
cells were analyzed using Nikon (Japan) bright field inverted light microscopy at 40x magnification. 
4.2.7 Fluorescence microscopic analysis of cell death 
Approximately 1 µL of a dye mixture of 100 mg/mL acridine orange (AO) and 100 mg/mL 
ethidium bromide (EtBr) in distilled water was mixed with 9 mL of cell suspension (1×10
5
 cells/mL) on 
clean microscope cover slips. The MCF-7 cells were collected, washed with phosphate buffered saline 
(PBS) (pH 7.2) and stained with 1 mL of AO/EtBr. After incubation for 2 min, the cells were washed 
twice with PBS (5 min each) and visualized under a fluorescence microscope (Nikon Eclipse, Inc, Japan) 
at 400x magnification with an excitation filter at 480 nm. The percentage of apoptotic cells was 
determined using the following formula 
Total number of apoptotic cells 
% of apoptotic cells =                        X 100 
    Total number of normal and apoptotic cells 
4.2.8 Flow cytometric analysis of cell cycle  
The DNA content during the cell cycle steps were evaluated with flow cytometric analysis. In 
brief, 5×10
6
 cells were treated with complexes 1c-3c at a specific concentration. After 24 hr, the cell 
pellets were washed and resuspended in 2 mL of 1% paraformaldehyde in PBS and incubated for 15 min 
at 4°C. Then, the cells were centrifuged and 1 mL of cold perm buffer III solution was added and 
incubated for 30 min at 4 °C followed by washing with PBS twice. Next, 500 µg of Propidium Iodide (PI) 
(Sigma-Aldrich, Steinbeim, Germany) staining buffer (50 μg/mL PI, 10 μg/mL RNase in PBS) was added 
and incubated for 1 hr at room temperature in the dark. After DNA staining by PI, samples were evaluated 
by a flow cytometer using Partec FloMax software (Version 2.3). 
4.2.9 Statistical analysis  
All the experiments were performed in triplicates for each group. The data are expressed as mean 
± standard deviation. Differences with p value < 0.05 were considered to be statistically significant. 
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4.3 Computational studies  
4.3.0.1 Molecular Docking 
This study was performed using AutoDock 4v software which performs docking calculations to 
identify the binding orientation or conformation of a complex in the active site of the protein [40]. The 
crystal structure of the cyclooxygenase-2 (COX-2) protein (PDB ID: 1CX2) was retrieved from the 
protein data bank. Complexes 1c-3c were sketched using Chemdraw software [41]. The geometry 
optimization and minimization for both protein and ligand was performed with the AM1-BCC charge 
method using AMBER software to obtain the correct bond length, bond angles and dihedral angles [42, 
43]. The minimized complexes 1c-3c and protein were saved in pdbqt format in AutoDock software. The 
active site residues of the protein, COX-2 was taken from the literature and grid was generated. Docking 
was performed using the Lamarckian genetic algorithm with default parameters and the best conformation 
or pose was chosen based on binding energy (kcal/mol). 
4.3 Results and discussion 
4.3.1 Synthesis of the ligand and complexes 
In the present work, the new half sandwich metal complexes 1c-9c have been synthesised using 
the new N,N' carbazole bidentate ligand (Scheme 4.1). A reaction between the chloro bridged dimer 
(MCl2Cp
*
)2 (M = Ir and  h) with N, N’ 9-ethyl-N-(pyridine-2-yl methylene)-9H-carbazole-3-amine (L) 
and NH4PF6 afforded the new [(η
5
-C5Me5)MCl(L)]PF6 (M = Ir (1c) and Rh (2c)) complexes in good 
yields in methanol (72% and 84%). Furthermore, a reaction between the chloro-bridged arene dimer 
(MX2(η
6
-arene))2 (M = Ru or Os; arene = benzene or p-cymene; X = Cl or Br or I) with N, N’ 9-ethyl-N-
(pyridine-2-yl methylene)-9H-carbazole-3-amine (L) and NH4PF6, afforded the new [(η
6
-
arene)MX(L)]PF6 complexes in good yields (65-88%). Complexes 1c-8c are orange-red crystalline solids 
(complex 9c = reddish brown color) and are air stable, non-hygroscopic and soluble in common polar 
solvents such as DMSO, DMF, acetonitrile, dichloromethane, acetone and partially soluble in water, 
chloroform, methanol, ethanol. These complexes are insoluble in diethyl ether, petroleum ether and 
hexane. 
 
Characterisation of the ligand and metal complexes 1c-9c was carried out by NMR, 2D NMR 
(COSY, NOESY), IR spectroscopy, melting point analysis, HR-MS spectroscopy and elemental analyses. 
The structures of the complexes 2c and 6c have been further authenticated by single crystal X-ray 




Scheme 4.1: Schematic diagram of ligand and complexes 1c-9c synthesis routes. 
4.3.2 NMR studies 
The spectral data of the ligand and metal complexes have been summarized in the Experimental 
section. The 
1
H NMR spectrum of the free N,N' carbazole ligand (L) showed a -CH imine proton singlet 
signal at 8.83 ppm and a doublet signal of the α proton in the pyridine ring appeared at 8.73 ppm. hen 
the N,N' carbazole ligand was coordinated with the iridium, rhodium and ruthenium metal precursor, the 
singlet peak of the imine proton signal shifted further down-field to 9.44 (1c), 9.04 (2c), 8.99 (3c), 8.99 
(4c), 8.98 (5c), 8.95 (6), 9.38 (7), 9.39 (8c) and 9.32 (9c) ppm respectively and the doublet peak of the α 
proton in the pyridine ring shifted down-field to 9.06 (1c), 9.08 (2c), 9.68 (3c), 9.59 (4c), 9.58 (5c), 9.57 
(6c), 9.62 (7c), 9.53 (8c) and 9.53 (9c) ppm respectively. The signals of the aromatic region of all metal 
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complexes 1c-9c were shifted down-field compared to the respective free ligand signals. The 
13
C NMR 
signals of the ligand imine carbon and α proton carbon in the pyridine ring appeared at 157.5 and 149.6 
ppm respectively, whilst the corresponding signals of the complexes 1c-9c shifted downfield to 167.0 and 
155.7 ppm for (1c), 165.6 and 154.1 ppm for (2c), 165.9 and 156.1 ppm for (3c), 165.5 and 156.9 ppm for 
(4c), 165.3 and 156.4 ppm for (5c), 164.8 and 155.7 ppm for (6c), 166.9 and 155.9 ppm for (7c), 166.5 
and 155.6 ppm for (8c) and 165.5 and 156.8 ppm for (9c), respectively. The 
1
H NMR and 
13
C NMR shifts 
confirmed that the N,N' carbazole ligand was coordinated with the respective metal centers and hence the 
formation of the respective complexes 1c-9c. 
4.3.3 Infrared spectroscopy 
IR spectra of the N,N' carbazole ligand exhibits a characteristic peak for the (C=N) stretching 
frequency at 1581 cm
-1
 and the stretching frequency of the carbazole moiety aliphatic ethyl group 
attached to the nitrogen atom ( N-CH2CH3) appeared in the range of 2932 - 3050 cm
-1
. In complexes 1c-




 (2c), 1595 cm
-1
 (3c), 1598 
cm
-1
 (4c), 1598 cm
-1
 (5c), 1599 cm
-1
 (6c), 1598 cm
-1
 (7c), 1597 cm
-1
 (8c) and 1596 cm
-1
 (9c), which are 
attributed to the N,N' carbazole nitrogen atom of the (C=N) group coordinated with the respective metal 
centers. The stretching frequency of the aliphatic ethyl group attached to the nitrogen atom (N-CH2CH3) 
was shifted to higher frequencies in all metal complexes 2941 to 3069 cm
-1 
(1c), 2939 to 3094 cm
-1 
(2c), 
2980 to 3089 cm
-1 
(3c), 2979 to 3054 cm
-1 
(4c), 2932 to 3054 cm
-1 
(5c), 2962 to 3058 cm
-1 
(6c), 2973 to 
3062 cm
-1 
(7c), 2976 to 3063 cm
-1 
(8c) and 2975 to 3039 cm
-1 
(9c). The characteristic peak of the PF6 
counter ion appeared at 826 cm
-1
 (1c), 833 cm
-1
 (2c), 822 cm
-1
 (3c), 829 cm
-1
 (4c), 834 cm
-1





 (7c), 830 cm
-1
 (8c) and 832 cm
-1
 (9c).  
4.3.4 Stability of the complexes (1c-9c) in DMSO-d6 and DMSO-d6 / D2O solvent system 
The stability of metal complexes is important in biological drug delivery systems. DMSO is a 
widely used solvent in preparing metal complexes stock solutions for therapeutic studies. DMSO acts as a 
good ligand for coordination with metal ions in some transition metal complexes via S or O atoms [44]. In 
order to confirm the stability of complexes 1c-9c, they were dissolved in DMSO-d6 and monitored via 
1
H 
NMR for 48 h at 25 °C (see SI). New peaks were not observed in the 
1
H NMR spectra indicating that 
complexes 1c-9c are stable in DMSO-d6 solution.  
Time dependent hydrolysis 
1
H NMR studies of complexes 1c-9c were carried out in a DMSO-d6 / 
D2O (20:80) solvent system for 72 h at 25 °C (See SI for complexes 4c-9c). The iridium complex is stable 
over a period of 72 h in the DMSO-d6 / D2O system at 25 °C (Fig. 4.1). No specific spectral changes were 
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observed for complex 1c during this study, whilst after 48 h, the aqua complex was evident for complex 
2c (Fig. 4.2), which also appeared in less than an hour for complex 3c. Complex 3c thus hydrolyzed faster 
than the other two complexes (Fig. 4.3). To confirm the hydrolysis of complex 3c, NaCl was added to 
equilibrium solutions containing the chloride complex and their aqua adducts to final concentrations of 1 
mM, 2 mM and 3 mM NaCl, mimicking the chloride concentrations in the cell nucleus, cell cytoplasm 
and blood plasma, respectively [45]. The 
1
H NMR spectra were recorded 15 min after addition of NaCl to 
the equilibrium solution. The intensity of the aqua complex peaks decreased with increase in the 
concentration of NaCl in the equilibrium solution. 
 
Fig. 4.1 Time dependent hydrolysis 
1





Fig. 4.2 Time dependent hydrolysis 
1
H NMR spectra of the rhodium complex (2c) in DMSO-d6 / D2O at 
25 °C. 
 
Fig. 4.3 Confirmation of the ruthenium complex (3c) hydrolysis by 1, 2 and 3 mM of NaCl addition to an 
equilibrium solution (1 mM) of the complex in DMSO-d6 / D2O at 25°C. 
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4.3.5 Structural information 
Structural refinement and crystal data (Table 4.1), and selected bond angles and distances of the 
complexes 2 and 6 (Table 4.2) are presented. The perspective view of complexes 2c and 6c are shown in 
Figs. 4.4 and 4.5. The complexes are arranged in the orthorhombic / crystal system with the P212121 / C 
2/c space group respectively. The crystal structure of the complexes 2c and 6c showed typical pseudo-





-p-cymene (Rh(1)-centroid = 1.79 Å / Ru(1)-centroid = 1.70 Aº), a chloride / iodide atom (Rh(1)-Cl(1) 
= 2.41 Å / Ru(1)-I(1) = 2.71 Å) and the N,N’ carbazole ligand in a bidentate manner forming a 5 or 6 
membered metallocycle respectively. 
The bond distances of the N(1)-Rh(1) = 2.09 Å, N(2)-Rh(1) = 2.11 Å, Cl(1)-Rh(1) = 2.41 Å and 
centroid-Rh(1) = 1.79 Å, whilst N(1)-Ru(1) = 2.08 Å, N(2)-Ru(1) = 2.08 Å, I(1)-Ru(1) = 2.70 Å and 
centroid-Ru(1) = 1.70 Å also consistent with reported literature [46] [35]. The angles of the N(1)-Rh(1)-
Cl(1) = 88.00°, N(2)-Rh(1)-Cl(1) = 90.53° and N(2)-Ru(1)-I(1) = 89.61º are close to 90° is also consistent 
with literature data [35, 46, 47]. The rhodium complex 2c exhibits a head to tail arrangement, non-
covalent C-H···F (Table 4.3) and C-H···π interactions in the crystal packing (Fig. 4.6). 
 
Fig. 4.4 The ORTEP diagram of the rhodium complex 2c. Displacements of the ellipsoids are drawn at 




Fig. 4.5 The ORTEP diagram of the ruthenium complex 6c. Displacements of the ellipsoids are drawn at 
50% probability. PF6 and hydrogen atoms are omitted for clarity. 
 





Table 4.1 Structure refinement and crystal data of complexes 2c and 6c 
Complex 2c 6c 
Empirical formula C30H32ClF6N3PRh C30H31IN3Ru, 0.5(F6P), 0.5(F6 P1.90) 
Formula weight 717.92 820.15 
Temperature/K 100.02 100.02 
Crystal system orthorhombic monoclinic 
Space group P212121 C 1 2/c 1 
a/Å 10.1972(4) 21.5315(13)  
b/Å 15.0901(6) 27.6362(17)  
c/Å 19.0469(8) 10.4424(6)  
α/° 90 90 
β/° 90 103.079(3) 
γ/° 90 90 
Volume/Å3 2930.9(2) 6052.5(6) 
Z 4 8 
ρcalcg/cm
3 1.6269 1.775 
μ(Mo Kα)/mm-1 0.793  
F(000) 1456.0 3200 
Crystal size/mm3 0.331 × 0.283 × 0.268 0.110 x 0.176 x 0.184 
Radiation Mo Kα (λ = 0.71073) Mo Kα (λ = 0.71073) 
2ɵ range for data collection/° 3.44 to 65.08 1.47 to 28.70 
Index ranges -15 ≤ h ≤ 13, -22 ≤ k ≤ 22, -28 ≤ l ≤ 27 -28 ≤ h ≤ 28, -36 ≤ k ≤ 36, -13 ≤ l ≤ 14 
Reflections collected 58813 64503 
Independent reflections 9644 [Rint = 0.0277, Rsigma = 0.0200] 7665 [Rint = 0.0406] 
Data/restraints/parameters 9644/0/384 7665/0/392 
Goodness-of-fit on F2 1.110 1.051 
Final   indexes [I>=2σ (I)] R1 = 0.0280, wR2 = 0.0730 R1 = 0.0816, wR2 = 0.2225 
Final R indexes [all data] R1 = 0.0294, wR2 = 0.0749 R1 = 0.0936, wR2 = 0.2334 
Largest diff. peak/hole / e Å-3 1.30/-1.14 4.178/-9.348 
Flack parameter 0.006(18)  
 
Table 4.2 Selected bond distances (Å) and angles (°) of the complexes 2c and 6c 
Complex 2c Complex 6c 
Selected bond distances (Å) 
N(1) – Rh(1) 2.091(16) N(1) – Ru(1) 2.080(3) 
N(2) – Rh(1) 2.108(17) N(2) – Ru(1) 2.078(3) 
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Cl(1) – Rh(1) 2.408(5) I(1) – Ru(1) 2.707(4) 
C(1) – Rh(1) 2.154(18) C(1) – Ru(1) 2.188(4) 
C(2) – Rh(1) 2.166(19) C(2) – Ru(1) 2.209(4) 
C(3) – Rh(1) 2.179(2) C(3) – Ru(1) 2.260(4) 
C(4) – Rh(1) 2.147(2) C(7) – Ru(1) 2.221(4) 
C(6) – Rh(1) 2.180(19) C(8) – Ru(1) 2.173(4) 
Centroid – Rh(1) 1.787 C(9) – Ru(1) 2.208(4) 
  Centroid – Ru(1) 1.696 
Selected bond angles (°) 
N(1) – Rh(1) – N(2) 76.65(6) N(1) – Ru(1) – N(2) 76.43(12) 
N(1) – Rh(1) – C(1) 161.93(7) N(1) – Ru(1) – C(1) 94.80(14) 
N(1) – Rh(1) – C(2) 123.97(7) N(1) – Ru(1) – C(2) 118.21(14) 
N(1) – Rh(1) – C(3) 97.31(7) N(1) – Ru(1) – C(3) 154.58(13) 
N(1) – Rh(1) – C(4) 103.76(7) N(1) – Ru(1) – C(7) 161.59(14) 
N(1) – Rh(1) – C(6) 139.07(7) N(1) – Ru(1) – C(8) 123.71(14) 
N(1) – Rh(1) – Centroid 129.58 N(1) – Ru(1) – C(9) 96.38(14) 
N(1) – Rh(1) – Cl(1) 88.00(5) N(1) – Ru(1) – I(1) 84.07(9) 
N(2) – Rh(1) – Cl(1) 90.53(5) N(2) – Ru(1) – I(1) 89.61(9) 
N(2) – Rh(1) – C(1) 119.67(7) N(2) – Ru(1) – C(1) 146.60(15) 
N(2) – Rh(1) – C(2) 158.60(7) N(2) – Ru(1) – C(2) 165.15(13) 
N(2) – Rh(1) – C(3) 143.88(7) N(2) – Ru(1) – C(3) 128.49(13) 
N(2) – Rh(1) – C(4) 106.97(8) N(2) – Ru(1) – C(7) 98.86(13) 
N(2) – Rh(1) – C(6) 96.65(7) N(2) – Ru(1) – C(8) 90.29(13) 
N(2) – Rh(1) – Centroid 129.82 N(2) – Ru(1) – C(9) 110.18(14) 
Cl(1) – Rh(1) – Centroid 126.39 N(1) – Ru(1) – Centroid 132.13 
Cl(1) – Rh(1) – C(1) 98.89(5) N(2) – Ru(1) – Centroid 129.57 
Cl(1) – Rh(1) – C(2) 95.47(6) I(1) – Ru(1) – Centroid 127.67 
Cl(1) – Rh(1) – C(3) 125.18(5) I(1) – Ru(1) – C(1) 121.93(12) 
Cl(1) – Rh(1) – C(4) 160.65(6) I(1) – Ru(1) – C(2) 94.24(11) 
Cl(1) – Rh(1) – C(6) 132.79(6) I(1) – Ru(1) – C(3) 90.52(10) 
  I(1) – Ru(1) – C(7) 113.92(10) 
  I(1) – Ru(1) – C(8) 151.28(11) 




Table 4.3 C-H···F interaction in the complex 2c 
C-H···F D-H H···A D···A D-H···A 
C(8)-H(8A) ···F(3) 0.981(16) 2.485(17) 3.412(4) 157.4(6) 
C(16)-H(16) ···F(5) 0.950(3) 2.450(3) 3.189(3) 134.5(2) 
C(28)-H(28) ···F(5) 0.950(3) 2.520(3) 3.263(3) 135.2(2) 
 
4.3.6 Cytotoxic Activity 
The aim of the present study is to investigate the in vitro potential of the synthesized complexes 
1c-3c on the viability of MCF-7 human breast cancer cells for 48 h. The experimental results indicated 
that complexes 1c-3c inhibited cell proliferation in a dose dependent manner (Fig. 4.7). The determined 
IC50 value of the tested complexes are Ir(III) (5 μM) (1c),  h(III) (6 μM) (2c), and  u(II) (8 μM) (3c) 
against MCF-7 breast cancer cells by MTT assay. All the three complexes (1c-3c) inhibited MCF-7 
cancer cells by dose and in a time-dependent manner. The IC50 value of the complexes 1c-3c reveals that 
inhibition of MCF-7 cells depends on the mode of interaction of the complexes with MCF-7 cell lines. 
The activity of the complexes 1c-3c falls in the following order 1c > 2c > 3c, which may be due to the 
hydrophobicity of Cp* being higher than the benzene ring and therefore effective in penetrating the cell 
membrane [48]. Morris et al. reported [Ru(arene)(ethylenediamine)Cl]
+
 compounds containing arene as a 
η
6
-benzene (IC50:17.0 μΜ) or η
6
-p-cymene (IC50:9.0 μΜ) moiety which showed different cytotoxicity 
effects on A2780 human ovarian cancer cells. These results supported the hydrophobicity nature of the 
complexes which could play a role against penetration in the cell membrane [14]. Very recently, Yellol et 
al. also reported a Cp* moiety containing [Ir(Cp*)(methyl-1-butyl-2-phenyl-1H-benzo[d]imidazole-5-
carboxylate)Cl]
+
 complex showing better potential anti-cancer activity against the HT29 (IC50:0.98 μΜ), 





 complexes, due to the 
mode and greater extent of interaction of the iridium complex with DNA and protein, as well as the 
effective penetrating nature into the cell membrane [19]. Gupta et al. also reported similar trend of the in 
vitro anticancer activity of Ir(III), Rh(III) and Ru(II) complexes against the Dalton lymphoma cell line 
[49]. The lower levels of toxicity of metal based drugs were well explained by Bergamo et al. [50]. The 




Fig. 4.7 In vitro cytotoxicity of complexes 1c-3c against MCF-7 human breast cancer cells after 
incubation for 48 h. 
4.3.7 Cell morphology analysis 
Fig. 4.8 shows morphological changes in MCF-7 human breast cancer cells after treatment with 
complexes 1c-3c for 24 h. Phase-contrast micrographs reveal that the Ir(III) (1c) complex induces 
increased cell shrinkage, membrane blebbing and forms floating cells, compared to the Rh(III) (2c) and 
Ru(II) (3c) complexes in a dose-dependent manner. Cytological investigations elucidate the 
antiproliferative effect routed through membrane blebbing, membrane instability and disturbing the 
cytoskeleton of the cells by the complexes. In Fig. 4.8, the arrows indicate the appearance of membrane 
blebbing and formation of floating cells in the treated MCF-7 breast cancer cells. All three complexes 1c-






Fig. 4.8 Images of complexes 1c-3c treated MCF-7 cells after 24 h exposure to the complexes at the IC25 
& IC50 concentrations. 
4.3.8 Fluorescence microscopy analysis of nuclear fragmentation  
4.3.8.1 Acridine orange / Ethidium bromide (AO/EtBr) staining Method 
The fluorescence microscopic studies reveal that concentration effects of complexes 1c-3c 
significantly induce the apoptosis in MCF-7 human breast cancer cells. A control cell did not show any 
significant change compared to the treated MCF-7 breast cancer cells (Fig. 4.9). The complexes 2c and 3c 
required increased concentration relative to complex 1c to induce apoptosis and the nuclear condensation 
effect on the cells. The arrows in Fig. 4.9 show the significant nuclear fragmentation, and induced 
apoptosis was observed in treated MCF-7 cells by complexes 1c-3c. However, lower to moderate levels 
of induce apoptosis and nuclear fragmentation was observed in cells treated with complexes 2c and 3c, 




Fig. 4.9 Fluorescence microscopy images of MCF-7 breast cancer cells. (a) Control (untreated cells), (b) 5 
µM (1c), (c) 6 µM (2c), (d) 8 µM (3c) for 24 h stained with DAPI. The fluorescent spectrum was detected 
at 360 nm/470 nm excitation/emission. 
4.3.8.2 DAPI staining Method 
Similarly, DAPI staining also revealed a significant level of nuclear fragmentation for complex 1c 
treated MCF-7 cancer cells when compared to complexes 2c and 3c (Fig. 4.10). Many mechanisms have 
been proposed to explain MCF-7 inhibition through activation apoptosis [51]. However, the 
mitochondrial pathways of both intrinsic and extrinsic related efficacy of complexes have thus far not 
been reported explicitly. Herein, the complexes 1c-3c caused significant reduction of viability in human 
MCF-7 breast cancer cells through activation of apoptotic related pathways (Fig. 4.10). The 
pharmacological target of antitumor ruthenium, rhodium and iridium complexes has not been 
unequivocally identified, but it is generally accepted that their cytotoxicity is related to their ability to 
bind DNA, although some exceptions have been reported [52, 53].  
A chemotherapeutic anticancer drug should be able to inhibit uncontrolled cell growth or cause 
death to the affected metastatic cells. On the other hand, the drug has to have few weak side effects and 
show no genotoxicity on living normal cells in the host body. Complexes 1c-3c appear to have a high 
affinity to interact with biomolecules like DNA, protein and RNA. Through this interaction with DNA, 
the synthesized complexes 1c-3c have been shown to disrupt DNA synthesis, and thereby inhibit cell 
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viability. In Fig. 4.10, the bright fetch indicates the condensed chromatins and nuclear fragmentations in 
the MCF-7 cancer cells, marked by arrows. The fluorescence microscopy analysis reveals the nuclear 
changes and shrinking morphology in the drug treated MCF-7 cancer cells, which is another important 
hallmark of apoptosis.   
 
Fig. 4.10 Fluorescence microscopy images of the complexes 1c-3c treated MCF-7 breast cancer cells after 
24 h stained with DAPI. (a) Control (untreated cells), (b) 5 µM (1c), (c) 6 µM (2c), (d) 8 µM (3c). The 
fluorescent spectrum was detected at 360 nm/470 nm excitation/emission. 
4.3.9 Cell cycle analysis 
To investigate the effect of the new complexes 1c-3c on the cell growth of cancer cell lines, the 
cell cycle distribution was analyzed after exposure of these cells to the complexes 1c-3c. As shown in Fig. 
4.11, the untreated control cells were mainly in G0/G1 phase and with the treatment of the complexes 1-3 
(5-8 µM) for 24 hr, the percentage of S phase cells was significantly reduced to 33% (1c), 41% (2c) and 
38% (3c) (in the case of control 44%), that of G2/M phase cells was also decreased to 10% (1c), 19% (2c) 
and 12% (3c). The synthesized complexes 1c-3c have different effects on the cell cycle status in MCF-7 





Fig. 4.11 Flow cytometric analysis effects of complexes 1c-3c on cell cycle distribution in human breast 
cancer MCF-7 cells. 
4.4.0 Docking studies  
Docking studies were performed for all three complexes (1c-3c) to identify the mode of binding 
and binding affinity with the COX-2 receptor (PDB ID: 1CX2) (see Fig. 4.12 and SI). This study reveals 
that all three complexes bind in the active site of COX-2 via H-bonding and a hydrophobic contact with 
binding energy of -7.13 to -8.18 kcal/mol (Table 4.4). Among the three complexes, the iridium complex 
(1c) shows high binding energy with the selective amino acid (N2 --- OH of val 523) H-bond interaction 
of the COX-2 receptor, which initiates conformational changes to access the hydrophobic pocket of COX-
2. Furthermore, the iridium complex (1c) shares H-bond interaction with the surrounding amino acid Glu-
524 (N3 --- OH of Glu-524) of COX-2 receptor. The rhodium complex (2c) shares a H-bond interaction 
with the active site residue His-90 (N3 --- NH of His-90) and Ser-353 (N3 --- OH of Ser-353), whilst the 
ruthenium complex (3c) shares a similar interaction with His-90 of the COX-2 receptor like the rhodium 
complex (2c).  
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The prime region of COX-2 is the hydrophobic pocket where binding of the inhibitor will result 
in the inhibition of COX-2 [54]. The ligand moiety of the complexes 1c-3c is crucial for establishing 
hydrophobic interactions in the active site of COX-2. The molecular docking results clearly show that the 
iridium complex (1c) is closer to the hydrophobic pocket, comprising of residues of Val 523, Tyr 355, 
Tyr 385, Ser 530, Gly 526 and Ala 527, than complexes 2c and 3c. Additionally, the iridium complex (1) 
also shares another H-bond interaction with the surrounding amino acid residue Glu 524 (N3 --- OH of 
Glu 524) of the active site, indicating that the iridium complex (1c) is highly stable in the hydrophobic 
pocket of COX-2. The docking study correlates with the experimental results which indicate that the 
iridium complex (1c) actively inhibits the COX-2 receptor compared to the other two complexes.  
 
Table 4.4 Binding energy, H-bond and hydrophobic interactions of the complexes 1c-3c with the COX-
2 receptor 
Complexes Binding energy 
(kcal/mol) 
H-bond interaction Hydrophobic interaction 
1c -8.18 N2 --- OH of Val-523 
N3 --- OH of Glu-524 
 
Val 523, Tyr 355, Tyr 385,  
Ser 530, Gly 526 and Ala 527. 
2c -7.34 N3 --- NH of His-90 
N3 --- OH of Ser-523 
Val 523 and 
Leu 352 






Fig. 4.12 Binding mode of complex 1c in the active site of COX-2 receptor. 
4.4 Conclusions 
In conclusion, the synthesis and characterisation of new half sandwich Ir(III), Rh(III), Ru(II) and 
Os(II) complexes coordinated with a N,N' carbazole bidentate ligands have been shown. The rhodium and 
ruthenium complexes displayed the pseudo octahedral “piano-tool” geometry in the crystal structure. 
NMR studies reveal that all complexes are stable in DMSO-d6. On the other hand, the Ru(II) (3c) 
complex hydrolyzed faster than the Ir(III) and Rh(III) complexes in a DMSO-d6 / D2O (2:8) solvent 
system due to formation of the respective aqua complexes.  
Anticancer study clearly demonstrated that the new half sandwich Ir(III), Rh(III) and Ru(II) (1c-
3c) complexes displayed potent anticancer properties against human breast cancer cells (MCF-7) at very 
low concentrations. Among the three complexes, the Ir(III) complex showed the best and most promising 
results, in all the experiments conducted, at a lower dose (5 µM). Overall studies concluded that all three 
synthesized complexes very effectively inhibit the cancer cell growth by causing damage to nuclear 
material, as well as membrane integrity. Molecular docking studies revealed that the ligand moiety is 
important for the binding of all three complexes in the hydrophobic pocket of the COX-2 receptor and the 
iridium complex actively inhibits the COX-2 receptor more than the rhodium and ruthenium complexes. 
Furthermore, anti-cancer studies for the Ru(II) and Os(II) complexes are in progress and also need to be 
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aimed at elucidating the molecular mechanism of the complexes M(III) (M = Ir and Rh) and M(II) (M = 
Ru and Os) for anti-cancer drug development.  
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Binding interaction, conformational change, and molecular docking study of 
N-(pyridin-2-ylmethylene)aniline derivatives and carbazole Ru(II) complexes 
with human serum albumin 
 
Abstract 
New [RuCl2(COD)(L1)] (1d), [RuCl2(COD)(L2)] (2d), [RuCl2(COD)(L3)] (3d), [RuCl2(COD)(L4)] (4d), 
[RuCl2(COD)(L5)] (5d) (L = (p-R-N-(pyridin-2-ylmethylene)aniline), R = H (L1), Cl (L2), OCH3 (L3), 
CH3 (L4), L5 = (9-ethyl-N-(pyridin-2-ylmethylene)9H-carbazole-3-amine and COD = η
4
-cyclooctadiene) 




C NMR, melting point analysis, elemental 
analysis, HR-MS spectrometry, FT-IR and UV-vis spectroscopy. The single crystal X-ray structures of 
complexes 1d, 2d and 3d revealed coordination of the ligands to the Ru(II) centre in a bidentate manner 
via the N atoms. The geometry around the Ru(II) centre is pseudooctahedral with the two Cl atoms and 
the π-bonds of the cyclooctadiene occupying the coordination sites. Interactions of Ru(II) complexes 1d-
5d with human serum albumin (HSA) were investigated using UV-vis, synchronous emission and circular 
dichroism spectroscopy. The results demonstrated that the Ru(II) complexes 1d-5d have significantly 



















(5d) respectively. Circular 
dichroism (CD) studies revealed decreased α-helix content within HSA upon interaction with complexes 
1d-5d, suggesting a conformational change of the HSA secondary structure. Also, molecular docking 
studies were carried out to identify the binding models of the HSA-Ru complexes and binding energy of 
complexes 1d-5d in HSA, which further revealed the contribution of amino acid residues of HSA in 
Ru(II) complex binding. 
Keywords: Ru(II) complexes; N,N' chelated ligands; human serum albumin; synchronous fluorescence 




Metal-mediated drug discovery is of great interest for biological system applications and to 
pharmaceutical industries, since these molecules can strongly bind and cleave DNA or proteins under 
physiological conditions for use as therapeutic agents [1-3]. Over the last decades, platinum metal 
complexes such as cisplatin, carboplatin and oxaliplatin have been studied in clinical trials as anticancer 
agents, but due to high resistance to the metal complexes and severe side effects, alternative transition 
metal complexes are required as new therapeutic drugs [4, 5]. Highly active ruthenium(II) organometallic 
complexes have recently been reported in anticancer studies to replace the platinum metal drugs [6, 7]. 
Thus KP1019 (indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) and NAMI-A 
(imidazolium trans-[tetrachlorido(dimethyl sulfoxide)(1H-imidazole)ruthenate-(III)]) are pioneering 
ruthenium drugs for potential anticancer and antitumor activity in biological systems [8, 9]. In recent 
years, organo-ruthenium scaffold (arene) modified drugs such as RAPTA-T, RAPTA-C and RM175 (Fig. 
5.1) showed promising anticancer activities in preclinical studies [10-12]. 
 
 RAPTA-T    RAPTA-C       RM 175 
Fig. 5.1 Structure of ruthenium based anticancer compounds. 
The  interactions  of  metallo-drugs  with macromolecular  blood  components  have  been  
recognized  as crucial  for  their  bio distribution  and  efficacy. Studies on the interaction mechanism of 
Ru-based drugs to serum albumins are of great interest due to their potential biological applications. It is 
known that the distribution, excretion and efficiency of a drug are related to its ability to interact with 
serum proteins [13-16]. In particular, ruthenium complexes of known anticancer activity have been shown 
to interact with human serum albumin (HSA) [17-19]. Serum albumins are extensively used in 
biophysical and biochemical studies as a model system for protein folding, aggregation and drug delivery. 
HSA is one of the most abundant proteins present in the blood plasma, which assists in the disposition 
and transportation of various exogenous and endogenous ligands to specific targets [20]. HSA acts as a 
plasma carrier by nonspecific binding through several hydrophobic steroid hormones across organ-
circulatory interfaces such as the liver, intestine, kidney, and brain [21].  
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Structural aspects of HSA have been well explored. The primary structure of HSA has about 580 
amino acid residues in a single peptide chain, which assumes a solid equilateral triangular shape with 
sides of ~80 Å and depth of ~30 Å [22, 23]. The secondary and tertiary structure of HSA is composed of 
three α-helical domains I, II and III and each domain contains two subdomains, stabilized by disulfide 
bridges
22, 23
. Besides domains I (site I) and II (site II), a third (III) domain was recently identified as a 
binding pocket in subdomain IB [24]. The binding affinity offered by site I is mainly through 
hydrophobic interaction, while site II involves a combination of hydrophobic, hydrogen bonding and 
electrostatic interactions [25-28]. It has been reported that aromatic and hetero cyclic ligands possessing 
higher affinity for serum albumins and showing preferential binding at site II exhibit efficient therapeutic 







Therefore, the study of compounds with serum albumins is essential to establish pharmacokinetic 
behaviour in biological systems. It is widely accepted in the pharmaceutical industry that the overall 
distribution, metabolism, and efficacy of many drugs can be altered based on their affinity to serum 
albumin [30]. Obviously, understanding drug-protein interactions can suggest new approaches to drug 
therapy and design. 
In this study, we report the synthesis and characterization of Ru(COD)Cl2 coordinated with 
ligands (p-R-N-(pyridin-2-ylmethylene)aniline) (R = H (L1), Cl (L2), OCH3 (L3), CH3 (L4)) and 9-ethyl-
N-(pyridine-2-ylmethylene)-9H-carbazole-3-amine (L5). Their interaction with HSA is also investigated 
by UV-vis, emission, synchronous emission circular dichroism spectroscopy and molecular docking 
studies.  
5.2 Experimental section  
5.2.1 Reagents and general procedures  
Unless otherwise stated, all manipulations were performed using standard Schlenk tube 
techniques under argon atmosphere. The reagents 2-pyridinecarboxaldehdye, aniline, substituted anilines, 
1,5-cyclooctadiene (COD), hydrated RuCl3·xH2O (≥99% purity) and solvents were purchased from 
Sigma-Aldrich, Capital Labs, South Africa and were used without further purification. The NMR solvent 
CDCl3 was purchased from Merck, Germany. Solvents were dried by standard procedures and distilled 
prior to use [31]. The metal precursor Ru(COD)Cl2 and 3-amino-9-ethyl-9H-carbazole were synthesised 
as per reported procedures [30, 32, 33]. 
 
Melting points were recorded on a Stuart
TM





C (100 MHz) NMR were recorded in CDCl3 and recorded on a Bruker Topspin 400 
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spectrometer. Elemental analyses were performed on a Thermo-Scientific Flash 2000 CHNS/O analyser. 
Solid and liquid state infrared spectra were recorded using an FT-IR Perkin Elmer Spectrum 100 
spectrophotometer between 4000 - 400 cm
-1
. High resolution mass spectra were recorded using a Waters 
Micromass LCT Premier TOF-MS instrument. Single crystal XRD analysis of suitable crystals was 
performed on a Bruker Smart APEX11 Nonius Kappa-CCD diffractometer equipped with graphite 
monochromated Mo - K radiation ( = 0.71073 Å). The electronic absorption spectroscopy (UV/Vis) 
studies were recorded using a Perkin Elmer precisely Lambda35 and JASCO V-630 instrument.  
5.2.2 Synthesis and characterization of the ligands  
The ligands (L1-L4) were synthesized by using reported procedures and the spectral data of the 
ligands L1-L4 match reported data [34, 35]. The following procedure was used to synthesise ligand L5: 
A mixture of 9-ethyl-9H-carbazole-3-amine (2.5 mmol, 530 mg), 2-pyridinecarboxaldehyde (2.5 mmol, 
0.25 mL) and 2 drops of glacial acetic acid, in toluene (10 mL), was stirred at room temperature for 24 h. 
The reaction was monitored by TLC. Once the reaction was completed, the solvent was distilled in vacuo 
to leave the crude product. This was dissolved in diethyl ether (30 mL), and the organic layer was washed 
with brine (15 mL) and dried over anhydrous MgSO4. The combined organic layer was concentrated in 
vacuo, resulting in a brown oil. Yield (700 mg, 88%). 
1
H NMR (400 MHz, CDCl3, 25 ºC, ppm) δ = 8.87 
(s, 1H, imine CH), 8.75- 8.74 (d, 1H, α proton of Py), 8.31 (d, 1H, JH-H = 7.88 Hz, Py), 8.18 (d, 1H, JH-H = 
2.08 Hz, Carb 1
st
 ring), 8.14 (d, 1H, JH-H = 7.72 Hz, Carb 3
rd
 ring), 7.87 (t, 1H, Py), 7.61 (d-d, 1H, Carb 1
st
 
ring), 7.53 - 7.49 (m, 1H, Carb 3
rd
 ring), 7.46 (t, 2H, Carb), 7.39 - 7.39 (m, 1H, Py), 7.29 (t, 1H, Carb 3
rd
 
ring), 4.42 - 4.37 (q, 2H, N - CH2), 1.49 (t, 3H, N -CH3). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 
157.49 (imine C-H), 149.50 (C, Py), 136.76 (C, Py), 126.03 (Carb 3
rd
 ring), 124.67 (Py), 121.62 (Py), 
120.61 (Carb 3
rd
 ring), 120.05 (Carb 1
st
 ring), 119.11 (Carb 3
rd





 ring), 37.75 (C, N - (CH2)CH3), 13.87 (C, N - CH2(CH3)). FT-I  (γ/cm
-1
): 3050, 2974, 
2931, 1733, (C=N) 1581 (s), 1478 (s), 1469 (s), 1234 (s) 744 (s), 728 (s). UV-Vis (dichloromethane, v/v): 
λmax(nm) = 242, 291, 321, 377. 
5.2.3 Synthesis and characterization of the complexes 
The following common procedure was followed for the syntheses of complexes 1d-5d: 
A mixture of the ligand (0.36 mmol) and Ru(COD)Cl2 (0.36 mmol) was dissolved in dry ethanol (10 mL) 
and the resulting mixture was refluxed for 2 h. The reaction volume was concentrated to a third of its 
original volume and the suspension was kept at 4 ºC overnight to give brick red solid which was filtered 
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off, washed with cold ethanol and then diethyl ether. The solid was dissolved in chloroform and excess of 
n-hexane was added to induce the precipitation of the brick red solid product. 
5.2.3.1 [RuCl2(COD) (L1)] (1d) 
L1 (0.36 mmol, 66 mg) and Ru(COD)Cl2 (0.36 mmol, 100 mg). Yield: 72 % (120 mg). Mp. 
220.0 °C (dec. turns black without melting). 
1
H NMR (400 MHz, CDCl3, 25 ºC, ppm) δ = 8.45 (s, 1H, 
imine CH), 8.25 (d, 1H, JH-H = 5.16 Hz, α proton of Py), 8.01 -7.94 (m, 2H, Py), 7.58 - 7.54 (m, 1H, Py), 
7.82 (d, 2H, JH-H = 7.56 Hz, Ph), 7.39 - 7.34 (m, 3H, Ph), 4.75 - 4.74 (m, 2H, -CH, COD), 4.15 - 4.11 (m, 
2H, -CH, COD), 2.74 - 2.57 (m, 4H, -CH2, COD), 2.20 - 2.14 (m, 2H, -CH2, COD), 2.06 - 2.00 (m, 2H, -
CH2, COD). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 168.04 (imine C-H), 156.70 (Py), 150.60 (Py), 
149.44 (Py), 138.11 (Py), 135.94 (Py), 129.02 (Ph), 128.93 (Ph), 127.88 (Ph), 127.80 (Ph), 120.81 (Ph), 
92.25, 91.87 (C, -CH, COD), 29.64, 29.22 (C, -CH2, COD). FT-I  (γ/cm
-1
): (COD, C=C) 3038 - 2829 
(m), (C=N) 1594 (s), 1203 (s), 767 (s), 702 (s). UV-Vis (dichloromethane, v/v): λmax (nm) = 229, 292, 
345, 439. HR-MS (TOF MS ES
+
) C20H22N2Ru calculated: 393.0810, found: 393.0815. Anal. Calcd for 
C20H22Cl2N2Ru: C, 51.95; H, 4.80; N, 6.06; Found: C, 51.87; H, 5.10; N, 6.33. 
5.2.3.2 [RuCl2(COD)(L2)] (2d) 
L2 (0.36 mmol, 78 mg) and Ru(COD)Cl2 (0.36 mmol, 100 mg). Yield: 82 % (147 mg). Mp. 230.0 
°C (dec. turns black without melting). 
1
H NMR (400 MHz, CDCl3, 25 ºC, ppm) δ = 8.42 (s, 1H, imine 
CH), 8.25 (d, 1H, JH-H = 5.20 Hz, α proton of Py), 8.00 - 7.95 (m, 2H, Py), 7.59 - 7.56 (m, 1H, Py), 7.43 - 
7.42 (d, 1H, JH-H = 2.16 Hz, Ph), 7.41 (t, 1H, Ph), 7.39 (t, 1H, Ph), 7.40 - 7.36 (d, 1H, JH-H = 2.20 Hz, Ph), 
4.75 - 4.73 (m, 2H, -CH, COD), 4.11 - 4.10 (m, 2H, -CH, COD), 2.73 - 2.58 (m, 4H, -CH2, COD), 2.20 - 
2.14 (m, 2H, -CH2, COD), 2.07 - 2.00 (m, 2H, -CH2, COD). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ 
= 168.50 (imine C-H), 156.46 (Py), 150.67 (Py), 147.73 (Py), 138.17 (Py), 133.67 (Py), 129.20 (Ph), 
129.15 (Ph), 128.07 (Ph), 122.22 (Ph), 92.32, 91.86 (C, -CH, COD), 29.61, 29.20 (C, -CH2, COD). FT-IR 
(γ/cm
-1
): (COD, C=C) 3030 - 2830 (m), (C=N) 1595 (s), 1478 (s), 770 (s), 747 (s). UV-Vis 
(dichloromethane, v/v): λmax (nm) = 229, 292, 347, 445. HR-MS (TOF MS ES
+
) C20H20ClN2Ru calculated: 
425.0358, found: 425.0350. Anal. Calcd for C20H21Cl3N2Ru: C, 48.35; H, 4.26; N, 5.64; Found: C, 48.50; 
H, 4.10; N, 5.45. 
5.2.3.3 [RuCl2(COD)(L3)] (3d) 
L3 (0.36 mmol, 77 mg) and Ru(COD)Cl2 (0.36 mmol, 100 mg). Yield: 87 % (154 mg). Mp. 233.0 
°C (dec. turns black without melting). 
1
H NMR (400 MHz, CDCl3, 25 ºC, ppm) δ = 8.32 (s, 1H, imine 
CH), 8.15 (d, 1H, JH-H = 5.24 Hz, α proton of Py), 7.91 - 7.83 (m, 2H, Py), 7.47 - 7.44 (m, 1H, Py), 7.31 - 
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7.29 (d, 2H, JH-H = 8.72 Hz, Ph), 6.83 - 6.81 (d, 2H, JH-H = 8.80 Hz,Ph), 4.65 - 4.64 (m, 2H, -CH, COD), 
4.10 - 4.09 (m, 2H, -CH, COD), 2.65 - 2.50 (m, 4H, -CH2, COD), 2.23 (s, 3H, OCH3), 2.11 - 2.05 (m, 2H, 
-CH2, COD), 1.97 - 1.92 (m, 2H, -CH2, COD). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 167.97 
(imine C-H), 159.09 (Py), 156.81 (Py), 150.55 (Py), 142.95 (Py), 138.05 (Py), 128.81 (Ph), 127.71 (Ph), 
122.03 (Ph), 114.01 (Ph), 92.33, 91.77 (C, -CH, COD), 55.49 (C, OCH3), 29.65, 29.22 (C, -CH2, COD). 
FT-I  (γ/cm
-1
): (COD, C=C) 2949 - 2829 (m), (C=N) 1595 (s), 1500 (s), 1029 (s), 836 (s) 767 (s). UV-
Vis (dichloromethane, v/v): λmax (nm) = 229, 281, 360, 454. HR-MS (TOF MS ES
+
) C21H24N2ORu 
calculated: 421.0854, found: 421.0842. Anal. Calcd for C21H24Cl2N2Ru: C, 52.94; H, 5.08; N, 5.88; 
Found: C, 52.80; H, 5.10; N, 5.95.  
5.2.3.4 [RuCl2(COD)(L4)] (4d) 
L4 (0.36 mmol, 75 mg) and Ru(COD)Cl2 (0.36 mmol, 100 mg). Yield: 80 % (140 mg). Mp. 227.0 
°C (dec. turns black without melting). 
1
H NMR (400 MHz, CDCl3, 25 ºC, ppm) δ = 8.41 (s, 1H, imine 
CH), 8.25 - 8.24 (d, 1H, JH-H = 5.16 Hz, α proton of Py), 7.98 - 7.92 (m, 2H, Py), 7.56 - 7.53 (m, 1H, Py), 
7.35 - 7.33 (d, 2H, JH-H = 8.12 Hz, Ph), 7.20 - 7.18 (d, 2H, JH-H = 8.00 Hz, Ph), 4.74 - 4.73 (m, 2H, -CH, 
COD), 4.16 - 4.15 (m, 2H, -CH, COD), 2.70 - 2.59 (m, 4H, -CH2, COD), 2.37 (s, 3H, CH3), 2.19 - 2.13 
(m, 2H, -CH2, COD), 2.05-1.99 (m, 2H, -CH2, COD). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 
167.90 (imine C-H), 156.77 (Py), 150.57 (Py), 147.15 (Py), 138.06 (Py), 137.71 (Py), 129.44 (Ph), 128.86 
(Ph), 127.76 (Ph), 120.62 (Ph), 92.28, 91.86 (C, -CH, COD), 29.64, 29.23 (C, -CH2, COD), 21.11 (C, 
CH3). FT-I  (γ/cm
-1
): (COD, C=C) 2950 - 2830 (m), (C=N) 1594 (s), 1499 (s), 1298 (s), 770 (s). UV-Vis 
(dichloromethane, v/v): λmax (nm) = 229, 291, 350, 432. HR-MS (TOF MS ES
+
) C21H23N2Ru calculated: 
405.0905, found: 405.0897. Anal. Calcd for C21H24Cl2N2ORu: C, 51.22; H, 4.91; N, 5.69; Found: C, 
51.10; H, 5.10; N, 5.77. 
5.2.3.5 [RuCl2(COD)(L5)] (5d) 
L5 (0.36 mmol, 108 mg) and Ru(COD)Cl2 (0.36 mmol, 100mg). Yield: 67 % (138 mg). Mp. 
246.0 °C (dec. turns black without melting). 
1
H NMR (400 MHz, CDCl3, 25 ºC, ppm) δ = 8.54 (s, 1H, 
imine CH), 8.28(d, 1H, JH-H = 5.24 Hz, α proton of Py), 8.15 (s, 1H, Carb, 1
st
 ring), 8.13(d, 1H, JH-H = 2.08 
Hz Carb, 3
rd 
ring), 8.01 - 7.95 (m, 2H, Py), 7.63(d-d, 1H, Carb, 1
st
 ring), 7.58 - 7.54 (m, 1H, Ph), 7.52 (d-
d, 1H, Carb, 1
st
 ring),7.45 (d,1H, JH-H = 8.16 Hz Carb, 3
rd 
ring), 7.40 (d,1H, JH-H = 8.60 Hz Carb, 3
rd 
ring), 
7.27 (t, 1H, Carb, 3
rd
 ring) 4.77 - 4.76 (m, 2H, -CH, COD), 4.42 - 4.37 (m, 2H, -CH, COD), 4.25 (q, 2H, 
N - CH2), 2.74 - 2.58 (m, 4H, -CH2, COD), 2.20 - 2.14 (m, 2H, -CH2, COD), 2.02 - 1.96 (m, 2H, -CH2, 
COD),1.49 (t, 3H, N - CH3). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 168.13 (imine C-H), 157.04 
(Py), 150.56 (Py), 138.07 (Py), 128.82 (Py), 127.64, 126.41 121.08, 119.27, 119.05, 112.51, 108.76, 
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108.32(Carb), 92.39, 91.78 (C, -CH, COD), 37.78 (C, N - CH2), 29.64, 29.27 (C, -CH2, COD), 13.89 (C, 
N - CH3).FT-I  (γ/cm
-1
): (COD, C=C) 2951 - 2879 (m), (C=N) 1595 (s), 1468 (s), 1285 (s), 775 (s). UV-
Vis (dichloromethane, v/v): λmax (nm) = 239, 268, 297, 336, 351, 422. HR-MS (TOF MS ES
+
) 
C28H28N3Ru calculated: 508.1327, found: 508.1334. Anal. Calcd for C28H29Cl2N3Ru: C, 58.03; H, 5.04; 
N, 7.25; Found: C, 57.95; H, 5.10; N, 7.33. 
5.2.4 X-ray crystal structure determination of complexes 1d, 2d and 3d 
Suitable crystals for X-ray analysis were grown by slow evaporation of hexane into an acetone 
solution for 1d, and slow evaporation of chloroform into an ethanol solution for 2d and 3d. The crystals 
were selected and glued onto the tip of glass fibers, then mounted in a stream of cold nitrogen at 173 ( 2) 
K and centered in the X-ray beam by using a video camera. The crystal refinement and data collection 
were performed on a Bruker Smart APEX11 diffractometer using graphite crystal monochromatised Mo - 
K radiation (λ= 0.71073 Å) and a diffractometer to crystal distance of 4.00 cm. The initial cell matrix 
was obtained from three series of scans at different starting angles. Each series consisted of 12 frames 
collected at intervals of 0.5° in a 6° range with the exposure time of about 10 seconds per frame. The 
reflections were successfully indexed by an automated indexing routine built in the APEXII program 
suite. The final cell constants were calculated from a set of 6460 strong reflections from the actual data 
collection. The data collection method involved ω scans of width 0.5°. Data reduction was carried using 
the program SAINT+ [36]. The structure was solved by direct methods using SHELXS and refined by 
SHELXL [37]. All structures were checked for solvent-accessible cavities using PLATON [38] and the 
graphics were performed with the DIAMOND [39] visual crystal structure information system software 
and ORTEP-3 [40]. Non-H atoms were first refined isotropically and then by anisotropic refinement with 
full-matrix least-squares calculations based on F
2
 using SHELXS. All H atoms were positioned 
geometrically and allowed to ride on their respective parent atoms. All H atoms were refined 
isotropically. The absorption correction was based on fitting a function to the empirical transmission 
surface as sampled by multiple equivalent measurements [38]. Crystal data and structure refinement 
information for compounds 1d, 2d and 3d are summarized in SI.  
5.2.5 HSA binding studies 
Human serum albumin (HSA (Fatty acid and Globulin free), fraction V, Product No: A3782) was 
purchased from Sigma-Aldrich, USA and used without further purification. The stock solution of HSA 
was prepared by using phosphate buffer saline (PBS) of pH = 7.2. An incubation time of 10 minutes was 
used to achieve a homogeneous and uniform of mixing of both the HSA and the complexes. The 
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) was measured spectrophotometrically by a reported procedure 
[41].  
UV-vis absorption measurements were carried out by using a JASCO V-630 UV-vis 
spectrophotometer. Quartz cuvettes of path length 1 cm were used to record the absorption spectra. The 
emission spectral studies were performed with a JASCO FP-6600 spectrofluorometer. All the titration 
experiments were carried out by adding appropriate amounts of Ru(II) complexes 1d-5d into 1 mL of 
HSA solution in a 5 mL standard measuring flask and then made up to the mark with phosphate buffer 
solution. The solution was allowed to equilibrate for 10 minutes before recording the spectra in a quartz 
cuvette (1 cm). Blank experiments of complexes with PBS buffer and HSA solutions with PBS buffer 
were carried out to determine any influence of the buffer solution. No shift in the absorption peaks of 
either the complex or the protein were observed. It seems the complexes were relatively stable in buffer 
solution. HSA was excited at 295 nm and the emission was monitored in the absorption region between 
300 nm to 500 nm. The emission and excitation slit widths used throughout the experiment were 5 nm 
and 2 nm, respectively. The synchronous fluorescence spectra were recorded at Δλ = 15 nm and Δλ = 60 
nm. Stock solutions of serum albumins and Ru(II) complexes were always freshly prepared before use at 
ambient temperature.  
5.2.6 Circular dichroism studies 
Circular dichroism (CD) measurements were performed with a JASCO-180 spectropolarimeter 
using a 0.1 cm path length quartz cell. The CD spectra were recorded in the range of 200–300 nm with 
0.1 nm step resolution and averaged over two scans at a speed of 50 nm min
-1
. All observed spectra were 
baseline subtracted for buffer solution and the α-helical content was calculated on the basis of change of 
molar ellipticity values. 
5.2.7  Molecular docking studies for complexes 1d-5d   
Molecular docking studies were performed for complexes 1d-5d with human serum albumin 
protein, to identify the binding mode and the crucial functional groups interacting with the human serum 
albumin protein using Autodock v4 [42]. Crystal structure of human serum albumin with PDB ID: 1H9Z 
was taken from protein data bank [43].  The water molecules and the crystal ligand were removed from 
the crystal structure of protein. Ligands and protein were prepared by adding the Gasteiger charges and 
polar hydrogen bonds using AutoDock 4.0 and saved as PDBQT files. For the Ruthenium atom the van 
der Waals and other parameters were obtained from the Autodock website. The grid was generated for the 
active site residues of the human serum albumin protein using Autogrid. The size of the grid was set up 
with the spacing 0.375 Å and x, y and z dimensions of 56 x 54 x 40. In the docking tab, docking 
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calculations were carried out using Lamarckian genetic algorithm to generate the possible conformations 
of the ligand in the active site of human serum albumin. The best conformation was selected with the 
lowest binding energy (kcal/mol). 
5.3 Results and discussion 
5.3.1 Characterization of the ligands and complexes 
The ligands L1-L5 and complexes 1d-5d were synthesized and characterized by different spectral 
techniques. The metal complexes are soluble in solvents such as DMSO, DMF, dichloromethane, ethyl 
acetate, chloroform, acetonitrile and 3 mg per mL in water at pH 7.20. They are insoluble in petroleum 
ether, hexane and diethyl ether. 
 
Scheme 5.1: Synthesis of the ruthenium(II) complexes 1d-5d. 
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5.3.2 NMR studies 
The 
1
H NMR spectra of the free Schiff base ligands L1-L5, show a -CH imine proton singlet in 
the range of 8.67 - 8.87 ppm and the doublet of the α proton of the pyridine ring appeared in the range of 
8.77 - 8.75 ppm. When the Schiff base ligands were coordinated with the ruthenium precursor, the singlet 
peak of the imine proton signal shifted up-field to 8.44 - 8.54 ppm and the doublet peak of the α proton of 
the pyridine ring shifted up-field to 8.28 - 8.26 ppm. The signals in the aromatic region for all the metal 
complexes shifted up-field compared to their respective ligand signals. On the other hand, the 
13
C NMR 
signals of the imine carbon and the α proton carbon of the pyridine ring of L5 appeared at 157.5 and 
149.5 ppm respectively, whilst in complex 5d the signals were shifted down-field to 168.1 and 150.6 




C NMR confirms that the 
Schiff base ligands were coordinated to the ruthenium center through the N atoms. 
5.3.3 Infrared spectroscopy 
IR spectra of the all ligands L1-L5 exhibit a sharp peak for C=N stretching in the range 1579 - 
1585 cm
-1
, but for the complexes 1d-5d, these bands were shifted to higher frequencies in the range of 
1594 - 1595 cm
-1
. This is attributed to the nitrogen atom of the C=N group now being coordinated to 
ruthenium. The unsaturated cyclic (C=C) stretching frequency was observed for all the complexes at 
around 2829 - 2957 cm
-1
, which indicates that the 1,5-cyclooctadiene group is present in the metal 
complexes. Thus, IR data show that the Schiff base ligands were coordinated to ruthenium through the N 
atoms.    
5.3.4 UV-vis spectroscopy 
UV-vis spectra of the ligands L1-L5 and complexes 1d-5d were obtained at 10 µM 
concentrations, in dichloromethane. The spectra of the ligands exhibit one band in the range of 239 - 242 
nm, which is attributed to a π-π* transition. Two other bands appeared in the range of 278 - 291 nm and 
319 - 338 nm, which are assigned to n-π* transitions of the C=N group in the ligands. The low energy 
bands for the complexes appeared at 438 nm (1d), 445 nm (2d), 453 nm (3d), 432 nm (4d), and 422 nm 
(5d) and the bands at 344 nm (1d), 346 nm (2d), 359 nm (3d), 350 nm (4d) and 351 nm (5d) may be 
attributed for the metal to ligand charge transfer (MLCT) transitions. The conjugated intra ligand based π-
π* transitions appeared in the UV region at 292 nm (1d), 292 nm (2d), 281 nm (3d), 290 nm (4d), and 
296 nm (5d). The observed band shift variations in the complexes were due to the different donor 
strengths of the Schiff base nitrogen atoms. 
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5.3.5 HR-MS spectral studies 
The mass spectra of the complexes 1d-5d were recorded to understand the composition of the 
metal complexes. The accurate mass of the most abundant peaks present in the metal complexes matched 
M
2+
 (m/z) 393.0815 (1d), 425.0350 (2d), 421.0842 (3d), 405.0897 (4d), 508.1334 (5d), thus indicating 
the loss of two chloro groups from the respective metal complexes. It seems that the chloro group is more 
labile than the other groups present in the metal complexes. 
5.3.6 Structural characterization studies 
Suitable crystals for structural analysis were grown by vapour diffusion of hexane into an acetone 
solution for 1d, and vapour diffusion of chloroform into ethanol solution for 2d and 3d. The respective 
ORTEP diagrams for 1d, 2d and 3d are given in Figs. 5.2-5.4, while selected bond distances and bond 
angles are given in Table 5.1. 
 
Fig. 5.2 The ORTEP diagram of complex 1d. Displacements of the ellipsoids are drawn by 50% 





Fig. 5.3 The ORTEP diagram of complex 2d. Displacements of the ellipsoids are drawn by 50% 
probability and hydrogen atoms are omitted for the clarity. 
  
 
Fig. 5.4 The ORTEP diagram of complex 3d. Displacements of the ellipsoids are drawn by 50% 
probability and hydrogen atoms are omitted for the clarity. 
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 Whereas the asymmetric unit of complex 1d has the ruthenium complex and an acetone solvent 
molecule, the asymmetric units for 2d and 3d only contain the complexes. The molecular structures of all 
three complexes consist of the N-pyridinylmethylene aniline (1d) or a methoxy (2d) or chloro (3d) 
substituted ligand which coordinates to the Ru(II) center via the two N atoms in a bidentate manner 
forming 5 member metallocycles. The geometry around the Ru(II) center can be described as 
pseudooctahedral in which four coordination sites are occupied by two Cl atoms and N atoms from the 
ligand and the remaining by π-bonds of the cyclooctadiene moiety. Cyclooctadiene is bonded to Ru(II) 
with an η
4
 mannered π-olefin bond similar to what is observed in literature [44, 45]. The pseudooctahedral 
compounds are comparable to piano stool type complexes in which Ru(II) compounds are coordinated to 
5 member rings in an η
5
 manner [44-47]. The angles around the centre range between 77.90º and 177.28º.  
 
 There are two distinct planes in the complex described by (i) the pyridine aryl ring, the C=N 
imine and the Ru(II) centre, and (ii) the phenyl ring (chloro and methoxy substituted in 2d and 3d 
respectively). The angle between these two planes in all three complexes differ, where in 1 it is 89.53°, in 
2d it is 72.32° and in 3d it is 78.29°. This correlates to the deviation of the Ru atom from the 5 member 
metallacycle which is 0.007 Å in complex 1d, 0.095 Å in complex 2d and 0.303 Å in complex 3d. This 
supports that the bite angles between the Naryl and Nphenyl mean planes (ligand) affect the binding nature of 
the complexes with HSA. In addition, the torsion angles of C7 – C8 – N2 – Ru in complexes 1d and 2d 
crystal structures fall at -0.88° and -4.52° and for complex 3d, the torsion angle of C16 – C17 – N2 – Ru 
was -8.21°, which indicates the Naryl ring of complex 1 is more co-planner to ruthenium than the others. 
The Ru - C(COD) and Cl - Ru - Cl distances and bond angles of the complexes 1d-3d were in good 
agreement with reported values in related complexes [45-47]. Non covalent C-H···X and C-H···Cg (Cg = 
Centroid of the phenyl ring) inter-molecular interactions are observed in the crystal structure of the 









Table 5.1 Selected bond distances (Å) and bond angles (°) for complexes 1d, 2d and 3d 
Complex 1  Crystal 
data 
Complex 2d Crystal 
data 
Complex 3d Crystal 
data 
Distances (Å)  Distances (Å)  Distances (Å)  
Ru(1) – M1 2.100 Ru(1) – M3 2.092 Ru(1) – M5 2.105 
Ru(1) – M2 2.115 Ru(1) – M4 2.100 Ru(1) – M6 2.105 
Ru(1) – Cl(1) 2.432(7) Ru(1) – Cl(1) 2.441(4) Ru(1) – Cl(1) 2.447(10) 
Ru(1) – Cl(2) 2.438(6) Ru(1) – Cl(3) 2.428(4) Ru(1) – Cl(2) 2.437(9) 
Ru(1) – N(1) 2.093(2) Ru(1) – N(1) 2.108(12) Ru(1) – N(1) 2.105(3) 
Ru(1) – N(2) 2.113(2) Ru(1) – N(2) 2.096(12) Ru(1) – N(2) 2.098(4) 
Angles (°)  Angles (°)  Angles (°)  
N(1)-Ru(1)-N(2) 77.96(8) N(1)-Ru(1)-N(2) 77.99(5) N(1)-Ru(1)-N(2) 78.22(12) 
N(1)-Ru(1)-Cl(1) 81.25(6) N(1)-Ru(1)-Cl(1) 82.95(3) N(1)-Ru(1)-Cl(1) 83.10(8) 
N(1)-Ru(1)-Cl(2) 82.89(6) N(1)-Ru(1)-Cl(3) 80.28(3) N(1)-Ru(1)-Cl(2) 80.69(8) 
N(2)-Ru(1)-Cl(1) 82.85(6) N(2)-Ru(1)-Cl(1) 82.04(3) N(2)-Ru(1)-Cl(1) 82.17(10) 
N(2)-Ru(1)-Cl(2) 80.53(6) N(2)-Ru(1)-Cl(3) 81.97(3) N(2)-Ru(1)-Cl(2) 81.21(10) 
Cl(1)-Ru(1)-Cl(2) 159.05(2) Cl(1)-Ru(1)-Cl(3) 158.86(2) Cl(1)-Ru(1)-Cl(2) 158.80(3) 
Cl(1)-Ru(1)-M1 97.18 Cl(1)-Ru(1)-M3 98.16 Cl(1)-Ru(1)-M5 97.63 
Cl(2)-Ru(1)-M1 98.49 Cl(3)-Ru(1)-M3 97.53 Cl(2)-Ru(1)-M5 97.65 
N(1)-Ru(1)-M1 97.96 N(1)-Ru(1)-M3 175.09 N(1)-Ru(1)-M5 176.10 
N(2)-Ru(1)-M1 175.88 N(2)-Ru(1)-M3 97.39 N(2)-Ru(1)-M5 98.06 
Cl(1)-Ru(1)-M2 97.96 Cl(1)-Ru(1)-M4 98.99 Cl(1)-Ru(1)-M6 98.91 
Cl(2)-Ru(1)-M2 97.25 Cl(3)-Ru(1)-M4 96.42 Cl(2)-Ru(1)-M6 96.81 
N(1)-Ru(1)-M2 177.28 N(1)-Ru(1)-M4 177.28 N(1)-Ru(1)-M6 98.91 
N(2)-Ru(1)-M2 99.38 N(2)-Ru(1)-M4 98.99 N(2)-Ru(1)-M6 176.72 
M1 = Midpoint of C14-C13 (1d); M2 = Midpoint of C17-C18 (1d); M3 = Midpoint of C16-C17 (2d); M4 
= Midpoint of C13-C20 (2d); M5 = Midpoint of C1-C8 (3d); M6 = Midpoint of C4-C5 (3d). 
134 
 
5.3.7 Emission spectral studies of HSA in the presence of complexes 1d-5d 
HSA possess intrinsic emission properties owing to the tryptophan (Trp), tyrosine (Tyr), and 
phenylalanine (Phe) residues. The interaction of complexes with HSA often leads to changes in the 
intrinsic emission property of the protein with respect to the complexes concentration. As a result, 
fluorimetric titrations have been frequently used to study the interactions of proteins with metal 
complexes. In the present study, the effect of Ru(II) complexes 1d-5d on the intrinsic emission property 
of HSA was monitored using emission spectroscopy. The emission spectra recorded for HSA with 
different concentrations of complexes 1d-5d are shown in Fig. 5.5. The emission spectrum of HSA in the 
absence of complexes 1d-5d shows an emission maximum at 345 nm, when excited at 295 nm. The 
excitation wavelength of 295 nm was chosen to avoid any contribution from the Tyr residue and the 
resulting emission spectrum is exclusively ascribed to the intrinsic Trp fluorophore [48]. As  an  example,  
Fig. 5.5 shows  the emission spectra  resulting  from  the  addition  of complex 1d to HSA. The addition 
of increasing concentrations of complexes 1d-5d notably reduces the intrinsic emission of HSA without 
any significant shift in the emission maximum (SI S15). Since the emission spectrum of HSA depends on 
the degree of exposure of the Trp residues to the solvent polarity and upon its proximity to specific 
quenching groups, the observed decrease in emission intensity could be attributed to the binding of 
complexes 1d-5d with HSA. The above interpretation shows that the binding site of complexes 1d-5d on 
HSA is most probably located near the Trp residue of HSA (Trp-214) [49]. It is well known that 
quenching of a fluorescent macromolecule can occur due to inner-filter effect, collisional quenching, and 
binding-related quenching. The mechanism of quenching is obtained from the emission intensity data and 
not from the emission maximum value. The binding-related quenching is further subdivided into ground-
state complex formation between the ligand and the macromolecule, excited-state quenching in the 
complex (e.g. energy transfer), or structural changes around the fluorophores [50]. To rule out the 
influence of an inner filter effect, a correction was applied to all the fluorescence data, by the use of 
equation 1 [50].  
             
           
               
Fobs and Fcorr are the observed and corrected emission intensities, and Aexi and Aemi are the solution 
absorption at the excitation and emission wavelengths. 
Since the concentrations of the complexes 1d-5d used in the titration experiments were low, most 
compounds had minimum correction factors. Although overall inner-filter effects were minimal, corrected 
values were used in all the data treatment and analysis.  
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. The arrow shows that emission intensity decreases while 
increasing the concentration of complex 1d.  
5.3.8 Quenching Mechanism of HSA in the presence of complexes 1d-5d  
Fluorescence quenching refers to any process that results in a decrease of fluorescence intensity 
of a fluorophore. A variety of molecular interactions can result in quenching, including excited-state 
reactions, molecular rearrangements, energy transfer, ground-state complex formation, and collisional 
quenching. In order to gain insight into the quenching mechanism, the fluorescence quenching data for 
complexes 1d-5d were analyzed by using the Stern-Volmer equation (2) [50], 
F0/F = 1 + Kq τ0 [Q] = 1 + KSV [Q] (2) 
where, F0 and F are the relative corrected emission intensities in the absence and presence of quencher. Kq 
is the bimolecular quenching rate constant; τ0 is the average lifetime of the fluorophore in the absence of 
quencher and [Q] is the concentration of the quencher. Ksv is the Stern-Volmer quenching constant which 
measures the efficiency of quenching. 
136 
 
Fig. 5.6 shows the plot of relative corrected emission intensity at maximum wavelength of HSA 
vs the concentration of complexes 1d-5d. It demonstrates a good linear relationship within the 
experimental concentrations of complexes 1d-5d. The values of the Stern-Volmer quenching constant Ksv 
were obtained from the slope and intercept of the linear plot (Fig. 5.6). The Kq values for the quenching of 
HSA by the Ru(II) complexes were calculated and are given in Table 5.2.  It can be noted that the Kq 
values of all the complexes 1d-5d were higher than the accepted limit for diffusion controlled bimolecular 
quenching constants [50], providing further evidence for the occurrence of static quenching. These 
combined data strongly suggests that the complexes 1d-5d bind to HSA and form a dark protein-complex 
in ground state. 
 
Fig. 5.6 Stern-Volmer plot for HSA with complexes 1d-5d. 
5.3.9 Binding constants and the number of binding sites 
The fluorescence quenching data obtained from the interaction of complexes 1d-5d with HSA 
were further analyzed to obtain binding constants and the number of binding sites (n) by using the 
modified double logarithm regression equation (3) [28, 51]. Equation 3 is valid for determining both 
dynamic and static quenching processes, and the use of equation 3 can give information on the binding 
site and degree of cooperativity of complexes of HSA [28]. 
    
    
 
                  (3) 
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where, F0 and F are the corrected emission intensities of HSA in the absence and presence of the 
complexes 1d-5d, where n is the average binding number for complexes 1d-5d, Kb is the binding 
constant. In Fig. 5.7, the plots of log[(F0-F)/F] against log(Ru complexes 1d-5d) showed linear 
relationship with the slope equal to n. The average binding site for the complexes 1d-5d is almost equal to 
1 for HSA. Moreover, the binding between HSA and complexes 1d-5d is in a 1:1 stoichiometric ratio. 
The double logarithmic plot for complexes 1d-5d is shown in Fig. 5.7, and obtained data for all the 
complexes are given in Table 5.2. 
HSA consists of three homologous domains (I, II and III) and each domain contains two sub 
domains labelled as “A” and “B”. The primary regions of the ligand or complex binding sites of HSA are 
located in hydrophobic cavities in sub domains IIA and IIIA [50]. The higher binding constant (Kb) and 























, 1.11 (5d) respectively, demonstrating stronger affinity to HSA than complexes 2d 
and 4d. It may be attributed to the electron withdrawing chlorine group and electron releasing methyl 
group present on the phenyl ring of complexes 2d and 4d which may affect the planarity of the 
complexes. In the case of the complex 1d there is no substitution on the phenyl ring which may assist 
complex planarity and high interaction with HSA that correlates with experimental results. However, the 
electron releasing methoxy group present in complex 3d showed better binding capability with HSA than 
complex 2d. The carbazole ligand moiety present in complex 5d also showed good binding affinity with 
HSA that may be due to planarity of the carbazole moiety in the complex. The planarity of the complexes 
1d-3d were discussed in Section 3.6 
Recently, the binding nature of Ru(II) and Cu(II) complexes with DNA or protein were shown to be 
dependent on the aromatic ring planarity present in the ligands, as reported by Rajendiran et al. and 
Ramakrishnan et al. respectively [52, 53]. The binding constants of these synthesized complexes are close 
to those of reported Ru(II) complexes [54, 55]. These values suggest that these ruthenium complexes bind 
with HSA in a 1:1 stoichiometric ratio.  
Binding interaction of Ru(II) complexes with HSA also depends on the nature of the metal, COD 
and other groups present in the complex. From the experimental results, in complex 3d the p-methoxy 
(OCH3) group might show better interaction compared to the p-Cl present in complex 2d. Complex 5d 
shows both electronic and steric effects in the HSA binding studies. The electronic effect of the pyridine 
ring and the steric effect of the fused carbazole rings of complex 5d played an important role during the 
binding study with HSA. According to the experimental studies, the steric effect plays a major role in 




Fig. 5.7 Double logarithmic plot for HSA-complexes 1d-5d. 
 
Table 5.2 Calculated Stern-Volmer constants (Ksv), bimolecular quenching constants (kq), binding 













































































 The mean value of the three individual experiments. 
b
 ± 0.20. 
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5.4.0 Conformational studies of HSA in the presence of complexes 1d-5d 
Further changes in the serum albumin secondary structure imparted by the presence of the 
complexes are confirmed by UV-vis absorption, synchronous fluorescence and circular dichroism 
analyses.  
5.4.1  Absorption spectral studies of HSA with complexes 1d-5d  
UV-vis absorption is a simple but efficient technique to explore structural changes and to show 
complex formation. The absorption profile of HSA is characterized by a strong absorption at 208 nm 
which is ascribed to the π-π* transition of the polypeptide backbone structure C=O of HSA [30, 56]. 
 
In 
addition the absorption peak at 278 nm mainly originates from the aromatic amino acid residues, viz Trp, 
Tyr, and Phe. It is well known that the absorption maximum of HSA is highly sensitive to the surrounding 
micro environment and it displays a substantial spectral shift upon changes in protein conformation [57]. 
In order to explore the structural changes of HSA and to establish the quenching mechanism, the 
absorption spectra of HSA was recorded in the presence of increasing concentrations of complexes 2d-5d 
(See SI S16). As depicted in Fig. 5.8, the absorption intensity of HSA at 208 nm and 278 nm increased 
simultaneously with the incremental addition of complex 1d. It is pertinent to note that the absorption 
maximum at 278 nm is red shifted to 283 nm. It is widely reported that the interaction between serum 
proteins and complexes leads to perturbation of the protein absorption spectrum [56]. It is believed that 
the increase in absorption maxima of HSA at 208 nm and 278 nm is solely due to the interaction of 
complexes 1d-5d with HSA and increase in the hydrophobicity around Trp residues of HSA. It is widely 
reported that the formation of the ground state complex between the protein and complex often leads to 
alteration in the absorption spectrum of the proteins [30, 56]. Blank UV-vis experiments were done to 
allow comparison of the spectra of HSA alone, complex 1d alone and HSA with complex 1d. No 
significant overlap was observed in the range of 220-310 nm in UV-vis spectra, as shown in SI S16. 
 
Subsequently, the perturbation in the absorption spectra of serum protein suggests that complexes 
1d-5d are primarily initiated by the static quenching process and this corroborates well with the results 









5.4.2 Synchronous fluorescence spectroscopy of HSA with complexes 1d-5d 
Synchronous fluorescence spectroscopy, introduced by Lloyd [58, 59], involves a simultaneous 
scanning of the excitation and the emission monochromators while maintaining a constant wavelength 
interval between them. It is used to study the conformation change of proteins and gives information 
about the molecular environment in the vicinity of Tyr and Trp residues. According to the theory of 
Miller [60], when Δλ between excitation and emission wavelength is stabilized at 15 nm or 60 nm, the 
spectral characteristics of the protein Tyr or Trp residues are observed. The synchronous fluorescence 
spectrum of HSA in the presence of complex 1d is shown in Fig. 5.9 (For complexes 2d-4d See SI S17). 
As can be seen from Fig. 5.9, the maximum emission wavelength of Trp in HSA has a slight blue shift 
from 344 nm to 341 nm and a slight red shift from 301 nm to 303 nm for HSA. The above results indicate 
that in the presence of complexes 1d-5d the conformation of HSA was altered and the polarity around the 
Trp residues was decreased with increase in hydrophobicity [49, 61]. It is apparent from the above 
analysis that the synchronous emission intensity of both Tyr and Trp decreased instantaneously upon the 
addition of complexes 1d-5d and this corroborates the occurrence of emission quenching in the binding 
process. The results from these synchronous fluorescence studies further suggest that the binding regions 
of complexes 1d-5d are located in the vicinity of both Tyr and Trp residues of HSA, since a distant event 
cannot cause the synchronous emission quenching of both Tyr and Trp residues. Therefore, from 
synchronous fluorescence experiments it can be concluded that the binding site of complexes 1d-5d in 
HSA is located adjacent to both Tyr and Trp residues. 
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5.4.3 Circular dichroism spectroscopy of HSA-Complexes 1d-5d 
To gain a better understanding of the conformational behavior of the HSA-complexes system, the 
CD spectra of HSA in the absence and presence of complexes 1d-5d were obtained. The observed CD 
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results were first transformed into mean residue ellipticity (MRE) according to the following equation 
[62], 
     
                
         
  (4) 
where, CP is the molar concentration of the protein, n is the number of amino acid residues (585 
amino acids for HSA) and l is the path length of the cell.  
The helicity content of the protein is then determined from the calculated MRE values at 222 nm 
using the following equation, 
α                      
             
           
       (5) 
where, M E 208 is the observed M E value at 208 nm, 4000 is the M E of the β-form and 
random coil conformation cross at 208 nm and 33000 is the MRE value of a pure α-helix at  
208 nm. 
In free HSA, the secondary structure consists of ~58% α-helix, ~20% β-sheets and ~22% random 
coils. The CD spectrum of HSA exhibits two negative peaks in the ultraviolet region at 208 and 222 nm, 
which are characteristic of the α-helix structure in proteins. The binding of complex 4d (Fig. 5.10 and for 
complexes 1d-3d & 5d SI S19) to HSA caused a decrease in band intensity at all wavelengths of the CD 
spectra without any significant shift of the peaks, which indicates a decrease of the α-helix content in the 
protein structure at molar ratio of the complexes to HSA of 1:1. The acting force of these HSA-complex 
interactions might be hydrophobic or hydrophilic interactions, as well as hydrogen bonding. The 
decreasing α-helix content suggests that the binding of complexes with HSA induces a slight unfolding of 
the constituent polypeptides of the protein, some secondary-structure changes in HSA, and the exposure 
of some hydrophobic regions increased [63]. It is possible that the hydrophobic interaction occurred in the 
region of the IB sub domain due to the presence of the L-Trp and L-Tyr hydrophobic amino acid residues 
in this sub domain of HSA [64]. This is consistent with the results of the synchronous fluorescence 
spectroscopy.  
Thus complexes 1d-5d cause a conformational change of the protein, with the loss of α-helical 
stability. The quantitative analyses of the α-helix content was determined by using Eqns. 4 and 5 and the 
obtained results are reported in Table 5.3, which show the decrease in the α-helix content in HSA upon 
addition of complexes 1d-5d. The difference in CD spectral values of HSA protein conformation upon 
binding with Ru(II) complexes may be attributed to different substituent groups in the ligand moieties of 
the complexes. The carbazole ligand containing complex 5d showed highest α-helix stability, which 
decreased from values of 57.84 to 52.36%, which may be due to the additional phenyl rings present in the 
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carbazole moiety. The Ru(II) complex bound to HSA causes the conformational change in α-helix 
stability, due to the inherent flexibility at the IIA domain [28]. 
 






Table 5.3 Circular dichroism spectral values (±2) % of HSA and complexes 1d-5d 
 
5.4.4 Molecular docking studies 
A molecular docking study was performed to understand the possible binding conformation and 
binding location of complexes 1d-5d in the protein environment, which is important [57]. The lowest 
binding energy conformation of the complexes was used for docking analysis, out of 10 different possible 
conformations. During the docking analysis, possible binding sites of complex 1d were obtained, of 
which the lowest free energy for HSA has been shown in Fig. 5.11. The diagram (Fig. 5.11) of the 
docking study reveals that HSA subdomain IIA has more favourable binding sites for complexes 1d-5d. 
System Complex 1d Complex 2d Complex 3d Complex 4d Complex 5d 
% of α-Helix content  












% of α-Helix content  













The HSA subdomain IIA entrance pocket is surrounded by Trp 214, Arg 222, His 242, Leu 238 and Ala 
291. These amino acid residues are responsible for the hydrophobic and van der Waals interaction with 
complexes 1d-5d. Docking studies reveal that complexes 1d-5d are located closer to the active site 
residues of Trp 214, Arg 222, His 242, Leu 238 and Ala 291 in HSA subdomain IIA. The phenyl group of 
complexes 1d-5d forms π-π stacking with Trp 214 and His 242. The secondary interactions between  u 
metal and His 242 nitrogen for complexes 1d-5d are given in the SI S19. This interaction indicates that 
the phenyl groups of the complexes are crucial for inducing conformational changes in the protein [49]. 
These complexes bind in the drug binding pocket of HSA subdomain IIA in a similar fashion to the 
warfarin [43]. The binding energies of complexes 1d-5d were obtained in the range of -5.73 to -6.67 
kcal/mol, listed in Table 5.4. Complex 1 shows the highest binding energy among complexes 1d-5d, with 
a binding energy of -6.67 kcal/mol. The hydrophobic interaction within the protein active sites is 
increased, which leads to the stabilization of the HSA-complexes. 
Table 5.4 Binding energy values of the complexes 1d-5d 








Fig. 5.11 Molecular docking of the complex 1d with HSA. 
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5.5 Conclusions  
In conclusion, new Ru(II) aniline and amine complexes were synthesized and characterized. 
Single crystal X-ray studies showed the expected pseudooctahedral geometry in the crystal structures. The 
emission spectra revealed that interactions of complexes 1d-5d occurred with HSA and caused an 
increase in the hydrophobicity around the Trp residues of HSA. Fluorescence quenching of HSA is 
induced by the Ru(II) complexes following the static quenching mechanism. The binding constant study 
revealed that the planarity and substitution of the ligands present in the complexes were responsible for 
the binding affinity with HSA.  
 
In synchronous emission spectra, blue and red shifts for complexes 1d-5d confirmed that the 
binding site of the complexes in HSA are most probably located adjacent to both Trp and Tyr residues. 
The circular dichroism study further confirmed the loss of α-helix stability during the addition of the 
complexes 1d-5d to HSA, whilst the binding of the Ru(II) complexes with HSA initiates the secondary 
structure change and increases hydrophobic interactions in HSA. Furthermore, the molecular docking 
study revealed that the amino acid residue Trp-214 in the HSA subdomain IIA is the most favourable 
binding location for complexes 1d-5d. Further, the binding energies of complexes 1d-5d were found 
between -5.73 to -6.67 kcal/mol.  
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C NMR data, HR-MS, UV-vis, emission spectra, synchronous emission spectra, and circular 
dichroism spectra for complexes 1d-5d are also shown in the SI. Selected intermolecular interactions in 
the crystalline structures of Ru(II) complexes 1d-3d can be consulted in the SI. CCDC-1408763 (1d), 
CCDC-1408764 (2d), and CCDC-1408765 (3d) contain the supplementary crystallographic data in this 
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Synthesis and characterization of C,N cyclometalated new half sandwich 
Ir(III) and Rh(III) complexes 
 
Abstract 
Six new complexes [(η
5
-C5Me5)IrCl(para-R-N-benzylidene-9-ethyl-9H-carbazol-3-amine)] (R = F (1e), 
CH3 (2e), OCH3 (3e)), and [(η
5
-C5Me5)RhCl(para-R-N-benzylidene-9-ethyl-9H-carbazol-3-amine)] (R = 





C NMR, 2D NMR, melting point analysis, infrared spectroscopy, HR-MS and elemental 
analyses. The crystal structures of 2e and 5e have been determined by single crystal XRD.  
Keywords: Half sandwich; Ir(III), Rh(III) complexes; C,N ligands 
6.1 Introduction  
C-H activation is a popular field in organometallic chemistry due to it is important potential for 
producing functionalized hydrocarbons and direct arylation and alkenylation in chemical reactions [1]. 
Intra-molecular C-H functionalized platinum metal complexes were first reported by Cope and Siekman 
in 1965 [2] and have since shown promise in different fields of catalysis [3]. Cyclometallation in platinum 
metal complexes is well known and adding of Pd(OAc)2 salt to a PdCl2 complex can induce the 
cyclometallation of the ligand [4]. In 2003, Davies et al. reported sodium acetate salts which were used to 
promote cyclometalation of nitrogen donor C,N ligands at room temperature [4]. Cyclometalated arene 
ruthenium complexes coordinated to N,N'-dimethylbenzylamine are well known and are versatile and 
active catalysts for C-C bond forming reactions with ethene and alkynes [4]. Furthermore, C,N donor 
ligands also improve the nature of the complexes by enhancing the electron density at the metal center 
which stabilizes the oxidation states of metal and promotes the rapid hydrolysis of the labile chloro group 
attached to the metal [5].  
In recent years, half sandwich complexes with cyclometalated ligands containing nitrogen donors 
have become an important emerging field in organometallic chemistry. Octahedral Ir(III) and Rh(III) 
complexes with C,N ligands have significantly improved the scope of applications in biological studies 
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and catalysis [6, 7]. Their photochemical and electrochemical properties are of interest in various 
applications, such as photodynamic therapy, photovoltaic cells, luminescent sensors and anticancer 
studies [8]. Also, a number of iridium and rhodium cyclometalated catalysts are reported for transfer 
hydrogenation, hydrogenation, oxidation reactions, reductive amination, imine hydrogenation and olefin 
hydrogenation reactions [9-11].    
In medicinal chemistry, half sandwich Ir(III) and Rh(III) complexes containing C,N ligands have 
shown promising anticancer activity through intercalation with the target DNA in the cancer cells [6]. The 
fine tuning of the functional groups present in the ligands and varying metal centers can have a definite 
effect on biological systems [6, 12]. Furthermore, Ru, Ir, Rh and Os complexes containing cyclometalated 
ligands are appropriate for anticancer compounds due to their favorable kinetic aspects, rate of ligand 
exchange, variable oxidation states, low toxicity and intercalating target in DNA in the cancer cells. Thus, 
they could resolve many of the negative aspects which exist with platinum based anticancer drugs [13-
17]. 
This work describes the synthesis and characterization of new half sandwich complexes 





C NMR, 2D NMR, IR spectroscopy, HR-MS spectroscopy, single crystal XRD and 
elemental analysis.   
6.2 Experimental Section 
6.2.1 Reagents and Methods 
 Unless otherwise noted, all manipulations were performed using standard Schlenk tube techniques 
under nitrogen atmosphere. Reagents such as the substituted benzaldehydes, sodium acetate, IrCl3·3H2O 
(≥99% purity) and  hCl3·3H2O (≥99% purity) and solvents were purchased from Sigma-Aldrich, Capital 
Labs, South Africa and were used without further purification. The NMR solvent CDCl3 was purchased 
from Merck Germany. The solvents were dried by standard procedures and distilled prior to use [18]. 
Melting points were recorded on a Stuart
TM





C (100 MHz) NMR were recorded in CDCl3 using a Bruker Topspin 400 MHz 
spectrometer. Elemental analyses were performed on a Thermo-Scientific Flash 2000 CHNS/O analyser. 
Solid and liquid state infrared spectra were recorded using an FT-IR Perkin Elmer Spectrum 100 
spectrophotometer between 4000 - 400 cm
-1
. High resolution mass spectra were recorded using a Waters 
Micromass LCT Premier TOF-MS instrument. X-ray single crystal intensity data were collected on a 
Bruker Smart APEX11 Nonius Kappa-CCD diffractometer using graphite monochromated MoK 
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radiation ( = 0.71073 Å). The ligand precursor 3-amino-9-ethyl-9H-carbazole [19], ligands (p-R- N-
benzylidene-9-ethyl-9H-carbazol-3-amine) (R = F (L1), CH3 (L2) & OCH3 (L3)) [20] and metal 
precursors (IrCl2Cp*)2 and (RhCl2Cp*)2 were prepared according to literature methods [21-23].  
6.2.2 Synthesis of the complexes 1e-6e 
A common procedure was followed to synthesize the complexes [(η
5
-C5Me5)IrCl(para-R-N-
benzylidene-9-ethyl-9H-carbazol-3-amine)] (R = F (1e), CH3 (2e), OCH3 (3e)), and [(η
5
-
C5Me5)RhCl(para-R-N-benzylidene-9-ethyl-9H-carbazol-3-amine)] (R = F (4e), CH3 (5e), OCH3 (6e)).  
A mixture of (MCl2Cp
*
)2 (M = Ir / Rh), the Schiff base carbazole ligands (L1-L3) and sodium 
acetate was stirred at room temperature in dichloromethane (15 mL) for 48 hours. The solvent was then 
removed under vacuum and the residue was dissolved in dichloromethane (10 mL), and filtered through a 
pad of celite. Evaporation of the solvent in vacuo, followed by the addition of diethyl ether, produce a 







)2 (100 mg, 0.13 mmol), Schiff base carbazole ligand L1 (80 mg, 0.26 mmol) and 
CH3COONa (53 mg, 0.65 mmol). Yield (140 mg, 0.21 mmol, 82%). Mp. 332 °C (dec.). 
1
H NMR (400 
MHz, CDCl3, 25 ºC, ppm) δ = 8.40 (s, 1H, imine CH), 8.23 (d, 1H, JH-H  = 1.88 Hz), 8.16 (d, 1H, JH-H  = 
7.68 Hz), 7.84 (d-d, 1H, JH-H  = 2.04 Hz), 7.67 (m, 1H), 7.56 (m, 2H), 7.48 (d, 1H, JH-H  = 8.20 Hz), 7.42 
(d, 1H, JH-H  = 8.56 Hz), 7.30 (m, 1H), 6.79 (t, 1H), 4.45 - 4.40 (q, 2H, N - CH2), 1.51 (m, 18H, C5Me5 & 
N -CH3). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 170.21 (imine C-H), 164.76, 162.18, 143.47, 
142.80, 138.98, 130.37, 130.27, 126.23, 122.82, 122.76, 122.56, 120.88, 120.69, 119.16, 113.35, 108.86, 
108.54, 89.04 (C, C5Me5), 37.82 (CH2, N - CH2CH3), 13.84 (CH3, N - CH2CH3), 8.98 (CH3, C5Me5). FT-
I  (γ/cm
-1
): 3040, 2977, 2911, 1625, 1592 (s, C=N), 1538, 1480, 1470, 1460, 1234, 1173, 1147, 1027, 
813, 747, 428. HR-MS (TOF MS ES
+
) C31H31FIrN2 Calculated: 643.2101, Found: 643.2110. Anal. Calcd 







)2 (100 mg, 0.13 mmol), Schiff base carbazole ligand L2 (79 mg, 0.26 mmol) and 
CH3COONa (53 mg, 0.65 mmol). Yield (146 mg, 0.22 mmol, 86%). Mp. 342 °C (dec.). 
1
H NMR (400 
MHz, CDCl3, 25 ºC, ppm) δ = 8.38 (s, 1H, imine CH), 8.24 (d-d, 1H, JH-H  = 1.92 Hz), 8.16 (d, 1H, JH-H  = 
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7.72 Hz), 7.86 (d-d, 1H, JH-H  = 2.00 Hz), 7.70 (s, 1H), 7.56 (m, 2H), 7.48 (d, 1H, JH-H  = 8.20 Hz), 7.41 (d, 
1H, JH-H  = 8.68 Hz), 7.30 (m, 1H), 6.89 (d, 1H, JH-H  = 7.48 Hz), 4.45 - 4.40 (q, 2H, N - CH2), 2.49 (s, 3H, 
CH3), 1.50 (m, 18H, C5Me5 & N -CH3). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 174.19 (imine C-
H), 169.60, 144.97, 144.54, 142.44, 140.65, 138.85, 135.77, 128.97, 126.11, 123.13, 122.87, 122.68, 
121.19, 120.68, 119.07, 116.24, 113.86, 108.80, 108.55, 108.34, 89.03 (C, C5Me5), 37.80 (CH2, N - 
CH2CH3), 22.16 (C, CH3), 13.85 (CH3, N - CH2CH3), 8.84 (CH3, C5Me5). FT-I  (γ/cm
-1
): 3041, 2974, 
2908, 1583 (s, C=N), 1532, 1481, 1471, 1459, 1230, 1174, 1147, 1028, 814, 747, 728, 567. HR-MS (TOF 
MS ES
+
) C32H34IrN2 Calculated: 639.2351, Found: 639.2360. Anal. Calcd for C32H34ClIrN2: C, 57.00; H, 






)2 (100 mg, 0.13 mmol), Schiff base carbazole ligand L3 (83 mg, 0.26 mmol) and 
CH3COONa (53 mg, 0.65 mmol). Yield (141 mg, 0.20 mmol, 82%). Mp. 315 °C (dec.). 
1
H NMR (400 
MHz, CDCl3, 25 ºC, ppm) δ = 8.32 (s, 1H, imine CH), 8.22 (d-d, 1H, JH-H  = 1.44 Hz), 8.15 (D, 1H, JH-H  = 
7.72 Hz), 7.85 (d-d, 1H, JH-H  = 1.44 Hz), 7.61 (d, 1H, JH-H  = 8.28 Hz), 7.54 (t, 1H), 7.46 (d, 1H, JH-H  = 
8.08 Hz), 7.42 (m, 2H), 7.29 (m, 1H), 6.64 (d-d, 1H, JH-H  = 2.20 Hz), 4.45 - 4.40 (q, 2H, N - CH2), 2.49 
(s, 3H, CH3), 1.50 (m, 18H, C5Me5 & N -CH3). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 173.13 
(imine C-H), 171.93, 162.27, 144.55, 140.97, 140.63, 138.74, 130.66, 126.07, 122.87, 122.67, 121.30, 
120.65, 119.45, 119.02, 113.86, 108.78, 108.44, 108.32, 89.01 (C, C5Me5), 55.07 (C, OCH3), 37.79 (CH2, 
N - CH2CH3), 13.84 (CH3, N - CH2CH3), 8.84 (CH3, C5Me5). FT-I  (γ/cm
-1
): 3046, 3024, 2979, 2910, 
1623, 1587 (s, C=N), 1527, 1480, 1470, 1454, 1256, 1240, 1206, 1169, 1147, 1030, 861, 748, 731, 607. 
HR-MS (TOF MS ES
+
) C32H34IrN2O Calculated: 655.2301, Found: 655.2312. Anal. Calcd for 






)2 (100 mg, 0.16 mmol), Schiff base carbazole ligand L1 (102 mg, 0.32 mmol) and 
CH3COONa (66 mg, 0.80 mmol). Yield (176 mg, 0.28 mmol, 93%). Mp. 249 °C (dec.). 
1
H NMR (400 
MHz, CDCl3, 25 ºC, ppm) δ = 8.27 (m, 1H), 8.25 (s, 1H, imine CH), 8.18 (d, 1H, JH-H  = 8.04 Hz), 7.91 
(d-d, 1H, JH-H  = 1.96 Hz), 7.59-7.52 (m, 3H), 7.48 (d, 1H, JH-H  = 8.12 Hz), 7.43 (d, 1H, JH-H  = 8.64 Hz), 
7.31 (m, 1H), 6.80 (t, 1H), 4.45 - 4.40 (q, 2H, N - CH2), 1.51 (m, 3H, N -CH3). 1.45 (s, 15H, C5Me5). 
13
C 
NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 170.20 (imine C-H), 164.79, 160.21, 143.46, 142.83, 140.71, 
138.99, 130.28, 126.23, 122.85, 122.75, 122.57, 120.84, 120.69, 119.16, 113.39, 110.33, 110.10, 108.86, 
108.53, 96.42, 96.36 (C, C5Me5), 37.81 (CH2, N - CH2CH3), 13.82 (CH3, N - CH2CH3), 8.96 (CH3, 
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C5Me5). FT-I  (γ/cm
-1
): 3045, 2978, 2911, 1590 (s, C=N), 1574, 1550, 1481, 1470, 1460, 1372, 1238, 
1173, 1149, 1024, 815, 747, 453. HR-MS (TOF MS ES
+
) C31H31FN2Rh Calculated: 553.1526, Found: 






)2 (100 mg, 0.16 mmol), Schiff base carbazole ligand L2 (101 mg, 0.32 mmol) and 
CH3COONa (66 mg, 0.80 mmol). Yield (160 mg, 0.27 mmol, 85%). Mp. 259 °C (dec.). 
1
H NMR (400 
MHz, CDCl3, 25 ºC, ppm) δ = 8.28 (s, 1H, imine CH), 8.26 (d, 1H, JH-H  = 3.84 Hz), 8.18 (d, 1H, JH-H  = 
7.72 Hz), 7.95 (d-d, 1H, JH-H  = 1.96 Hz), 7.70 (s, 1H), 7.55 (m, 1H), 7.47 (m, 2H), 7.43 (d, 1H, JH-H  = 
8.64 Hz), 7.30 (m, 1H), 6.90 (d, 1H, JH-H  = 7.40 Hz), 4.45 - 4.40 (q, 2H, N - CH2), 2.49 (s, 3H, CH3), 1.51 
(t, 3H, N-CH3), 1.44 (s, 15H, C5Me5). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 171.05 (imine C-H), 
144.08, 143.76, 141.38, 140.64, 138.90, 137.07, 128.67, 126.12, 123.86, 122.90, 122.81, 121.03, 120.71, 
119.08, 113.35, 108.80, 108.48, 96.14, 96.08 (C, C5Me5), 37.81 (CH2, N - CH2CH3), 22.24 (C, CH3), 
13.85 (CH3, N - CH2CH3), 9.02 (CH3, C5Me5). FT-I  (γ/cm
-1
): 3039, 2975, 2906, 1624, 1599, 1579 (s, 
C=N), 1481, 1471, 1460, 1230, 1175, 1147, 1024, 816, 747, 731, 562. HR-MS (TOF MS ES
+
) 
C32H34N2Rh Calculated: 549.1777, Found: 549.1776. Anal. Calcd for C32H34ClN2Rh: C, 65.70; H, 5.86; 






)2 (100 mg, 0.16 mmol), Schiff base carbazole ligand L3 (106 mg, 0.32 mmol) and 
CH3COONa (66 mg, 0.80 mmol). Yield (130 mg, 0.22 mmol, 67%). Mp. 283 °C (dec.). 
1
H NMR (400 
MHz, CDCl3, 25 ºC, ppm) δ = 8.25 (s, 1H, imine CH), 8.19 (m, 2H), 7.92 (d, 1H, JH-H  = 8.28 Hz), 7.54 - 
7.40 (m, 5H), 7.30 (t, 1H), 6.63 (d, 1H, JH-H  = 8.00 Hz), 4.44 - 4.39 (q, 2H, N - CH2), 3.94 (s, 3H, OCH3), 
1.50 (t, 3H, N-CH3), 1.45 (s, 15H, C5Me5). 
13
C NMR (100 MHz, CDCl3, 25 °C, ppm) δ = 170.19 (imine 
C-H), 160.99, 143.79, 140.63, 140.04, 138.77, 130.17, 126.07, 122.89, 122.79, 121.17, 121.09, 120.68, 
119.03, 113.37, 109.01, 108.79, 108.47, 96.15, 96.08 (C, C5Me5), 55.16 (C, OCH3), 37.79 (CH2, N - 
CH2CH3), 13.85 (CH3, N - CH2CH3), 9.04 (CH3, C5Me5). FT-I  (γ/cm
-1
): 3046, 2980, 2909, 1624, 1584 
(s, C=N), 1541, 1531, 1480, 1470, 1460, 1239, 1205, 1168, 1147, 1088, 1033, 859, 748, 586. HR-MS 
(TOF MS ES
+
) C32H34N2ORh Calculated: 565.1726, Found: 565.1725. Anal. Calcd for C32H34ClN2ORh: 
C, 63.95; H, 5.70; N, 4.66; Found: C, 63.98; H, 5.70; N, 4.79. 
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6.3 Results and discussion 
6.3.1 Synthesis of the ligands and complexes 
In this work, new half sandwich metal complexes 1-6 have been synthesized using C,N carbazole 
bidentate ligands (Scheme 6.1). The reaction between the chloro bridged dimer (MCl2Cp
*
)2 (M = Ir and 
Rh) with C, N [para-R-N-benzylidene-9-ethyl-9h-carbazol-3-amine)] (R = F (L1), CH3 (L2) and OCH3 
(L3)] ligands afforded the new [(η
5
-C5Me5)MCl(L)] (M = Ir and Rh; L = L1-L3) complexes 1e-6e in 
good yield in dichloromethane (67% to 93%). Complexes 1e-6e are orange-red crystalline solids and are 
air stable, non-hygroscopic and soluble in common polar solvents such as DMSO, DMF, acetonitrile, 
dichloromethane, acetone, chloroform, methanol, ethanol and partially soluble in water. These complexes 
are insoluble in diethyl ether, petroleum ether and hexane. 
Characterisation of the ligands L1-L3 and metal complexes 1e-6e was carried out by NMR, 2D 
NMR (COSY, NOESY), IR spectroscopy, melting point analysis, HR-MS spectroscopy and elemental 
analyses. The structures of the complexes 2e and 5e have been further authenticated by single crystal X-
ray crystallography.  
 
Scheme 6.1: Schematic diagram for the synthesis of ligands (L1-L3) and complexes 1e-6e. 
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6.3.2 NMR spectral studies 
The spectral data of the ligands and metal complexes have been summarized in the Experimental section. 
The 
1
H NMR spectra of the free C,N Schiff base carbazole ligands L1-L3 showed a CH imine proton 
singlet signal at 8.65 (L1), 8.53 (L2) and 8.61 (L3) ppm respectively. When the C,N Schiff base 
carbazole ligands were coordinated with the iridium and rhodium metal precursors, the singlet peak of the 
imine proton signal shifted up-field to 8.40 (1e), 8.38 (2e), 8.32 (3e) for the Ir complexes and to 8.26 (4e), 
8.28 (5e) and 8.23 (6e) ppm for the Rh complexes, respectively. The signals of the aromatic region of all 
metal complexes 1e-6e were shifted up-field compared to the respective free ligands signals. The 
corresponding signals of the benzaldehyde protons in complexes 1e-6e shifted further up-field to 6.79 for 
(1), 6.89 for (2), 6.64 for (3), 6.80 for (4e), 6.90 for (5e) and 6.63 (6e) ppm respectively. The electron 
density around the imine hydrogen was increased by metal-carbon bond, while C-H activated carbon 
formed five-membered metallocycle with metal. Electron density around the imine hydrogen was further 
increased by the para-substituents presented in the benzaldeyde moiety. On the other hand, the nitrogen 
(N) coordination with the metal center might not influence an electron density on the imine ligand as per 
the 
1
H NMR and IR shifts. Due to an increasing electron density around the imine hydrogen, both 
1
H 
NMR and IR frequencies were shifted to up-field in iridium and rhodium complexes. Both rhodium and 
iridium metals showed similar trend of coordination to C,N ligands. The rhodium complexes showed 
more 
1
H NMR and IR upfield shifts compared to the iridium complexes, due to the smaller atom size of 
the rhodium atom. The 
1
H NMR shifts confirmed that the C,N Schiff base carbazole ligands were 
coordinated to the respective metal centers and hence the formation of the respective complexes 1e-6e. 
6.3.3 Infrared spectroscopy 
The IR spectra of the C,N Schiff base carbazole ligands L1-L3 exhibit a characteristic peak for 
the (C=N) stretching frequency at 1595 cm
-1
 (L1), 1609 cm
-1
 (L2) and 1602 cm
-1
 (L3) and the stretching 
frequency of the carbazole moiety aliphatic ethyl group attached to the nitrogen atom (N-CH2CH3) 
appeared in the range of 2835 - 2998 cm
-1
. In complexes 1e-6e, these bands are shifted to lower 




 (2e), 1587 cm
-1
 (3e), 1590 cm
-1
 (4e), 1579 cm
-1
 (5e) and 1584 
cm
-1
 (6e), which are attributed to the C,N Schiff base carbazole nitrogen atom of the (C=N) group 
coordinated with the respective metal centers. The stretching frequency of the aliphatic ethyl group 
attached to the nitrogen atom (N-CH2CH3) was shifted to higher frequencies in all metal complexes, from 
2911 to 3040 cm
-1 
(1e), 2908 to 3041 cm
-1 
(2e), 2910 to 3046 cm
-1 
(3e), 2911 to 3045 cm
-1 
(4e), 2906 to 
3039 cm
-1 
(5e) and 2909 to 3046 cm
-1 
(6e), respectively. The IR stretching frequency shifts confirmed that 
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the C,N Schiff base carbazole ligands were coordinated to the respective metal centers and hence the 
formation of the respective complexes 1e-6e. 
6.3.4 HR-MS spectral studies 
The mass spectra of the complexes 1e-6e were recorded to confirm the composition of the 
complexes. The accurate mass of the most abundant peaks present in the metal complexes matched M - Cl 
(m/z) 641.1827, 643.1855 (1e), 637.2231, 639.2254 (2e), 653.2072, 655.2103 (3e), 553.1523, 555.1517 
(4e), 549.2016, 549.2018 (5e) and 565.1760, 566.1796 (6e), thus indicating the loss of a chloro group 
from the respective metal complexes. It seems that the chloro group is more labile than the other groups 
present in the metal complexes. 
6.3.5 Structural information 
Selected crystallographic and refinement data (Table 6.1) along with selected bond angles and 
distances (Table 6.2) of the iridium 2e and rhodium 5e complexes are presented. The perspective view of 
complexes 2e and 5e are shown in Figs. 6.1 and 6.2. The complexes 2e and 5e are arranged in the 
monoclinic crystal system with the P21/n space group. The crystal structures show typical pseudo-
octahedral “piano-stool“ geometry with the iridium / rhodium coordinated to an η
5
-cyclopentadienyl 
ligand (Ir(1)-centroid = 1.82 Å / Rh(1)-centroid = 1.83 Å), a chloride atom (Ir(1)-Cl(1) = 2.40 Å / Rh(1)-
Cl(1) = 2.27 Å) and the C,N Schiff base carbazole ligand in a bidentate manner forming a five membered 
metallocycle. 
The bond distances of the N(1)-Ir(1) = 2.11 Å, C(11)-Ir(1) = 2.04 Å, Cl(1)-Ir(1) = 2.40 Å, N(1)-
Rh(1) = 2.12 Å, C(11)-Rh(1) = 2.03 Å and Cl(1)-Rh(1) = 2.27 Å are consistent with similar bonds 
reported in the literature [4, 6, 7, 24-26]. The bond angles of the N(1)-Ir(1)-Cl(1) = 88.02°, N(1)-Rh(1)-
Cl(1) = 90.57°, C(11)-Ir(1)-Cl(1) = 87.85° and C(11)-Rh(1)-Cl(1) = 88.87° are close to 90°, whilst the 
centroid of the Cp* ring to iridium and rhodium distances = 1.82 and 1.83 Å respectively, which are also 







Table 6.1 Crystallographic data and summary of structural refinement of the metal complexes 2e and 5e 
Complex 2e 5e 
Empirical formula C33H36Cl3IrN2 C33H36Cl3N2Rh 
Formula weight 759.24 669.90 
Temperature/K 173(2) 173(2) 
Crystal system Monoclinic Monoclinic 
Space group P21/n P21/n 
a/Å 11.5604(4) 11.5862(2) 
b/Å 14.3378(3) 14.3937(2) 
c/Å 18.4761(4) 18.4023(2) 
α/° 90 90 
β/° 101.3710(10) 101.3800(10) 
γ/° 90 90 
Volume/Å3 3002.31(14) 3008.59(7) 
Z 4 4 
ρcalcg/cm
3 1.680 1.479 
μ(Mo Kα)/mm-1 4.740 0.860 
F(000) 1504.0 1376 
Crystal size/mm3 0.21 x 0.16 x 0.14 0.281 x 0.247 x 0.190 
Radiation Mo Kα (λ = 0.71073) Mo Kα (λ = 0.71073) 
2ɵ range for data collection/° 3.62 to 55.94 1.81 to 28.63 
Index ranges -13≤ h ≤15, -18≤ k ≤18, -24≤ l ≤23 -15≤ h ≤14, -19≤ k ≤19, -24≤ l ≤24 
Reflections collected 49723 71253 
Independent reflections 7077 [Rint = 0.0217] 7650 [R(int) = 0.0174] 
Data/restraints/parameters 7077/0/359 7650/0/359 
Goodness-of-fit on F2 1.347 1.108 
Final   indexes [I>=2σ (I)] R1 = 0.0185, wR2 = 0.0403 R1 = 0.0227, wR2 = 0.0564 
Final R indexes [all data] R1 = 0.0214, wR2 = 0.0412 R1 = 0.0242, wR2 = 0.0577 










Table 6.2 Selected bond lengths (Å) and bond angles (°) data for metal complexes 2e and 5e 
Complex 2e Crystal data Complex 5e Crystal data 
Bond distances (Å) 
 
Bind distances (Å) 
 
Ir(1) – C1 (Cp*) 2.269(2) Rh(1) – C1 (Cp*) 2.271(14) 
Ir(1) – C2 (Cp*) 2.259(2) Rh(1) – C3 (Cp*) 2.262(14) 
Ir(1) – C3 (Cp*) 2.158(2) Rh(1) – C4 (Cp*) 2.154(14) 
Ir(1) – C5 (Cp*) 2.159(2) Rh(1) – C6 (Cp*) 2.171(15) 
Ir(1) – C6 (Cp*) 2.149(2) Rh(1) – C8 (Cp*) 2.145(15) 
Ir(1) – Centroid (Cp*) 1.828 Rh(1) – Centroid (Cp*) 1.832 
Ir(1) – Cl(1) 2.401(5) Rh(1) – Cl(1) 2.395(4) 
Ir(1) – N(1) 2.111(17) Rh(1) – N(1) 2.117(12) 
Ir(1) – C(11) 2.041(2) Rh(1) – C(11) 2.030(14) 
Bond angles (°) 
 
Bond angles (°) 
 
N(1)-Ir(1)-C(11) 78.05(7) N(1)-Rh(1)-C(11) 78.79(5) 
N(1)-Ir(1)-Cl(1) 88.02(5) N(1)- Rh(1)-Cl(1) 90.57(3) 
N(1)-Ir(1)-C(1) 103.82(7) N(1)- Rh(1)-C(1) 102.81(5) 
N(1)-Ir(1)-C(2) 132.10(7) N(1)- Rh(1)-C(3) 131.16(5) 
N(1)-Ir(1)-C(3) 166.89(7) N(1)- Rh(1)-C(4) 165.50(5) 
N(1)-Ir(1)-C(5) 134.57(8) N(1)- Rh(1)-C(6) 133.75(6) 
N(1)-Ir(1)-C(6) 103.22(7) N(1)- Rh(1)-C(8) 102.17(5) 
N(1)-Ir(1)-Centroid (Cp*) 132.43 N(1)-Rh(1)-Centroid (Cp*) 131.20 
C(11)-Ir(1)-Cl(1) 87.85(6) C(11)-Rh(1)-Cl(1) 88.87(4) 
C(11)-Ir(1)-C(1) 155.39(8) C(11)-Rh(1)-C(1) 152.96(6) 
C(11)-Ir(1)-C(2) 149.76(8) C(11)-Rh(1)-C(3) 149.99(6) 
C(11)-Ir(1)-C(3) 112.08(8) C(11)-Rh(1)-C(4) 111.80(6) 
C(11)-Ir(1)-C(5) 97.11(8) C(11)-Rh(1)-C(6) 95.51(6) 
C(11)-Ir(1)-C(6) 117.01(8) C(11)-Rh(1)-C(8) 114.60(6) 





Fig. 6.1 The ORTEP diagram of iridium complex 2e. Displacements of the ellipsoids are drawn at 50% 
probability and hydrogen atoms are omitted for clarity. 
 
Fig. 6.2 The ORTEP diagram of rhodium complex 5e. Displacements of the ellipsoids are drawn at 50% 




In conclusion, the new half sandwich Ir(III) and Rh(III) complexes were synthesized and 
characterized. 
1
H NMR, IR spectroscopy, HR-MS spectroscopy and elemental analysis further confirmed 
the formation of the Ir(III) and Rh(III) complexes. The crystal structures confirm that the synthesized 
Ir(III) and  h(III) complexes exhibit a “piano-stool” pseudooctahedral geometry in their crystal 
structures.  
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C NMR, 2D NMR, HR-MS spectroscopy and crystal data of the complexes are also shown 
in the SI.  
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7.1 Chapter 2 
The preparation of a N,N' (N-(pyridin-2-ylmethylene)aniline) bidentate imine ligand was 




C NMR, IR spectroscopy and UV-vis 
spectroscopy and the successful complexation of the ligand to iridium, rhodium and ruthenium was 




C NMR, IR 
spectroscopy, UV-vis spectroscopy, mass spectroscopy, melting point analysis and elemental analyses. 
The crystal structures of complexes [Cp*MCl(N-(pyridin-2-ylmethylene)aniline)]PF6 (M = Ir (1a) and 
Rh(2a)) and [(η
6
-arene)RuCl(N-(pyridin-2-ylmethylene)aniline)]PF6 (3a) were determined by single 
crystal XRD confirming that the N,N' ligands were coordinated to the metal center via the nitrogen atoms. 
The catalytic performance of these complexes for the dehydrogenation of primary alcohols to their 
respective aldehydes with different bases and solvents was demonstrated. The complexes of iridium (1a) 
and ruthenium (3a) gave a good conversion in different alkaline solutions.  
A theoretical approach using DFT and Gibbs free energy calculations unambiguously explained 
the reactivity of the complexes and a reaction mechanism was proposed. The energy difference between 
the HOMO and LUMO for complexes 1a-3a are 120.59 kcal\mol, 130.67 kcal/mol and 124.49 kcal/mol 
respectively, which indicates that the lower energy gap of the iridium complex makes it more reactive 
than the latter complexes. The calculations thus supported the experimental results. Also, the NPA 
analysis for the iridium complex clearly shows that N,N' bidentate ligand donor strength on the iridium 
(N1 = -0.441 & N2 = -0.405) is higher than on rhodium and ruthenium, which facilitated the iridium 
complex to be more reactive than the other two.  
The Gibbs free energy      calculation of the reaction intermediates of the proposed rhodium 
catalytic cycle clearly shows that the catalytic cycle progressed through a metal-hydride intermediate. The 
Gibbs free energy for the Rh-H is -8.50 kcal/mol, which is much lower than the transition states Rh-
benzyloxo A (21.41 kcal/mol), Rh-dihydride complex C (20.34 kcal/mol) and 16e
-
 Rh complex D (31.85 
kcal/mol). The Rh-benzyloxo to Rh-H formation step is attributed to the rate determining step of the 
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proposed reaction mechanism. Additionally, the reaction mechanism which goes via C as compared to D, 
is explained by the free energy barrier of the transition states. 
7.2 Chapter 3 




C NMR and IR spectroscopy. All ligands were successfully coordinated to iridium and 
rhodium. The resultant six new complexes [Cp*IrCl(para-R-N-(pyridin-2-ylmethyl)aniline)]PF6 (R = H 
(1b); F (2b); OCH3 (3b)) and [Cp*RhCl(para-R-N-(pyridin-2-ylmethyl)aniline)]PF6 (R = H (4b); F (5b); 
OCH3 (6b)) were characterized by different spectral techniques. The crystal structures (RM, SN-H) of 
[Cp*IrCl(N-(pyridin-2-ylmethyl)aniline)]PF6 (1b) and [Cp*RhCl(para-OCH3-N-(pyridin-2-
ylmethyl)aniline)]PF6 (6b) were unambiguously determined by single crystal X-ray diffraction. 
Interestingly, the iridium and rhodium complexes showed diastereomers and cross interactions between 
the CH2 to Cp* moiety, as well as the CH2 to the phenyl ring in solution, which was further confirmed by 
1
H NMR and 1D NOE NMR analysis.  
The catalytic transfer hydrogenation of aromatic ketones and aldehydes in water was 
demonstrated for these complexes under pH dependent acidic reaction conditions. Generally, the Ir(III) 
amine complexes (1b-3b) required longer reaction times (4 to 6 hr) than the Rh(III) amine complexes 
(4b-6b) under the specified reaction conditions. This is due to the highly acidic N-H proton, which 
promoted the formation of imine Ir(III) complexes in the reaction. Though the Ir(III) imine complexes 
remain active in the reaction medium, they required a longer reaction times to reduce the aromatic 
ketones. Overall, the Rh(III) amine and imine complexes proved to be most efficient catalysts, as they 
gave significantly higher conversions as compared to the Ir(III) amine complexes. Another feature of this 
system is that the catalyst was recovered and that the recovered catalyst was active for at least three 
catalytic cycles. 
7.3 Chapter 4 





C NMR and IR spectroscopy. New carbazole N,N' imine ligand successfully coordinated with 
iridium, rhodium, ruthenium and osmium metals via nitrogen atoms. The resultant nine new complexes 
[(η
5










cymene)OsX(L)]PF6 X = Cl (8c), I (9c)) (L = 9-ethyl-N-(pyridine-2-yl methylene)-9H-carbazole-3-




C NMR, 2D NMR, melting point analysis, IR 





C5Me5)RhCl(L)]PF6 (3c) and [(η
6
-p-cymene)RuI(L)]PF6 (6c) further confirmed that the N,N' imine 
ligands were coordinated to the metal center via nitrogen atoms.  
Anticancer study of the synthesized complexes 1c-3c clearly showed them to be potent inhibitors 
of human breast cancer cells (MCF-7) under in vitro conditions. The inhibitory concentrations (IC50) of 
the complexes 1c-3c were determined at low (5, 6 and 8 μM) concentration against the MCF-7 human 
breast cancer cell line. The activity of the complexes 1c-3c were explained by the hydrophobicity of the 
Cp* ring, higher than that of the benzene ring, which was effective in penetrating the cell membrane. 
Experimental results for complexes 1c-3c showed the mode of interaction and that a greater extent of 
interaction occurred with the iridium complex with DNA and protein, and that it had a higher effective 
penetrating nature into the cell membrane than the other two complexes. Furthermore, the docking studies 
for complexes 1c-3c with the COX-2 receptor showed that the iridium complex binding energy (-8.18 
kcal/mol) was higher than those of the rhodium (-7.34 kcal/mol) and ruthenium (-7.13 kcal/mol) 
complexes, which indicated that the iridium complex is most stable in the hydrophobic pocket active site 
of COX-2. 
7.4 Chapter 5 
New [RuCl2(COD)(L1)] (1d), [RuCl2(COD)(L2)] (2d), [RuCl2(COD)(L3)] (3d), 
[RuCl2(COD)(L4)] (4d), [RuCl2(COD)(L5)] (5d) (L = (p-R-N-(pyridin-2-ylmethylene)aniline), R = H 
(L1), Cl (L2), OCH3 (L3), CH3 (L4), L5 = (9-ethyl-N-(pyridin-2-ylmethylene)9H-carbazole-3-amine and 
COD = η
4
-cyclooctadiene) complexes containing N,N’ bidentate ligands were successfully synthesized 
and characterized by various spectral techniques. The crystal structure of complexes 1d-3d showed 
coordination of the ligands to the Ru(II) centre in a bidentate manner via the N atoms and exhibited 
pseudooctahedral geometry.  
The complexes 1d-5d showed binding interaction with human serum albumin (HSA). Among the 
complexes 1d-5d, complex 1d showed strongest binding interaction with HSA compared to the other 
complexes, which is explained by the planarity of the complexes. In the case of complex 1d there is no 
substitution on the phenyl ring present in the ligand which may assist complex planarity which gives the 
high interaction with HSA as seen in the experimental results. Complex 3d with the p-methoxy (OCH3) 
group showed better interaction compared to complex 2d with the p-Cl group. Complex 5d showed both 
electronic and steric effects in the HSA binding studies. A molecular docking study of complexes 1d-5d 
with HSA confirmed that complex 1d (-6.67 kcal/mol) showed the highest binding energy among the 
complexes 1d-5d. Overall, docking studies confirmed that complexes 1d-5d are located close to the 
active site residues of Trp 214, Arg 222, His 242, Leu 238 and Ala 291 in HSA subdomain IIA. 
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7.5 Chapter 6 
 A series of the C,N bidentate Schiff base ligands [para-R-N-benzylidene-9-ethyl-9H-carbazol-3-





C NMR and melting point analysis. These three ligands were successfully cyclometalated with 
iridium and rhodium. The resultant six new complexes [Cp*IrCl(L)] [L = (para-R-N-benzylidene-9-
ethyl-9h-carbazol-3-amine)] R = F (1e), CH3 (2e), OCH3 (3e)), and [Cp*RhCl(L)] R = F (4e), CH3 (5e), 




C NMR, IR spectroscopy and elemental analysis. The 
crystal structure of the complexes 2e and 5e showed a pseudooctahedral geometry in their crystal 
structures. 
 Finally, it can be concluded that the main goals of this study were achieved because the 
complexes were successfully synthesized, characterized and investigated for their catalytic activities in 
oxidation of primary alcohols and transfer hydrogenation of aromatic ketones under green conditions. 
Some of the metal complexes were also investigated in an anti-cancer cytotoxicity study and in binding 
interactions with human serum albumin. All the synthesized complexes showed excellent catalytic 
activities for their respective catalytic systems as well as in biological applications. The majority of the 
synthesized bidentate half sandwich complexes exhibited the common “piano-stool” geometry. The 
geometries around the metal centers of the complexes is “piano-stool” in which the N,N' / C,N atoms and 
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